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ABSTRACT OF THE DISSERTATION 
 
 
The Effects of Molecular and Biochemical Disruptions Posed 
 by Harm-Reduction Tobacco Products on Developing Tissues  
Using Human Pluripotent Stem Cells 
 
 
By 
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 Focus on tobacco-related disease concerns has shifted from cigarettes to other 
forms of tobacco use over the last 20 years. Due to their perception as “safer than a 
cigarette” by the general public, harm-reduction tobacco products (HRTPs) offer an 
appealing alternative for women struggling with nicotine addiction who find themselves 
pregnant. Some studies, however, suggest that HRTPs may increase risk of adverse 
pregnancy outcomes and hinder fetal skeletal development. To date, the mechanistic 
etiology of HRTP embryotoxicity is unreported. This thesis aims to address this knowledge 
gap by answering some of the questions surrounding how HRTPs molecularly and 
biochemically cause changes in the developing skeleton.  
 Early in vivo studies reported herein indicated that HRTP exposure directly targets 
early osteogenesis of the skull following in utero exposure of mouse embryos. To explore 
the molecular etiology of this outcome, the embryonic stem cell test (EST) protocol was 
 viii 
 
adapted to an in vitro model of developmental osteogenesis using human pluripotent stem 
cells (hPSCs). Cultures were concurrently exposed to conventional sidestream cigarette 
smoke (CSC), harm-reduction sidestream cigarette smoke (HSC), or harm-reduction Snus 
smokeless tobacco extract (STE). While conventional and harm-reduction extracts both 
inhibited in vitro osteogenesis, only the HSC and STE harm-reduction extracts did so at 
sub-cytotoxic doses. Furthermore, inhibitory doses increased cellular levels of reactive 
oxygen species and reduced endogenous antioxidant enzyme activity. Molecular analysis 
found that CSC exposure incurred both DNA damage and a concurrent apoptotic response 
that was absent in cultures exposed to either HRTP extract. Biochemical exploration of 
HRTP impact on developing cultures found exclusive activation of survival kinase AKT 
and reduction of stress rescue kinase JNK in STE-exposed cultures. Concurrent treatment 
with an isoform-specific inhibitor of AKT or JNK activator rescued osteogenesis in STE 
cultures, implicating the specific misregulation of these kinases in poor osteogenic 
outcomes. Global proteomic analysis of AKT signaling targets also identified exclusive 
hyperphosphorylation of FOXO transcription factors—required for oxidative stress 
defense and adult bone homeostasis—in STE-treated cultures, marking FOXOs for nuclear 
exclusion. Collectively, our data suggest that HRTPs inhibit normal osteogenesis by 
disrupting the balance between embryonic osteogenesis, survival, and redox equilibrium 
mechanisms. 
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CHAPTER 1 
 
Addressing the global birth defects burden 
 
Introduction 
Each year, over 8 million children are born with a birth defect resulting from genetic 
causes, maternal nutritional deficiency, or maternal exposure to environmental agents (i.e., 
chemical, infectious, pharmaceutical) [1]. Of these children, an estimated 3.3 million under 
the age of 5 die from serious birth defects, with over 300,000 children succumbing within 
the first month of life [2]. Affected infants who survive past childhood and their families 
must continue to manage lifelong physical, mental, auditory, and/or visual disabilities. 
Birth defects may be structural (e.g., cleft palate, heart defects) or functional (e.g., 
behavioral disorders, muscular dystrophy, etc.) in nature [3].  Some structural and 
functional defects can be corrected through surgical and pharmacological intervention, 
respectively. Societal cost of care and medical intervention associated with birth defects, 
however, can be quite burdensome—especially for low- and middle-income families. For 
instance, the cost of care for a child born with fetal alcohol spectrum disorder (FASD) in 
the United States was estimated to be about $23,000 per person annually in addition to 
productivity losses for caregivers of children born with FASD [4], [5]. More broadly, 
domestic hospitalization costs alone for individuals with birth defects was estimated to be 
$23 billion [6]. In this way, long-term disability caused by birth defects can have significant 
impacts on individuals, their families, health-care systems, and communities (Fig. 1.1).  
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Figure 1.1. Percentage of hospital stays in the United States associated with at least one 
birth defect-associated diagnosis by age group for 2013 (Arth, 2017). 
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Birth defects are one of many public health issues that comprise the current global 
health burden. At present, the causes of about 30% of birth defects are somewhat 
understood [7]. Given the body of knowledge on the role of environmental factors and 
adult health [8-11], it follows that the remaining 70% of birth defects may have etiology 
rooted in environmental conditions and can therefore be preventable with appropriate 
precautions. To date, environmental contaminants such as industrial solvents, metals, 
pesticides, and environmental tobacco smoke have all been suggested to disrupt normal 
development [12]. The full extent of developmental toxicity risks, however, remains 
unclear. In 2011, a study found that 98% of drugs approved by the US Food and Drug 
Administration lacked data on whether or not those drugs posed a risk to pregnancy 
outcomes [13]. In addition, the majority of the commercial chemicals registered for use in 
the United States lack comprehensive human toxicity and exposure data [14], which also 
poses a challenge to birth defects prevention. Without sufficient documentation on birth 
defect etiology, global public health policies are unlikely to change. 
 
In Vitro Solutions to Current Challenges in Birth Defects Research 
Traditional approaches to birth defects and developmental biology research utilize 
animal models to study embryonic developmental processes and associated diseases [15].  
The prenatal developmental toxicity test uses pregnant mice, rats, or rabbits to identify 
chemicals that disrupt normal pregnancy and/or development.  This test is also routinely 
used alongside other in vivo methods to establish human exposure guidelines [16-21]. 
Animal models benefit from generally conserved biological principles governing gene 
 4 
expression and tissue morphogenesis. Mouse models, in particular, are regarded as the 
premier system for investigating human organ development as most protein-coding genes 
are shared between the human and laboratory mouse genome [22]. This similarity is best 
evidenced by mutant mouse models that recapitulate human disease phenotypes. For 
instance, null mutations in pancreas specific transcription factor 1a (Ptf1a) result in 
impaired pancreas development in both mice and humans [23-25]. Despite the overall 
success of animal models, traditional developmental animal studies still suffer from their 
expensive and time-consuming nature [26]. Cost and time requirements alone make 
traditional developmental animal model approaches impractical for use in testing all 
commercially used chemicals and pharmaceuticals. As such, the rate at which 
environmental contaminant risks are identified is often slowed. These challenges highlight 
a need for robust, low-cost, and swift screening methods that can detect and prioritize 
chemicals that present developmental toxicity risks. 
 In response to challenges presented by traditional developmental screening 
approaches, several in vivo and in vitro screening approaches have been proposed to 
mitigate challenges posed by traditional methodologies. Each of the in vivo assays—the 
zebrafish embryotoxicity test and the Frog Embryo Teratogenesis Assay (FETAX), and the 
mouse whole embryo culture assay—operate similarly in that each exposes whole animal 
embryos to the chemical(s) of interest for 72-120 hours before the developmental stages of 
specified structures and organs are scored to assess embryotoxic effects [27-30]. In 
contrast, the in vitro limb bud micromass test and mouse embryonic stem cell test (mEST) 
measure the ability of rat limb bud cells and mid brain cells or mouse embryonic stem cells, 
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respectively, to successfully differentiate into directed cell types with concurrent chemical 
exposure [31], [32]. While accuracy data has yet to be reported for the FETAX approach, 
each of the other methods offer prediction accuracy rates of 70% or higher, with the mouse 
whole embryo assay at the highest accuracy rate of 80% [27], [29], [33]. Furthermore, the 
MM test, WEC test, and mEST have been officially validated via independent studies 
coordinated by the European Center for the Validation of Alternative Methods (ECVAM) 
[33]. 
While all of these approaches truncate the completion time for embryotoxicity 
assessments, only the mEST addresses the cost of routine animal use and subsequent 
sacrifices. In lieu of whole animal embryos, the EST uses embryonic stem cells to model 
developmental processes and tissue commitment. Embryonic stem cells (ESCs) are derived 
by isolating cells from the inner cell mass of a preimplantation blastocyst and cultivating 
the isolated cells in vitro [34], [35] (Fig. 1.2). During normal development, the inner cell 
mass (ICM) gives rise to all the cell types of the body but does not contribute to placental 
tissues. Because of this lineage restriction, ICM are regarded as pluripotent instead of 
totipotent [36]. ESCs are also characterized by their ability to “self-renew” or proliferate 
indefinitely without differentiating into more 
specialized cell types [37] (Fig. 1.3). This feature 
allows for prolonged cell stock maintenance and 
thus swift, cost-effective generation of starting 
materials for in vitro embryotoxicity assessments. 
Mouse ESCs (mESCs) can be maintained in in  
Figure 1.2. Blastocyst illustration 
demonstrating the inner cell mass 
(ICM) and trophoectoderm cell 
populations.  
Inner Cell Mass
Trophoectoderm
Blastocoel Cavity
Zona Pellucida
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this pluripotent state of self-renewal by supplementing culture medium with cytokine 
leukemia inhibitory factor (LIF) or by co-culture with murine embryonic fibroblast (MEF) 
feeder layers that provide a source of LIF [38]. When the LIF source is withdrawn from 
mESC culture, mESCs pluripotency is lost as the cells differentiate into distinct cell types. 
mESC differentiation is classically directed through the formation of embryoid body (EB) 
formation [39]. Here, suspensions of mESCs are allowed to form cell aggregates of densely 
packed cells with fluid filled cavities [40-42].  EBs execute polarity and tissue 
regionalization processes that coincide with the sequential activation of genes responsible 
for gastrulation and early embryo patterning processes [43-45]. The mEST takes advantage 
of this capacity to recapitulate the gastrulation process with mESCs in the context of 
embryotoxicity assessments.  
In the original mEST protocol, mouse ESCs are induced to differentiate into 
cardiomyocytes during concurrent chemical exposure and embryotoxic risk is 
quantitatively measured [46]. Here, mouse D3 ESCs are used to recapitulate embryonic 
cardiogenesis as they differentiate into actively contracting cardiomyocytes. 
Differentiation inhibition and cytotoxicity are measured as reductions in formation of 
functional contractile clusters and cell metabolic activity, respectively. The mEST also 
accounts for cytotoxic impacts on maternal tissues via the inclusion of 3T3 fibroblasts in 
the screening protocol. Cytotoxicity in exposed 3T3 cultures is used to identify potential 
maternal toxicity events that could affect the likelihood of embryotoxicity. Half-maximal 
inhibitory doses for differentiation (ID50) and cell viability (IC50) are determined from 
dose-response curves generated from screen endpoints. The values, in turn, are entered into  
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a biostatistical prediction model which was developed for use with the EST protocol to 
classify chemicals under evaluation as non-embryotoxic, weakly embryotoxic, or strongly 
embryotoxic (Fig. 1.4).  
Since its ECVAM validation, the mEST has been employed in embryotoxicity 
screens for a variety of commodities including industrial chemicals [47], [48], 
pharmaceuticals [49], [50], and cosmetics [51]. The mEST has also been used in 
embryotoxicity evaluations for a number of environmental contaminants [52-56]. Though 
the mEST is validated for a cardiomyocyte endpoint, traditional in vivo developmental 
screens evaluate changes in all soft tissues as well as the developing skeleton [16]. Thus, 
there is a need for additional endpoints in the EST protocol in order to more thoroughly 
assess the embryotoxic potential of chemicals. Some progress has been made to address 
these additional needs through the development of defined differentiation protocols. To 
date, protocols have been reported for directing differentiation of mESCs to bone, neural 
tissue, and muscle tissue [57-59]. Thus, the mEST protocol can be adapted to address 
embryotoxicity for chemicals that may additionally or more specifically target tissues other 
than cardiac tissue.  
 
Updating the mEST with Human Pluripotent Stem Cells 
Over the last few decades, most in vitro developmental toxicity testing has been 
predominantly executed using mESCs [33], [50], [60-64]. The first isolation of human 
ESCs (hESCs) from a human blastocyst [65], however, started a dialogue on the possibility 
of incorporating hESCs into developmental testing protocols. While the laboratory mouse 
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Figure 1.4. Overview of the Embryonic Stem Cell Test. Inhibition of differentiation and 
cell viability in differentiating embryonic stem cells (ESCs) is compared with inhibition 
of terminally differentiated fibroblasts in the EST biostatistical model to determine 
embryotoxicity classification. 
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and human genome are largely conserved, variations in gene expression patterns and 
pluripotency maintenance signaling pathways for mouse and human ESCs have been well 
documented [29], [66], [67]. These discrepancies suggest the potential for additional 
variations regarding signaling pathways involved in differentiation processes that may 
have implications for embryotoxicity testing. Differences in metabolism and temporal gene 
regulation in in vivo rodent models have already been documented to sometimes yield 
inaccurate toxicity assessments and failed human clinical trials [68-71]. Furthermore, in 
vivo mouse models have been shown to not always fully replicate human disease [72]. 
In light of the potential challenges posed by mouse models, hESCs have been 
viewed as a means to offer a more biologically relevant approach to in vitro developmental 
modeling and embryotoxicity assessments. Like mESCs, hESCs are pluripotent, capable 
of self-renewal, and can be directed to differentiate into particular cell types [73–75]. While 
hESC stocks were previously more challenging to maintain in culture, recent advances in 
culturing techniques and approaches have made routine hESC culture more accessible [76].  
 Routine use of hESCs in developmental toxicity evaluations, however, has been 
slow despite proposed advantages over mESC-based models. One of the main challenges 
to hESC incorporation into regulatory evaluations has been the ethical and legal debate 
surrounding hESC derivation, which calls for the destruction of the donor embryo [77], 
[78]. In response to these concerns, human induced pluripotent stem cells (hiPSCs) have 
been proposed as “a more ethical alternative” to hESCs as well as an additional route for 
in vitro developmental models and toxicity screens. hiPSCs possess the same defining 
characteristics of hESCs (i.e., self-renewal, pluripotency) but differ in that they are derived 
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from biopsied somatic cells that have been genetically reprogrammed to a pluripotent, 
ESC-like state [79], [80] (Fig. 1.5).  
Because these hiPSCs can be derived from various individuals, these cells also offer 
the additional opportunity to create cell lines of varied genetic and disease backgrounds. In 
this way, hiPSC-based developmental models could also be used to explore the genetic 
interplay between toxicant exposure and outcomes. One caveat of hiPSCs, however, is that 
iPSCs may experience an incomplete reset of DNA methylation patterns during genetic 
reprogramming that may cause lineage bias during later differentiation [81].  High-
efficiency reprogramming protocols and hiPSC stock quality control practices have both 
been suggested to address this challenge [82], [83]. Nevertheless, which human pluripotent 
stem cell type—if either—is more advantageous in a developmental model remains to be 
reported. 
Despite strides made in the area of in vitro developmental toxicity screens over the 
last 20 years, hiPSC- and hESC-based developmental toxicity screens have yet to be 
incorporated into the regulatory framework of embryotoxicity assessments. In vivo species-
species discrepancies in toxicant response are well-documented [84–86], though it remains 
to be seen if mESCs are less sensitive than human pluripotent stem cells. Here, additional 
comparative analysis is required to support claims that human pluripotent stem cells are a 
superior in vitro developmental model system. hPSCs as a Means to Investigate Birth 
Defects in Understudied Tissues Like Bone 
 The capacity for hPSCs to be differentiated into any of the 3 germ layers formed 
during gastrulation also creates a potential avenue for studying processes and pathologies  
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Figure 1.5. How induced pluripotent stem cells (iPSCs) are made and used in 
research applications. Somatic cells like fibroblasts are biopsied and genetically 
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that have been previously difficult to study. One such area is that of skeletal defects and 
pathologies resulting from disruptions that occur during osteogenesis. Osteogenesis refers 
to the process by which bone is formed during embryonic development, adult bone 
homeostasis, or the bone healing process after a fracture event. Depending on the type of 
bone, osteogenesis can occur predominantly through one of two mechanisms: 
intramembranous ossification or endochondral ossification [87]. Intramembranous 
ossification produces the flat bones (i.e., craniofacial skeleton, pelvis). Intramembranous 
ossification occurs by proliferation and direct differentiation of osteoprogenitor cells into 
osteoblast bone cells. Endochondral ossification, conversely, produces the long bones (i.e., 
ribs, spine, humeri, femurs) that make up the axial and appendicular skeleton. During 
endochondral ossification, bone formation is preceded by chondrogenesis processes that 
create a cartilaginous base. Osteoprogenitors eventually replace the cartilaginous base with 
bone cells. With both modes of ossification, bone progenitor cells condense at bone 
formation sites before ultimately differentiating into osteoblasts that secrete and mineralize 
extracellular matrix. These osteoblasts later mature into osteocytes. 
 Bone formation and remodeling through either ossification mechanism is a 
dynamic process that is tightly regulated between bone-building osteoblasts and bone-
absorbing osteoclasts. Osteoblasts are defined by their ability to form a mineralized extra 
cellular matrix (ECM). Differentiation from pluripotent stem cells to osteoblasts is 
regulated by temporal expression of specific genes and proteins. In vitro approaches to 
recapitulate this process using ESCs have identified ascorbic acid, β-glycerophosphate and 
1,25-(OH)2 vitamin D3 as potent inductors of osteogenic differentiation [88]. Studies in 
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our group have found mESC-based osteogenesis to recreate temporal expression patterns 
of osteogenic genes involved in embryonic osteogenesis. During this process, expression 
of alkaline phosphatase (ALPL) is followed by activation of CBFA1, a master regulatory 
transcription factor [89] for osteogenesis that upregulates runt-related transcription factor 
2 (RUNX2) and osteopontin (OPN) expression. As the differentiation progresses, mature 
osteoblast markers bone sialoprotein (BSP) and osteocalcin (OCN) are expressed. These 
developments are followed by expression of osteocyte-affiliated genes CAPG and 
DESTRIN [90]. Given the tightly-regulated and timing dependent nature of osteogenesis, 
it follows that misregulation of any of these key stages during development may lead to 
skeletal birth defects or pathologies [59], [91].  
From a developmental perspective, different gastrulation layers contribute to 
different skeletal tissues. Neural crest cells arising from the ectoderm germ layer lineage 
largely contribute to the craniofacial skeleton, while the mesoderm layer ultimately 
produces the appendicular skeleton (lateral mesoderm) and cranial and axial skeleton 
(paraxial mesoderm) (Fig. 1.6). At present, the precise relationship between disruption of 
osteoblast precursor populations during development and adult skeletal function is not well 
understood. It is recognized, however, that some environmental toxicants can disrupt 
normal bone metabolism, increasing risk of bone fracture and causing osteoporosis [92-
94]. One such environmental toxicant, cigarette smoke, has been associated with a myriad 
of adverse pregnancy incomes [95]—including low bone mass [96] and increased bone 
fracture risk [97] for children exposed in utero. To date, however, very little investigation 
of the molecular mechanism of tobacco-related osteotoxicity in developing tissues has been  
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Figure 1.6. Overview of skeletal bone developmental origins in the early 
embryo. Lateral mesoderm and paraxial mesoderm give rise to the 
appendicular and axial skeleton, respectively. Neural crest cells give rise to 
the craniofacial skeleton, though the paraxial mesoderm contributes to other 
parts of the cranial skeleton. 
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reported. This dearth of information may be attributable in part at least to the costs and 
time associated with traditional in vivo developmental modeling approaches. It follows, 
then, that human pluripotent stem cell (hPSC)-based models of osteogenesis could offer a 
less-expensive and less-time consuming approach to investigating unknown mechanisms 
of embryotoxicants like tobacco in tissues that are challenging to study in vivo.  
Conclusion 
One of the main challenges to reducing the global birth defects burden is the dearth 
of knowledge regarding the precise influence of many environmental toxicants on 
particular developmental processes. Functional defects observed in developmental animal 
studies long been employed to investigate the potential for embryotoxic effects in humans 
[98], though this approach fails to provide a clear mode of action for embryotoxic etiology. 
Use of hESCs or hiPSCs in developmental modeling approaches offers a faster, more cost-
effective avenue to investigate molecular changes and embryotoxic mechanisms at play in 
adverse developmental outcomes. The development of defined differentiation protocols for 
hPSCs allows for the investigation of understudied embryotoxicity mechanisms like the 
impact of tobacco on bone. 
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Aims 
The current global birth defects burden exerts an annual toll of billions of dollars 
in preventable healthcare costs, emotional detriment, and lost economic productivity [5], 
[6]. Enhancing the traditional developmental toxicity tool kit with robust, biologically-
relevant human pluripotent stem cell approaches can help to reduce the bottleneck 
associated with traditional whole animal approaches. Furthermore, human pluripotent stem 
cell-based developmental modeling may offer the opportunity to explore embryotoxicant 
modes of action in a developmentally-relevant system. However, additional research 
support of hPSC-improved sensitivity compared to mESCs as well as the investigatory 
capacity of human pluripotent stem cells with regard to complex environmental 
contaminants remains to be reported. This thesis aims to provide knowledge on the robust 
nature of hPSCs in embryotoxicity assessments and mode of action studies by addressing 
three specific aims:  
 
Specific Aim 1: Determine comparative sensitivity of non-human primate and human 
pluripotent stem cells compared to mESCs (addressed in chapters 2 and 3). 
 
Specific Aim 2: Investigate embryotoxic mechanisms of conventional and harm-reduction 
cigarettes in developmental osteotoxicity screening model using hESCs (addressed in 
chapter 4). 
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Specific Aim 3: Evaluate the biochemical alterations driven by smokeless-tobacco 
exposure and down-stream ramifications on embryonic bone development (addressed in 
chapter 5). 
  
 19 
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CHAPTER 2 
 
Non-human primate and rodent embryonic stem cells are differentially sensitive to 
embryotoxic compounds 
 
Lauren Walker, Laura Baumgartner, Kevin C. Keller, Julia Ast, Susanne Trettner, and 
Nicole I. zur Nieden 
 
Abstract 
Many industrial chemicals and their respective by-products need to be 
comprehensively evaluated for toxicity using reliable and efficient assays. In terms of 
teratogenicity evaluations, the murine-based embryonic stem cell test (EST) offers a 
promising solution to screen for multiple tissue endpoints. However, use of a mouse model 
in the EST can yield only a limited understanding of human development, anatomy, and 
physiology. Non-human primate or human in vitro models have been suggested to be a 
pharmacologically and pathophysiologically desirable alternative to murine in 
vitro models. Here, we comparatively evaluated the sensitivity of embryonic stem cells 
(ESCs) of a non-human primate to skeletal teratogens with mouse ESCs hypothesizing that 
inclusion of non-human primate cells in in vitro tests would increase the reliability of 
safety predictions for humans. 
First, osteogenic capacity was compared between ESCs from the mouse and a New 
World monkey, the common marmoset. Then, cells were treated with compounds that have 
been previously reported to induce bone teratogenicity. Calcification and MTT assays 
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evaluated effects on osteogenesis and cell viability, respectively. Our data indicated that 
marmoset ESCs responded differently than mouse ESCs in such embryotoxicity screens 
with no obvious dependency on chemical or compound classes and thus suggest that 
embryotoxicity screening results could be affected by species-driven response variation. In 
addition, ESCs derived from rhesus monkey, an Old World monkey, and phylogenetically 
closer to humans than the marmoset, were observed to respond differently to test 
compounds than marmoset ESCs. Together these results indicate that there are significant 
differences in the responses of non-human primate and mouse ESC to embryotoxic agents. 
 
Introduction 
In the United States, one in 28 babies carries congenital anomalies [1]. Although 
50% of the causes for such birth defects are unknown, some may be traced back to 
involuntary environmental chemical exposure. There are more than 80,000 cataloged 
chemicals in the United States that may be released into the environment and most of them 
are inappropriately tested for safety. This lack of information is particularly concerning for 
sensitive populations such as pregnant women and children as adequate safety guidelines 
cannot always be confidently recommended. Furthermore, given that the developing fetus 
is especially sensitive to maternal environmental conditions and also that exposure during 
key points of development can lead to unique effects lasting through multiple 
generations [2], the potential embryotoxicity and teratogenicity of industrial compounds is 
of particular concern. 
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With appropriate data, acceptable exposure levels and actual safety of such 
products can be established for individuals that are most vulnerable to chemical exposure. 
Therefore, toxicology programs have been designed to identify toxicities that may 
potentially be encountered in human embryos. Under the worldwide trend for revision of 
chemical legislation, it will be necessary to test a large number of chemicals in a short time, 
which can only be achieved with predictive in vitro assays. 
A step in the direction of animal sacrifice free embryotoxicity screen was taken 
when the classic embryonic stem cell test (EST) was first described [3], [4]. This assay 
relies on embryonic stem cells (ESCs) from the mouse and compares two important aspects 
of prenatal toxicity. First, the EST has revealed the differences in sensitivity of mouse 
embryonic stem cells (ESCs) to chemical entities compared to adult fibroblasts. Second, 
the test determines the ability of a chemical to inhibit the differentiation of the ESCs into 
a differentiated cell type of interest [5], [6].  
Among the many birth defects, the ones that affect musculoskeletal tissues account 
for 5% of all infant deaths. Thus, skeletal toxicity has become a high priority screening 
phenotype and is currently integrated into the animal screens that assess general prenatal 
developmental toxicity (TG414, OECD) [7], [8], [9]. Assessing the inhibition of osteogenic 
differentiation of the ESCs, the EST may also be exploited to serve as predictor for 
developmental osteotoxicity [6], [10], [11], [12], [13], [14]. 
Despite the routine use of rodent models in research, the mouse model as used in 
the EST can only yield a limited understanding of human development, anatomy and 
physiology. Accordingly, human in vitro models are desirable from a pharmacological and 
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pathophysiological standpoint. Indeed, ESCs from humans were established around the 
turn of the century [15]. However, due to ethical considerations, the legality of their use 
varies widely between countries. A solution comes with human induced pluripotent stem 
cells (hiPSCs), which are artificially created from somatic cells, and are therefore not 
ethically challenged, but it is yet unclear how their quality or differentiation potential 
measures up to bona fide hESCs. Therefore, to provide a legal and ethical alternative to 
countries, which have banned hESC research, we test here whether the sensitivity of non-
human primate ESCs to a small set of classical and skeletal embryotoxic agents is similar 
to that of mouse ESCs in order to evaluate whether the inclusion of non-human primate 
cells into the EST would increase the reliability of safety predictions for human use. 
 
Materials and methods 
Murine ESC maintenance 
Murine D3 embryonic stem cells (American Type Culture Collection, Rockville, 
MD, USA) were expanded in high glucose DMEM containing L-glutamine (Corning). 
Media additionally contained 15% batch-tested fetal bovine serum (FBS), 1% non-
essential amino acids (NEAA), 50 U/ml penicillin, 50 µg/ml streptomycin, 0.1 mM 2-
mercaptoethanol (all Invitrogen) and 1000 U LIF/ml (Millipore). Cells were routinely 
passaged every 2–3 days with 0.25% Trypsin-EDTA (Life Technologies). 
 
 32 
Maintenance culture of non-human primate ESCs 
Embryonic stem cells from the common marmoset (cjes001) were cultured in 
feeder-free conditions as described [16]. Rhesus ESCs (R366.4, WiCell Research Institute) 
were cultured on mouse embryonic fibroblast feeder layers as previously 
described [17], [18]. 
 
Osteogenic differentiation of ESCs 
Murine ESCs were induced to differentiate via aggregation into embryoid 
bodies via hanging drops at 750 cells/drop, in the presence of control differentiation 
medium (CDM, mouse ESC maintenance medium without LIF [19]. Differentiating cells 
were replated on day 5 as a single cell suspension at a concentration of 
50,000 cells/cm2 [20]. Differentiation of marmoset and rhesus ESCs was initiated from 
intact ESC colonies in non-adherent conditions as described [16], [17]. In brief, 
undifferentiated colonies were trypsinized with TrypLE (Invitrogen) into clusters of 20–30 
cells. Approximately 100 such clusters were seeded in CDM to one bacteriological grade 
dish (100 mm diameter). Following 5 days of incubation, cell clusters were transferred onto 
cell culture plates coated with 0.1% gelatin at an approximate density of 10 cell 
clusters/cm2. On day 5 of differentiation, cells from all species received osteogenic 
differentiation medium containing the induction factors β-glycerophosphate (10 mM), 
ascorbic acid (25 µg/ml), and 1α,25-(OH)2 vitamin D3 (5 × 10−8 M) in CDM. 
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Test compounds 
5-fluorouracil, all-trans retinoic acid, penicillin G (all Sigma) were selected as 
control test compounds as the teratogenic potential of each has been well established by 
previous in vivo and in vitro investigations [21]. Stock solutions were made in DMSO and 
diluted to test concentrations in respective cell culture media. Lithium chloride was 
obtained from Fluka and aluminum chloride was obtained from Sigma. Sodium chloride 
(Fisher Scientific), lithium acetate (Aldrich), sodium acetate (Sigma), and aluminum 
hydroxide (Sigma) were included as controls for lithium and aluminum activity. Untreated 
control cultures containing appropriate vehicle were also included. Osteogenic 
differentiation was considered valid if the control solvent yielded osteoblast differentiation 
levels comparable to that of untreated vitamin D3 induced osteogenic cultures. 
 
Cytotoxicity assay 
Cellular viability was evaluated with an MTT assay following 14 days of 
osteogenic induction as described [22]. In brief, 0.5 mg/ml MTT solution was added to the 
cultures and cells were incubated at 37 °C for 2 h. Reagent was then aspirated and cells 
were gently rocked in pre-warmed MTT desorb solution (0.7% SDS in 2-propanol) for 
15 min. Absorbance of dissolved blue formazan product was measured 
spectrophotometrically at 570 nm with a 630 nm reference wavelength. Mitochondrial 
activity was normalized to solvent only controls and resulting percentages were graphed 
along the tested concentration range to construct a concentration–response curve. The half-
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maximal inhibitory effect (IC50) for each compound was subsequently 
established via linear interpolation of the curve. 
 
Alizarin Red S staining 
Attached cells were washed with 1X PBS and fixed with 4% paraformaldehyde in 
1× PBS and incubated at 4 °C for 1 h. Residual fixative was quenched via incubation with 
100 mM glycine for 15 min at room temperature. Samples were then washed three times 
in 1× PBS and once in dH2O. Fixed cells were then subjected to a 0.5% Alizarin Red S 
staining solution for 5 min. Following three washes with dH2O, subsequent washes were 
performed with ascending ethanol concentrations (i.e. 70%, 80%, 90%, and 100%). 
Cultures were kept in 100% ethanol for acquisition of images. 
 
Quantification of calcium deposition 
Cells were washed twice in 1× phosphate buffered saline (PBS) and lysed in a 
modified RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl 
sulfate in 1× PBS, pH 7.4). Each plate was incubated for 1 h at 4 °C with shaking to ensure 
complete cell lysis. Ca2+ concentration was measured against a set of standards using an 
Arsenazo III based spectrophotometric assay (Genzyme Diagnostics) at 650 nm as 
described [23]. The protein concentration in each sample was then measured against a set 
of standards using a Lowry spectrophotometric assay (Bio-Rad Laboratories) at 750 nm. 
Ca2+ content in each sample was then normalized to the respective protein concentration 
measured with the Bio-Rad DC protein assay reagent as described [23]. Calcium content 
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was normalized to solvent only controls and concentration-response curves charted. The 
half-maximal inhibitory dose (ID50) for each compound was taken from linear interpolation 
of the curve. 
 
Statistical analysis 
Data significance was decided using a web-based one-way ANOVA and Tukey 
HSD post hoc test (http://faculty.vassar.edu/lowry/anova1u.html) or unpaired Student's t-
test as appropriate. All results are represented as average of five independent 
replicates ± standard deviation. 
 
Results 
Osteogenic differentiation potential of marmoset ESCs 
ESCs from the marmoset, Callithrix jacchus, a New World monkey, have been 
previously derived [18], [24], [25] and been shown to be capable of producing osteoblasts 
that calcify their extracellular matrix [16]. Calcified extracellular matrices had been 
previously described as dark colored light-dense areas [26]. Those dark areas were 
observed in cultures from both mouse and marmoset ESCs via bright field microscopy on 
day 30 of osteogenic differentiation (Fig. 2.1A). Alizarin Red S staining of cultures 
confirmed the presence of calcified extracellular matrix in such dark areas. The overall 
amount of calcification between the marmoset and the mouse cells was comparable (Fig. 
2.1B). 
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Figure 2.1. Osteogenic differentiation ability in mouse and marmoset ESCs. (A) 
Brightfield images and Alizarin Red S staining identifying mineralized calcium. (B) 
Quantification of calcium deposit in osteogenic cultures determined with Arsenazo III, 
n = 3, five technical replicates each ± SD. p-value was established with a Student's t-
test. 
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Differential sensitivity of mouse and marmoset ESCs to lithium derivatives and controls 
Previous literature has suggested that lithium chloride, actively used in psychiatric 
pharmaceuticals, possesses the capacity for inducing skeletal teratogenicity [27]. In 
addition, our own research has suggested that lithium derivatives cause skeletal 
teratogenicity in certain concentration ranges [22]. To test the predictive aptitude of a non-
human primate-based EST for lithium derivatives, mouse and marmoset osteogenic ESC 
cultures were treated with lithium and aluminum compounds. Sodium chloride and lithium 
acetate served as a control for chloride in lithium chloride to ensure that observed effects 
were due to lithium activity. Sodium acetate was included as a control for acetate in lithium 
acetate. 
Lithium chloride treatment of mouse ESC osteogenic cultures did not result in the 
establishment of an ID50 value (Fig. 2.2). Instead, calcification was dose-dependently up-
regulated over control values in the absence of a cytotoxic effect. In contrast to mouse ESC 
cultures, LiCl induced a sharp drop in mitochondrial dehydrogenase activity, which is a 
routinely used and widely accepted test for cytotoxicity [3], [28], [29], in marmoset ESCs 
at a concentration of 100 µg/ml. LiCl-treated osteogenic marmoset ESC cultures also 
demonstrated a dose-dependent decrease in calcification as concentration increased with 
an ID50 at 0.4 ± 0.03 µg/ml, almost two orders of magnitude lower than the IC50. These 
results classify lithium chloride as teratogenic in marmoset, but not in mouse. 
Comparatively, murine osteogenic cultures treated with sodium chloride featured 
consistently elevated calcification levels with a 3-fold increase observed in the lowest 
tested concentration (Fig. 2.2B). No reduction in calcification was observed in any tested  
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concentration. Sodium chloride treated marmoset ESCs, in turn, displayed a half-maximal 
inhibitory dose at 790 ± 256 µg/ml. Sodium chloride-treated murine and marmoset 
osteogenic cultures followed relatively similar patterns of dose-dependent decreases in cell 
viability. In both cases, half maximal viability was approached, but not achieved within the 
test concentration range. The absent cytotoxicity coupled with a relatively high 
ID50 concentration qualified sodium chloride as non-cytotoxic and non-embryotoxic in 
neither species. 
Lithium acetate treatments resulted in a significant reduction in calcification at the 
highest tested concentration, while calcification levels remained above the 50% mark in 
marmoset ESCs for all concentrations tested (Fig. 2.3A and B). No decrease in cellular 
viability was noted upon exposure with this compound. In contrast, sodium acetate 
treatment induced a reduction in calcification at concentrations where viability was still 
around 100% (Fig. 2.3B). Although this effect was noted in both species, marmoset ESCs 
were more sensitive to sodium acetate than mouse ESCs. 
 
Common sensitivity of mouse and marmoset ESCs to aluminum and controls 
In order to further assess response variation between mouse and marmoset ESC 
osteogenic cultures, effects on calcification levels were also investigated in aluminum 
chloride, another compound actively used in certain classes of pharmaceuticals with known 
detrimental effects on the developing skeleton [30], [31], [32]. Cells were treated with 
aluminum hydroxide as a control for the chloride in aluminum chloride. In aluminum 
chloride- and aluminum hydroxide-treated mouse ESC cultures, a dose-dependent decrease  
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in calcification was observed with increasing concentration of the test compound (Fig. 2.4). 
A slightly steeper decrease in calcification was observed in aluminum hydroxide-treated 
cells. The similar response pattern between the aluminum chloride and hydroxide 
compounds infers that the observed teratogenic effect may be due to the presence of 
aluminum at those test concentrations. Comparable dose-dependent decreases in 
calcification were observed in marmoset ESC osteogenic cultures treated with aluminum 
chloride or hydroxide. However, calcification reduction in aluminum chloride-treated 
cultures was not as dramatic compared to osteogenic murine responses. 
The similarity between mouse and marmoset ESC responses to treatment with 
aluminum compounds as summarized in Table 2.1, suggests the potential for response 
overlap between species utilized for in vitro teratogenicity assessments. However, whether 
or not this overlap occurs may depend on the chemical in question. Lithium is chemically 
similar to aluminum and yet did not produce similar responses between mouse and 
marmoset ESC cultures following treatment with lithium compounds (Table 2.1). 
Therefore, observed variations in response may be due to variability in species sensitivity 
to particular compounds. 
 
Differential sensitivity to skeletal teratogens in ESCs from Old and New World monkeys 
Because of their close phylogenetic relationship with humans, primates share a 
large number of traits important in human reproduction. However, the reproductive biology 
of many small primates including Callithrix, is distinct from that of humans and Old World 
monkeys [33]. Because of the closer relationship between humans and Old World 
 42 
   
Fi
gu
re
 2
.4
. C
yt
ot
ox
ic
ity
 a
nd
 d
iff
er
en
tia
tio
n 
in
hi
bi
tio
n 
in
 a
lu
m
in
um
 tr
ea
te
d 
m
ou
se
 a
nd
 m
ar
m
os
et
 o
st
eo
ge
ni
c 
ES
C
 c
ul
tu
re
s. 
(A
) 
M
or
ph
ol
og
y 
on
 d
ay
 1
4 
of
 d
iff
er
en
tia
tio
n.
 (
B
) 
Va
lu
es
 m
ea
su
re
d 
fo
r 
ce
ll 
vi
ab
ili
ty
 a
nd
 c
al
ci
um
 d
ep
os
it 
w
er
e 
ch
ar
te
d 
in
 
pe
rc
en
t o
f 
th
e 
un
tre
at
ed
 c
on
tro
l. 
D
at
a 
is
 r
ep
re
se
nt
ed
 a
s 
m
ea
ns
 o
f 
si
x 
te
ch
ni
ca
l r
ep
lic
at
es
 o
f 
n 
= 
3 
± 
SD
. *
p 
< 
0.
05
 b
el
ow
 
un
tre
at
ed
 v
eh
ic
le
 c
on
tro
l, 
on
e-
w
ay
 A
N
O
VA
. 
C D
A B
co
nc
en
tr
at
io
n 
A
lO
H
3
[µ
g/
m
l]
co
nc
en
tr
at
io
n 
A
lO
H
3
[µ
g/
m
l]
Bone matrix mineral content
mouse ESC
[Ca2+ % non-treated]
Bone matrix mineral content
mouse ESC
[Ca2+ % non-treated]
Bone matrix mineral content
marmoset ESC
[Ca2+ % non-treated]
A
lC
l 3
A
lO
H
3
05010
0
15
0
20
0 0
.0
1
0.
1
1
10
10
0
10
00
0
5
0
1
0
0
1
5
0 0
.0
1
0
.1
1
1
0
1
0
0
1
0
0
0
0
5010
0 0
.0
1
0.
1
1
10
10
0
co
nc
en
tr
at
io
n 
A
lC
l 3
[µ
g/
m
l]
co
nc
en
tr
at
io
n 
A
lC
l 3
[µ
g/
m
l]
05010
0
15
0
20
0 0.
00
01
0.
01
1
05010
0
15
0 0.
00
01
0.
01
1
025507510
0
12
5 0.
00
01
0.
01
1
co
nc
en
tr
at
io
n 
A
lO
H
3
[µ
g/
m
l]
MTT mouse ESC
[% non-treated]
05010
0
15
0
20
0 co
nc
en
tr
at
io
n 
A
lO
H
3
[µ
g/
m
l]
MTT marmoset ESC
[% non-treated]
5010
0
15
0
15
0
10
0 50 0
Bone matrix mineral content
marmoset ESC
[Ca2+ % non-treated]
0.
01
0.
1
1
10
10
0
10
00
05010
0 0
.0
1
0.
1
1
10
10
0
MTT mouse ESC
[% non-treated]
MTT marmoset ESC
[% non-treated]
co
nc
en
tr
at
io
n 
A
lC
l 3
[µ
g/
m
l]
0.
00
01
1
0.
01
0
0.
00
01
1
0.
01
025507510
0
12
5 0.
00
01
0.
01
1
0.
01
0.
1
1
10
10
0
10
0 50 0
co
nc
en
tr
at
io
n 
A
lC
l 3
[µ
g/
m
l]
0.
1 
µg
/m
l
1 
µg
/m
l
10
 µ
g/
m
l
10
0 
µg
/m
l
0.
1 
µg
/m
l
1 
µg
/m
l
10
 µ
g/
m
l
10
0 
µg
/m
l
m
ou
se
m
ar
m
os
et
m
ou
se
m
ar
m
os
et
m
ou
se
m
ar
m
os
et
m
ou
se
m
ar
m
os
et
0.
1 
µg
/m
l
1 
µg
/m
l
10
 µ
g/
m
l
10
0 
µg
/m
l
0.
1 
µg
/m
l
1 
µg
/m
l
10
 µ
g/
m
l
10
0 
µg
/m
l
m
ou
se
m
ar
m
os
et
m
ou
se
m
ar
m
os
et
m
ou
se
m
ar
m
os
et
m
ou
se
m
ar
m
os
et
*
*
*
*
*
*
*
**
*
*
*
*
*
*
*
 43 
  
Table 2.1. Half-maximal inhibitory concentrations of osteogenic differentiation (ID50) 
and cell viability (IC50) for chloride and aluminum compounds determined with mouse 
and marmoset ESCs. 
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monkeys, we next investigated whether ESCs from the rhesus monkey, Macaca mulatta, 
showed similar responses to compounds as the marmoset ESCs. Rhesus ESCs are generally 
capable of responding to osteogenic triggers with enhanced matrix mineralization [17]. 
In order to compare the responsiveness of mouse, marmoset and rhesus ESCs to 
embryotoxic compounds, the embryotoxic potential of 5-fluorouracil (5-FU) and all-trans 
retinoic acid (atRA) in each species were compared against murine ESCs using the skeletal  
 EST protocol [34]. Both compounds were previously shown to act as strong skeletal 
teratogens in the mouse, both in vivo and in the EST [3], [6], [14], [35], 
[36], [37], [38], [39]. Penicillin G (PenG) was included as a non-embryotoxic 
compound [21]. Effects on differentiation were assessed via calcium deposition 
quantification assay while cell viability was again measured with the MTT assay. 
In 5-FU-treated cells, similar decreases in cell viability were observed in mouse, 
marmoset and rhesus ESC osteogenic cultures (Fig. 2.5A). However, the mouse ESCs were 
the most sensitive to the cytotoxic effects of this compound, while marmoset and rhesus 
ESCs were equally sensitive. Measured calcification patterns in mouse, marmoset and 
rhesus ESC osteogenic cultures all followed dose-dependent decreases in mineralization 
with increased 5-FU concentration. Compared to the mouse, the marmoset cells were more 
sensitive, but the rhesus cells were less sensitive (Fig. 2.5B and C). However, in both 
primate cells, the ID50was approximately two orders of magnitude lower that the IC50, 
indicating a strong teratogenic effect in both primate cell types. 
Exposure to atRA treatment again caused cytotoxicity at lower concentrations in 
mouse ESC cultures than in both primate cell cultures. However, both mouse and rhesus 
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ESC osteogenic cultures displayed a 2–2.5-fold increase in calcification at lower atRA 
concentrations, followed by a dose-dependent decrease in mineralization as concentration 
of atRA increased (Fig. 2.5A). Calcification levels in atRA-treated marmoset ESC 
osteogenic cultures resembled those of the untreated control at lower concentrations before 
gradually decreasing dose-dependently. Mouse ESC osteogenic cultures demonstrated the 
highest sensitivity as calcification at the highest tested concentration in the mouse ESC 
cultures was significantly lower than mineralization levels observed in marmoset and 
rhesus cultures at those same concentrations (Fig. 2.5B and C). 
According to its role as a non-embryotoxic agent, PenG induced cytotoxicity only 
at high test concentrations, but failed to cause inhibition of calcification in all species (Fig. 
2.5A–C). Results of this assay correctly identified 5-FU and atRA as strongly teratogenic 
compounds across the three species and PenG as non-teratogenic. 
Observed differences in primate cell viability and calcification at higher 
concentrations of 5-FU and atRA compared to the mouse ESC osteogenic cultures suggest 
that both marmoset and rhesus ESCs may be less sensitive than mouse ESCs to particular 
classes of cytotoxic compounds, while they are more sensitive toward embryotoxic effects 
of others, again underlining our results obtained with the lithium and aluminum derivatives. 
Thus, murine-based cytotoxicity and in vitro skeletal embryotoxicity assays may provide 
limited predictivity for extrapolation of results to other species. Though these results 
indicate that both marmoset and rhesus ESC osteogenic cultures are capable of assessing 
cytotoxicity and embryotoxicity, the lack of a defined pattern of variability between  
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Figure 2.5. Comparison of marmoset and rhesus ESCs for their sensitivity to skeletal 
embryotoxicants. (A) Juxtaposition of cell viability and mineralization measurements taken 
from osteogenic mouse, marmoset and rhesus ESC cultures treated with atRA, 5-FU and 
PenG. *p < 0.05 below untreated vehicle control, one-way ANOVA. (B) Table contrasting 
the resulting IC50 and ID50 values taken from the concentration-response curves. (C) Chart 
depicting the concentration difference between IC50 and ID50 for each species grouped by 
compound. The left cross on each line indicates the respective ID50 value, the right cross 
the IC50 value.  
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primate osteogenic cultures indicates that response of non-human primate ESCs may also 
vary between different compound classifications. 
Discussion 
Since its introduction and subsequent validation, the classic EST has been updated 
to include additional tissue and molecular endpoints. Such revisions have proven to be 
extremely useful in allowing for reductions in assay duration as well as providing 
embryotoxicity responses across tissue types. Skeletal toxicity evaluations in particular 
stand much to gain from recent improvements as musculoskeletal birth defects account for 
5% of all infant deaths. Previous work has demonstrated the capacity of the EST to identify 
inhibitory effects of toxicants on skeletal development based on the relationship between 
compound cytotoxicity as measured by reduction in mitochondrial dehydrogenase activity 
and inhibition of normal differentiation [6], [10]. 
In developmental toxicology, cytotoxicity of a chemical is often established with 
MTT assays and previous versions of stem cell based developmental toxicity assays also 
rely on this read-out measure [4], [40], [41]. However, strictly speaking the MTT assay is 
a measure for the mitochondrial activity of cells and is therefore only an indirect indicator 
of cytotoxicity. This could be of concern as mitochondrial activity in stem cells is different 
than in somatic cells. For instance, stem cells have a low number of mitochondria [42], 
which increases as cells differentiate concurrently with an increase in mitochondrial DNA 
content [43]. Future studies will need to compare different endpoints of cytotoxicity, such 
as apoptosis or proliferative capacity, for their predictivity in vitro, which is beginning to 
be done for other tissue endpoints [44]. 
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One of the main drawbacks of the murine based EST is that it provides a narrow 
mechanistic understanding of human development and response to toxicants. Yet, potential 
human sources of cells are either ethically unaccepted in some countries or have been 
suggested to be of flawed quality. For example, human induced pluripotent stem cells 
(hiPSCs) often exhibit varying differentiation potential, due to altered global methylation 
or transcript number of master regulators, which greatly affects their quality and 
usability [45], [46], [47] and seems dependent on the choice of reprogramming 
factors [48]. As such, a proposed solution has been to update the EST to feature non-human 
primate ESCs as a basis for embryotoxicity assessment. Here, we applied a marmoset ESC-
based EST in order to evaluate the efficacy of non-human primate ESCs in predicting 
potential negative side effects on the developing skeletal system. Our proof-of-concept 
results show that non-human primate ESCs and murine ESCs respond differently in 
embryotoxicity screens. 
Our preliminary comparison screen of murine and non-human primate ESC-based 
EST assessments indicated that non-human primate ESCs were more tolerant toward the 
toxic effects of 5-FU and atRA compared to murine ESCs. Thus, it is possible that EST 
embryotoxicity results could be affected by species-driven response variation. Such 
variations may be attributed to differences in mouse and non-human primate molecular and 
genomic response to test compounds. Similar species-based discrepancies attributed to 
variations in molecular and genomic response have been observed in other studies [49]. 
Discrepancies between the effects of trauma, burns, and exposure to endotoxemia on 
temporal gene response patterns and inflammation signaling pathways were noted between 
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mouse models and human patients. Though responses were similar among human subjects, 
comparison of mouse and human results showed poor correlation of responses between the 
two groups at the molecular and genomic levels. As all compounds function at the 
molecular and/or genomic level, these results call into question the extrapolation efficacy 
of mouse responses as predictors of response in humans [50], [51]. Given the evolutionary 
closeness between humans and non-human primates [52], it is probable that a mechanism 
of variation similar to that seen in the Seok et al. [49] study is operating in this study 
between the murine ESC and marmoset ESC cultures. 
Aluminum chloride assay results in murine and marmoset ESCs both demonstrated 
dose-dependent decreases in calcification. As decreases were observed in both AlCl3- and 
AlOH3-treated cultures, it is probable that Al3+ is responsible for the osteotoxic effects of 
AlCl3 exposure. Recent studies on aluminum osteotoxicity in infants have reported a strong 
connection between pre- and perinatal aluminum overexposure and metabolic bone 
diseases as well as potential long term consequences on bone health and development 
following exposure to aluminum compounds during critical periods of development [30]. 
At the molecular level, aluminum has been suggested to antagonize bone formation through 
activation of the oxidative-stress-mediated c-Jun N-terminal kinase signaling pathway and 
subsequent induction of apoptosis in osteoblasts [53]. 
Overall evaluation of cell viability and calcification assay results indicated that 
lithium chloride and its derivatives possess skeletal teratogenic capacity, though the 
potency of teratogenic effects may vary depending on the other members of the lithium 
compound complex. Treatment of marmoset ESC osteogenic cultures with both lithium 
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chloride and lithium acetate compounds demonstrated noteworthy, but species-specific 
decreases in calcification, which were absent in sodium chloride. In contrast, sodium 
acetate was teratogenic in both species. These results suggest lithium to not be the chief 
skeletal teratogenic component, but rather the combination with the complexed chemical 
that results in the detrimental outcome on differentiating osteoblasts. Additionally, varied 
response to lithium and sodium compound treatment between murine and marmoset ESC 
cultures suggests that species variation in embryotoxic assessments may yield a varied and 
potentially narrow scope of responses to the compounds under investigation. 
Within the cell, lithium chloride has been suggested to operate via inhibition of 
glycogen-synthase-kinase 3beta (GSK3β) to intensify canonical Wnt signaling, which 
ultimately encourages upregulation of genes required for osteogenic differentiation. 
Previous studies have reported dose-dependent bone defects incurred by disruption of the 
canonical Wnt signaling pathway with lithium chloride and support the dose dependent 
effects of lithium chloride treatment on mouse ESC cultures reported here [54], [55]. 
Conversely, marmoset ESCs were much more sensitive to the detrimental effects 
of lithium chloride. Although this may be largely due to increased cytotoxicity of lithium 
chloride at higher concentrations, the differentiation effect occurred at concentrations that 
were two orders of magnitude lower than the cytotoxic effect. Considering that other 
studies have reported variations between mouse and human response at the molecular level, 
it is likely that a similar explanation stands for the observed differences in lithium chloride 
response in this study. Lithium chloride is often included in embryotoxicity screens as a 
control compound in the class of the moderate embryotoxicants [21]. Intriguingly, the 
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classical EST has a low prediction value for the moderate embryotoxicants [56] and it 
stands to reason that this low predictivity in this specific class of teratogens stems at least 
partially from using a less predictive species such as the mouse instead of primate cells. 
Of concern are our findings on the differential sensitivity between marmoset and 
rhesus ESCs that exist even in the small set of chemicals tested here. Although the three 
control chemicals that were tested exhibited predictive effects, with 5-FU and atRA being 
teratogenic and PenG not, the actual half-maximal inhibitory doses varied substantially. It 
is thus evident that there may be significant general differences in the responses of different 
non-human primate cells to drugs and toxicants in a broader screen encompassing more 
chemicals as is typically done with mouse cells [6], [11]. However, our limited results 
already suggest that this existing dose discrepancy may make risk predictions for human 
use and the definition of adverse outcome doses difficult. For the reasons laid out in this 
manuscript, human embryonic stem cells, which are already beginning to be explored for 
such purpose [57], [58], [59], may provide the most accurate information regarding the 
teratogenic potential of chemicals and future studies will need to show whether the 
ethically accepted human induced pluripotent stem cells are also predictive in such assays. 
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CHAPTER 3 
 
Embryonic stem cell test revised: an evaluation of human induced pluripotent stem cells to 
test for cardiac developmental toxicity and comparison of differential embryotoxicity 
 
Lauren M. Walker, Nicole RL Sparks, Veronica Puig-Sanvicens, Beatriz Rodrigues, 
Nicole I. zur Nieden 
 
Abstract 
 Traditional embryotoxicity approaches are challenged by low throughput and 
species-species variation risks. The validated embryonic stem cell test (EST) developed in 
murine embryonic stem cells (mESCs) addressed the former problem over 10 years ago. 
Here, we address biological relevance by updating the EST protocol with human induced 
pluripotent stem cells (hiPSC). hiPSC-EST embryotoxicity screens with 5-flurouracil and 
all-trans retinoic acid inhibited cardiac differentiation at lower concentrations than in the 
mESC-EST, yielding accurate and more sensitive embryotoxicity classifications. The 
hiPSC-EST was also responsive to complex toxicants, represented here by cigarette smoke 
and smokeless Snus tobacco extract. Tobacco treatment inhibited cardiac differentiation at 
sub-cytotoxic doses.  Expression of early cardiac marker Tbx5 yielded toxicity patterns like 
those observed in the full-length hiPSC-EST. Together, the presented findings support the 
use of hiPSCs and early molecular endpoints in the EST as a higher throughput, 
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biologically relevant embryotoxicity screening approach for individual chemicals and 
mixtures. 
 
Introduction  
The mammalian developmental stage is a sensitive and highly-regulated period of 
life. During this time, developing mammalian organisms are subject to many complex 
processes that are critical for proper formation. As such, exposure to some chemicals, 
pharmaceuticals, or other agents during particular pregnancy windows could result in 
adverse developmental outcomes such as growth retardation, structural and/or functional 
abnormalities, and/or embryo lethality. Current regulations require commercially available 
industrial chemicals and pharmaceutical products to be evaluated for developmental 
repercussions [1,2].  For instance, industrial chemicals are subject to in vivo reproductive 
and developmental screening tests as outlined by the Organisation for Economic Co-
operation and Development (OECD) [3-8]. These screening approaches evaluate adverse 
pregnancy outcomes in relation to maternal toxicity to determine the overall embryotoxic 
specificity of the agent, if any. While traditional in vivo screening approaches offer a wealth 
of information regarding the developmental toxicity of an agent, exclusively animal-based 
screens are time-consuming, low throughput, expensive, and require a large number of 
animals to complete statistical evaluations. In recent decades, in vitro screening approaches 
have been sought as higher throughput alternatives to animal-based screens. 
Early iterations of in vitro developmental toxicity assays employed a variety of cell 
and tissue cultures, including primary embryonic cell cultures and whole mammalian 
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embryos to determine general embryotoxicity and specific malformations, respectively [9]. 
Discovering the capacity of mouse blastocyst-derived pluripotent embryonic stem cells 
(ESCs) to be established and maintained in culture [10], however, revolutionized in vitro 
toxicity screening approaches. Given their unspecialized nature, pluripotent ESCs can 
recapitulate key steps of the developmental process in vitro through directed differentiation 
into particular cell types. To date, numerous differentiation protocols using pluripotent 
ESCs have been reported to recapitulate a variety of processes including myogenesis, 
hematopoiesis, and osteogenesis [11-13]. The original embryonic stem cell test (EST) 
capitalizes on this ability by using differentiating mouse ESC cultures to evaluate the 
embryotoxicity of an agent without the requirement for routine animal sacrifice [14].  Here, 
mouse D3 ESCs are differentiated into contracting cardiac muscle cells and simultaneously 
exposed to the agent under evaluation. Differentiation inhibition imparted by the agent is 
determined by a reduction in active contractile clusters and is also compared to the 
cytotoxic impact on the ESCs to determine if an agent is predominantly embryotoxic (i.e., 
birth defect-inducing) or cytotoxic. Effects on ESCs are also compared to differentiated 
3T3 fibroblast cells to determine embryotoxic specificity. Here, 3T3 fibroblasts are 
included to mimic maternal tissues and identify maternal toxicity that could influence 
embryotoxicity outcomes. Results from all three endpoints are ultimately entered into a 
biostatistical prediction model developed by the ZEBET unit of The Federal Institute for 
Risk Assessment (Germany) to determine and rank the embryotoxicity of the agent as non-
embryotoxic, weakly embryotoxic, or strongly embryotoxic [15-16].  
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While the mouse EST prediction model approach was successfully validated by the 
European Center for the Validation of Alternative Methods (ECVAM) for in vitro 
embryotoxicity screens [15-16], it is limited by the possibility of species-species variation 
in response to particular agents. This, in turn, presents the risk of false negative results.  
Our group previously reported an in vitro study that assessed the sensitivity of non-
human primate and mouse-derived ESC lines in determining chemical embryotoxicity 
[17]. Notably, non-human primate ESCs showed differential sensitivity to assorted classes 
of compounds compared to mouse ESCs. Our results highlighted the analytical limitations 
introduced by species variation and highlight the need for robust methods that are as 
biologically relevant as possible to humans. 
The establishment of human pluripotent cell lines offers a biologically relevant 
alternative to the traditional mouse D3 line. Particularly promising are human induced 
pluripotent stem cells (hiPSCs) as such lines can be induced to differentiate like ESCs, 
without the potential ethical or legislative challenges presented by routine use of human 
ESC lines. hiPSCs are already routinely used as in vitro models of human cardiotoxicity 
and disease [18-19], though reported use of hiPSCs in the EST protocol for screening 
potential real-world toxicants is limited.  
In this study, we evaluate the sensitivity of hiPSCs in the EST prediction model 
against the traditional mESC-based EST using the traditional contractile assay and cell 
viability parameters. Moreover, we report the promise of using early molecular markers to 
increase assay throughput without reducing sensitivity and test our hiPSC-EST protocol in 
a proof-of-concept embryotoxicity screen. 
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Materials and Methods  
Culture of human induced pluripotent stem cells (hiPSCs) 
The hiPSC cell line Riv9 was obtained from the Stem Cell Core at the University 
of California, Riverside. hiPSCs were seeded on Matrigel (Corning)-coated tissue culture 
plates and maintained in a pluripotent state in mTeSR® medium (Stem Cell Technologies). 
Cells were cultured under a humidified atmosphere of 5% CO2 at 37⁰C, and passaged for 
maintenance or to seed for experiments approximately every 5 days as previously described 
[20-21]. 
 
Cardiac Differentiation of hiPSCs 
After cells reached 70% confluency (designated day 0), media was changed to 
control differentiation media supplemented with 0.06 mg/ml ascorbic acid (Sigma) to 
induce cardiac differentiation (Puig-Sanvicens et al., 2015). Control differentiation media 
was comprised of: Dulbecco’s modification of Eagle’s medium (DMEM with 4.5 g/L 
glucose, L-glutamine and sodium pyruvate; Corning cellgro) supplemented with 18% FBS 
(PAA), 0.8% penicillin/streptomycin (10,000 units/10,000 units, Gibco), 0.12% non-
essential amino acids (NEAA; Gibco), 0.1 mM β-mercaptoethanol (Gibco). Cultures were 
cultured in differentiation media for 25 days, starting from day 0. 
 
Culture of human foreskin fibroblasts (hFFs) 
Human foreskin fibroblasts were gifted from Dr. Derrick Rancourt (University of 
Calgary). hFFs were seeded onto 0.1% gelatin-coated tissue culture plates and maintained 
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in Dulbecco’s modification of Eagle’s medium (DMEM with 4.5 g/L glucose, L-glutamine 
and sodium pyruvate; Corning cellgro) supplemented with 10% FBS (Atlanta Biologicals) 
and 0.5% penicillin/streptomycin (10,000 units/10,000 units, Gibco). 
 
Immunocytochemistry 
hiPSC-derived cardiomyocytes were washed with sterile commercially available 
1x PBS (Gibco), and fixed with 4% paraformaldehyde (Sigma) 4°C for 30 minutes. Fixed 
cultures were then washed three times with 1x PBS for 5 min. Cell membranes were 
permeabilized with 0.1% Triton X-100 in 1x PBS (Fisher Scientific) for 15 min at room 
temperature before being washed three more times with 1x PBS for 5 min. Cultures were 
incubated in a blocking solution of 10% fetal bovine serum (PAA) and 0.5% bovine serum 
albumin (Fisher Scientific, BP1600-100) in 1x PBS for 1 h at room temperature. Primary 
antibodies against mouse anti-Myosin Heavy Chain (MHC, abcam, ab15, 1:500) and/or 
rabbit anti-Troponin I (Trop I, Santa Cruz, sc-15368, 1:200) were added directly to the 
blocking buffer solution following the initial blocking period and allowed to incubate 
overnight at 4°C. Cultures were washed with 1x PBS three times for 5 min prior to 
secondary antibody incubation. Cells were incubated with 20 µg/ml DAPI (4’-6-
Diamidino-2- Phenylindole, Sigma, D9542), anti-mouse 546 conjugated florescent 
antibody (ThermoFisher, A10036) and/or anti-rabbit 488 conjugated fluorescent antibodies 
(ThermoFisher, A21206) for 2 h at room temperature. Cells were washed three times in 1x 
PBS to remove background from non-specific secondary antibody binding prior to imaging 
on a Nikon Eclipse Ti inverted fluorescence microscope. 
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Preparation of 5-fluorouracil, retinoic acid, and penicillin G solutions 
5-flurorouracil (5-FU), all-trans retinoic acid (atRA), and penicillin G (PenG) were 
selected from a subset of chemicals used in the original EST validation study [22-23]. 5-
FU and atRA were selected as positive test compounds due to their established 
embryotoxic potential while PenG was used as a negative control. All chemicals were 
purchased from Sigma. Stock solutions were prepared in DMSO and filtered through a 0.2 
micron Acrodisc® PSF Syringe Filter (Pall Corporation, Port Washington, NY), aliquoted 
into sterile microcentrifuge tubes and stored at -20°C until use. Test chemicals were serially 
diluted to final concentrations in differentiation media. atRA concentrations (µg/ml): 100, 
1, 10-2, 10-3, 10-6, and 10-8. 5-FU concentrations (µg/ml): 10-2, 10-3, 10-4, 10-5, and 10-6. 
PenG concentrations (µg/ml): 600, 700, 800, 900, 1000. Cardiogenic cultures were treated 
with designated chemicals through day 25 of differentiation and hFF cultures were treated 
with each compound for a 25-day duration period. Compounds were replenished with each 
media change. 
 
Preparation of Marlboro Red tobacco smoke extract 
A University of Kentucky smoking machine was used to produce smoke extract 
solutions from commercially available conventional Marlboro Red 100 brand cigarettes as 
previously described [24-25]. The smoking machine took a 2.2 second puff of mainstream 
(MS) smoke every minute. Smoke solution concentrations were made in puff equivalents 
(PE), which are the number of cigarette puffs dissolved in 1 ml of medium. MS smoke 
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solutions were produced by pulling 30 puffs of MS smoke through 10 ml of DMEM. 
Resulting 3 PE smoke extracts were filtered through a 0.2 micron Acrodisc® PSF Syringe 
Filter (Pall Corporation, Port Washington, NY), aliquoted into sterile microcentrifuge 
tubes, and stored at -80°C until use. Serial dilutions were performed in differentiation 
medium to reach desired final exposure concentrations: 1 PE, 0.3 PE, 0.1 PE, 0.03 PE, 0.01 
PE, 0.003 PE, and 0.001 PE.  Cardiogenic cultures were treated with smoke solutions 
through 25 days of differentiation. Smoke solutions were replenished with each media 
change. 
 
Preparation of Camel Snus smokeless tobacco extract 
A 10% (w/v) Camel Snus extract was prepared as previously described [25]. Ten 
grams of Snus was added to 85 ml of DMEM and allowed to incubate at 37°C for 2 hours. 
This initial extract solution was centrifuged for 10 min at 4500×g. Supernatant from the 
first round of centrifugation was then centrifuged again at 13,000×g for 1 hour. The 
resulting supernatant was collected and pH adjusted to 7.4. 15 ml of FBS was added to the 
pH-adjusted Snus extract to produce a 10% stock solution of Snus tobacco extract (STE).  
The stock solution was then sterile-filtered with a 0.22 µm vacuum filter system. STE was 
aliquoted into sterile microcentrifuge tubes and stored at -80°C until use. Serial dilutions 
were performed in differentiation medium to reach desired final exposure concentrations 
of 0.001%, 0.01%, 0.1%, 1%, 3%, and 5%. Cardiogenic cultures were treated with STE 
through 25 days of differentiation. STE was replenished with each media change. 
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Cardiac viability assay 
Cardiomyocyte survival following concurrent exposure to each compound was 
evaluated by -[4,5-dimethylthiazol-2-yl]-2,5-diphenylterazolium bromide (MTT) assay. 
On day 25 of differentiation, cells were incubated with MTT (5 mg/ml) for 2 h at 37°C. 
MTT supernatant was removed and replaced with a desorb solution of 0.7% SDS in 2-
propanol. The absorbance of the solution was measured at 570 nm in an iMark™ 
microplate reader (Bio-Rad) with 655 nm as a reference wavelength. Here, mitochondrial 
dehydrogenase activity on the MTT in solution is directly proportional to a blue-purple 
product that is detected at 570 nm. Hence, a decrease in absorbance is interpreted as a direct 
measurement of any reduction in the number of viable cells [17, 25-27]. 
 
Cardiac contractile assay 
Contractile cardiac clusters and individual contractile, or “beating”, cells were 
counted and recorded on days 15, 20, and 25 of differentiation as previously described [28].  
Individual beating cells and beating cell clusters were cumulatively quantified between 
measurement time points. Untreated control cells served as a baseline for normal 
contractile incidence for each differentiation. Changes in beating incidence between 
treatment groups and days were reported as a percentage of beating incidence in solvent 
controls. 
 
Real-time Quantitative PCR (qPCR) 
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RNA was extracted using the protocol from NucleoSpin RNA II kit (Macherey 
Nagel). Quantification of RNA was determined by NanoDrop® 1000 spectrophotometer 
(Thermo Scientific) at 260 nm. 25 ng of total RNA was used as a template for cDNA 
synthesis with a mastermix including 5 µL 5x reaction buffer, 1.25 µL 10mM dNTPs, 1.25 
µL 400 U/µL RNase inhibitor, 0.1 µL 200 U/µL reverse transcriptase, 0.1 µL 3 µg/µL 
random primer, and 1.5 µL DEPC H2O for a total of 25 µL per reaction. 25 ng cDNA 
transcripts were used for quantitative polymerase chain reaction (qPCR) SYBR green 
technology on the MyiQ cycler (Bio-Rad). The reactions were setup for 10 minutes of 
denaturing at 94°C (initial), followed by 40 cycles of denaturing at 94°C, and annealing at 
60°C each 45 seconds. The n-fold expression in target samples was calculated with the 
ΔΔCT method by standardizing Ct values to GAPDH expression [29]. Primer sequences 
for human GAPDH were 5’-GAGTCAACGGATTTGGTCGT-3’ and 5’-
TTGATTTTGGAGGGATCTCG-3’. Target genes were cardiogenic markers TBX5 and 
MEF2c. Primer sequences for human TBX5 were 5’- CTGGACACCCCTAAACTGGA-3’ 
and 5’- TCCCACAGAGCTGAACTCCT-3’ and primer sequences for human MEF2c 
were 5’- CCATTGGACTCACCAGACCT-3’ and 5’- AGCACACACACACACTGCAA-
3’ [30]. 
 
Statistical Analysis 
Half-maximal inhibitory compound doses of differentiation (ID50) and cytotoxicity 
(IC50) were determined from concentration-response curves. ID50 and IC50 values were used 
to classify chemical embryotoxicity via a biostatistical prediction model developed 
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specifically and reported previously for the EST protocol [14-16]. The lowest 
concentrations at which cardiac contractile function or cell viability registered below that 
of the untreated control were also identified with one-way analysis of variance (ANOVA) 
statistical analysis and a subsequent post hoc test as appropriate. P-values below 0.05 were 
considered significant. 
 
Results 
hiPSCs efficiently differentiate into cardiomyocytes 
Prior to testing the efficacy of the hiPSC-based EST, Riv9 hiPSC cultures were 
evaluated for their cardiac differentiation potential and efficiency following a 25-day 
differentiation protocol (Fig. 3.1A). Successful differentiation into cardiomyocytes was 
visually confirmed with the generation of active contractile clusters on days 20 and 25 of 
differentiation. The cardiac identity of these clusters was confirmed molecularly via mature 
cardiomyocyte markers. Immunocytochemistry stains of differentiated cell cultures on day 
25 revealed positive staining for myosin heavy chain (MHC) and Troponin I (Trop I) in 
contractile clusters (Fig. 3.1B). Moreover, RT-PCR analysis of cardiac-specific 
transcription factors at differentiation day 10 showed a significant upregulation of TBX5 
and MEF2c in hiPSC cultures induced to a cardiac cell fate (Fig. 3.1C). Together, these 
results indicated that Riv9 hiPSCs successfully and efficiently differentiate into 
cardiomyocytes under the appropriate culture conditions. 
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Figure. 3.1. hiPSCs consistently and robustly differentiated into cardiomyocytes. 
Differentiated cardiomyocytes were assessed for cardiomyocyte-specific markers and 
gene expression. A) Schematic protocol for cardiomyocyte differentiation and 
embryotoxicity screen. B) Immunocytochemistry stains of differentiated cultures 
confirmed cardiomyocyte identity via myosin heavy chain (MHC) and Troponin I (Trop 
I). C) Differentiated cardiomyocytes expressed cardiac-specific genes TBX5 and MEF2c 
as measured by qPCR. hiPSC, human induced pluripotent stem cell; MHC, myosin heavy 
chain; Trop I, Troponin I. 
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The hiPSC-based EST is more sensitive to embryotoxic compounds than the mESC-based 
EST  
To evaluate the sensitivity of hiPSCs in the validated EST protocol, cardiogenic 
differentiation was induced in hiPSC cultures with concurrent treatment of one of the 
following compounds of known toxicity or nontoxicity in humans: PenG (non-toxic), 5-
FU (cytotoxic) and atRA (embryotoxic). Over the course of the differentiation, hiPSC-
derived cardiomyocytes were then subjected to visual quantitation of active contractile 
cells and clusters on days 15, 20, and 25. At the conclusion of the differentiation, cultures 
were also evaluated for changes in cell viability. 
While no actively contracting cells or clusters were observed on day 15 of 
differentiation for any treatment group, differences in contraction incidence were readily 
observed between days 20 and 25 of differentiation for 5-FU- and atRA-treated cultures 
compared to the untreated control. 5-FU exposure negatively impacted the formation of 
contractile structures at concentrations above 1 x 10-6 µg/ml (Fig. 3.2A) by day 20 and 
returned a half-maximal inhibitory dose (ID50) for differentiation of 2.7 x10-6 µg/ml on day 
25 (Fig. 3.2B). atRA-treated cells failed to form contractile clusters or cells at 
concentrations above 1 x 10-3 µg/ml (Fig. 3.2A), and exhibited significantly reduced 
contractile activity in doses above 1 x 10-8 µg/ml (Fig. 3.2B). The resulting ID50 value for 
atRA on day 25 was 1.65 x 10-7 µg/ml. Treatment with PenG did not inhibit the formation 
of contractile structures (Fig. 3.2A) and did not negatively impact contractile activity at 
most of the tested concentrations (Fig. 3.2B). Dips in contractile incidence were observed 
at 800 µg/ml and 900 µg/ml doses, though these reductions were not statistically  
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Figure. 3.2. Treatment with embryotoxicants 5-FU and atRA impeded cardiomyocyte 
differentiation. hiPSCs were treated with different concentrations of 5-FU, atRA, or 
PenG and evaluated for differentiation inhibition by visually scoring the number of 
actively contracting cardiomyocyte clusters. A) Contractile cardiomyocyte clusters. B) 
Contractile cardiomyocyte cluster screens for 5-FU, atRA, and PenG. Each data point 
represents the mean of three independent experiments ± standard deviation. *P<0.05 = 
the lowest concentration significantly below the untreated control group as determined 
by One-Way ANOVA. hiPSC, human induced pluripotent stem cell; 5-FU, 5-
fluorouracil; atRA, all-trans retinoic acid; PenG, penicillin G. 
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significant. Furthermore, contractile activity at 700 µg/ml and 1000 µg/ml were similar 
despite the difference in dosage which suggests that the dips seen at 800 µg/ml and 900 
µg/ml are likely anomalies. Because dosages above 1000 µg/ml are not physiologically 
relevant, validated EST protocol does not test compounds above a dose of 1000 µg/ml. As 
follows, an ID50 value was not determined for PenG. 
 Cell viability assessments did not find reduced cell survival in PenG-treated 
cultures at the conclusion of differentiation (Fig. 3.3A). 5-FU treatment, however, 
produced significant reductions in cell viability at concentrations above 1 x 10-6 µg/ml (Fig. 
3.3A) and returned a half-maximal inhibitory concentration for cell viability (IC50) of 4.7 
x10-5 µg/ml. Because 5-FU-driven reductions in cell viability were observed around the 
same doses at which contractile activity was inhibited, these results together suggest that 
the inhibitory impact of 5-FU primarily driven by cytotoxic activity rather than teratogenic. 
atRA-treated cultures only displaced reductions in cell viability at the highest tested 
concentrations of 1 and 100 µg/ml (Fig. 3.3A). Unlike 5-FU, atRA-driven inhibition of 
differentiation occurred at much lower concentrations than where cytotoxicity was 
observed. This outcome indicates that atRA operates predominantly through a teratogenic 
mechanism that inhibits differentiation without conveying outright cytotoxicity. The IC50 
value for atRA was 3 µg/ml. 
 The impact of the tested compounds in differentiating hiPSCs was also compared 
against treatment of differentiated hFF cells to determine embryotoxic specificity. Both 5-
FU- and atRA-treated hFF cells demonstrated a dose-dependent reduction in cell viability. 
Significant reductions were observed for 5-FU and atRA above concentrations of 1 x 10-4  
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Figure 3.3. 5-FU and atRA treatment reduced hiPSC-cardiomyocyte and hFF viability 
in a dose-dependent manner as assessed via MTT assay. A) hiPSC viability screens for 
5-FU, atRA, and PenG, n=3 ± SD. *P<0.05 = the lowest concentration significantly 
below the untreated hiPSC control group as determined by One-Way ANOVA. B) hFF 
viability screens for 5-FU, atRA, and PenG, n=3 ± SD. *P<0.05 = the lowest 
concentration significantly below the untreated hFF control group as determined by 
One-Way ANOVA. hiPSC, human induced pluripotent stem cell; MTT, mitochondrial 
dehydrogenase activity assay; 5-FU, 5-fluorouracil; atRA, all-trans retinoic acid; PenG, 
penicillin G; hFF, human foreskin fibroblast. 
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µg/ml and 0.01 µg/ml, respectively. Dosing hFF cultures with 5-FU returned an IC50 value 
of 4 x 10-4 µg/ml, which was larger than the IC50 value produced by hiPSC-cardiomyocyte 
evaluations. Observed differential outcomes in hFF and hiPSC-cardiomyocyte cultures 
exposed to 5-FU support the notion that developing cells (as represented by hiPSC-
cardiomyocytes) are more sensitive to cytotoxicants than terminally differentiated cells. 
hFF cells treated with atRA experienced significant cell death at the highest tested 
concentration of 1 µg/ml. atRA-dosed hFFs produced an IC50 value of 0.045 µg/ml, which 
was lower than the IC50 value found in the hiPSC-cardiomyocyte assessment. Here, hFFs 
may possess differences in cellular metabolic functions that may encourage a slightly 
higher sensitivity to the cytotoxic impact of atRA. PenG-treated hFF cultures did not 
display a reduction in cell viability at any tested concentration.  
To classify compounds under evaluation, the validated EST applies a 
biostatistically based prediction model to classify compounds as non-embryotoxic, weakly 
embryotoxic, or strongly embryotoxic based on differentiation and cell viability assay 
outcomes. The prediction model uses a series of equations to perform a linear discriminant 
analysis using determined IC50 and ID50 values determined from dose-response curves [31]. 
Using this model with the results of the hiPSC-EST resulted in the accurate classification 
of PenG as non-embryotoxic and 5-FU and atRA as embryotoxic (Table 3.1). More 
specifically, 5-FU was classified as strongly embryotoxic while atRA was classified as 
weakly embryotoxic. Comparing our findings to that of the mESC-based EST [32] (Table 
3.1) revealed the hiPSC-based EST to be a more sensitive method of identifying 
compounds that inhibit differentiation, based on the chemicals tested. Notably, the mESC-   
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Cell Type Toxicity Parameter Penicillin G 5-Flurouracil
all-trans
Retinoic acid
mESCs1
ID50 (µg/ml) > 1000 5.5 x 10-2 3.1 x 10-4
IC50 (µg/ml) > 1000 4.7 x 10-2 1.25 x 10-3
3T3 IC50 (µg/ml) 695 0.25 13.5
hiPSCs
ID50 (µg/ml) > 1000 2.7 x 10-6 1.65 x 10-7
IC50 (µg/ml) > 1000 4.7 x 10-5 3
hFF IC50 (µg/ml) > 1000 4 x 10-4 4.5 x 10-2
mESC Biostatistical
Embryotoxicity Classification
Not
embryotoxic
Weakly 
embryotoxic
Weakly 
embryotoxic
hiPSC (Day 25) Biostatistical
Embryotoxicity Classification
Not
embryotoxic
Strongly 
embryotoxic
Weakly 
embryotoxic
Table 3.1. Comparison of mESC- and hiPSC-EST IC50 and ID50 values and 
embryotoxicity classifications. mESC-EST conclusions were pulled from previously 
published data [32]. Inhibition of differentiation (ID50) was determined from dose-
response curves as 50% inhibition of functional cardiomyocytes in the control. 
Inhibition of cell viability (IC50) was determined from dose-response curves as 50% 
inhibition of viable cells in control cultures. hiPSC-EST correctly classified all-trans 
retinoic acid and 5-flurouracil as embryotoxic. mESC, murine embryonic stem cell; 
hiPSC, human induced pluripotent stem cell; EST, embryonic stem cell test. 
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EST classified both 5-FU and atRA as weakly embryotoxic. Higher ID50 values and 3T3 
mouse fibroblast IC50 values observed in the mESC-EST suggest some resistance to the 
toxic effects of both chemicals in mESC and 3T3 cultures, respectively. While hiPSC-
derived cardiomyocytes were more susceptible to 5-FU-driven cytotoxicity compared to 
mESC-derived cardiomyocytes, mESC-derived cardiomyocytes were more sensitive to 
atRA-driven cytotoxicity. hFF response was also found to be more sensitive than 3T3 cell 
viability outcomes, with lower IC50 values yielded from 5-FU and atRA treatment.  
Compared to the mESC-based EST, the hiPSC-based EST showed a higher 
capacity to discern between a strong embryotoxicant (due to the strong cytotoxic nature of 
5-FU) and a weak embryotoxicant (due to the differentiation inhibition in the absence of a 
strong cytotoxic response).  
 
hiPSC-EST models embryotoxicity of environmental toxicant mixtures 
Given their well-reported embryotoxicity, 5-FU and atRA were selectively tested 
in aforementioned comparison studies between the mESC-based and hiPSC-based EST 
assays. To test how well the hiPSC-based EST evaluated real-world embryotoxicants, the 
assay was used to classify two different types of tobacco products: conventional cigarette 
smoke (Marlboro Red 100) and Snus smokeless tobacco (Camel Snus). Tobacco was 
selected as a model embryotoxicant as maternal smoking has previously been linked to a 
suite of negative effects on fetal development including low birth weight, congenital heart 
defects, and negative impact on bone growth and bone mass [33]. Frequently advertised as 
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a harm-reducing alternative to cigarettes, Snus smokeless tobacco has also been linked to 
impaired embryonic development following use during pregnancy [33-36].  
 Contractile assays found dose-dependent reductions in the formation of active 
contractile clusters and structures for both Marlboro Red 100 mainstream (MS) smoke (Fig. 
3.4A) and Camel Snus (Fig. 3.4B) extract. Contractile assay dose-response curves returned 
ID50 values for 0.014 puff equivalent (PE) and 0.0054% w/v Camel Snus Extract. The 
viability of differentiating hiPSCs during concurrent tobacco exposure was not negatively 
impacted by either product in the tested concentration ranges. Viability of hFF cultures 
exposed to Marlboro Red 100 MS smoke and Camel Snus extract was reduced in a dose-
dependent manner. An IC50 value for Marlboro Red exposed hFF cultures was not 
determined within the dose range under evaluation, but was expected to occur at a dose 
above 0.1 PE. Camel Snus hFF exposure returned an IC50 value of 0.022% extract. Because 
hiPSCs failed to develop cardiomyocyte structures at sub-cytotoxic concentrations (Table 
3.2) with regard to both hiPSC and hFF MTT outcomes, these results collectively suggest 
that both products have embryotoxic characteristics.   
 
hiPSC-EST yields accurate early toxicity classifications based on TBX5 mRNA expression 
One of the main critiques of traditional whole animal developmental toxicity assays 
is the length of time it takes to complete toxicity evaluations. With the average gestation 
period for laboratory mice ranging from 18.5 to 21 days, the process of collection and 
evaluating pups is encumbered by slow throughput and variability due to subjective scoring 
methods.  As such, a shorter, quantifiable, and accurate in vitro embryotoxicity assessment  
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Toxicity Parameter Marlboro Red 100 MS (PE)
Camel Snus 
(%)
hiPSC  IC50 >0.1 >1%
hiPSC ID50 0.014 ± 0.0047 0.0054%
hFF IC50 >0.1 0.022 %
Table 3.2. List of IC50 and ID50 values determined from concentration-response 
curves for mainstream cigarette smoke and Snus smokeless tobacco. hiPSC, 
human induced pluripotent stem cell; hFF, human foreskin fibroblast. 
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approach could improve throughput without sacrificing accuracy. Given the accurate 
predictions of our full length hiPSC-based EST, we next investigated if our approach could 
be modified with an earlier, qPCR-based endpoint to determine differentiation inhibition. 
Here we selected two cardiogenesis-specific transcription factors, TBX5 and MEF2c [37- 
39], to determine if the adverse differentiation outcomes on day 25 of differentiation would 
be detectable as changes in TBX5 and MEF2c expression on day 10 of differentiation. 
Similar to the pattern observed in the contractile cluster assay, 5-FU-treated 
cultures demonstrated a dose-dependent reduction in TBX5 mRNA expression with an ID50 
value of 5 x 10-4 µg/ml (Fig. 3.4). However, d10 TBX5 mRNA expression was more 
dramatically reduced at concentrations above 1 x 10-4 µg/ml, compared to the lower dose 
of 1 x 10-6 µg/ml observed in the contractile assay. It is possible, however, that our d10 
analysis timepoint captured the beginnings of the full apoptotic response that were able to 
be fully manifested and observed in cultures on d25 of differentiation. It follows, then, that  
embryotoxicants would be the most detectable at d10 of differentiation in stronger 
concentrations with middle range doses producing a more moderate response.  
Cells exposed to atRA also showed a dose-dependent downregulation of TBX5 
mRNA expression. In these cultures, tested concentrations above 1 x 10-6 µg/ml featured 
significantly downregulated TBX5 and produced an ID50 value of 1.5 x 10-3 µg/ml (Fig. 
3.5). atRA treatment at 1 x 10-6 and 10-8 µg/ml yielded a significant upregulation in TBX5 
mRNA expression. This upregulation correlates with the almost 2-fold increase in 
contractile cluster incidence seen in cultures treated with 1 x 10-8 µg/ml atRA (Fig. 3.2B). 
As retinoic acid is a well-reported regulator of TBX5 expression in developing tissues, it is 
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possible that exposure of differentiating hiPSCs to low levels of atRA exposure may have 
encouraged TBX5 mRNA expression [99], while atRA exposure above a particular 
threshold elicited an embryotoxic response. While the response pattern in TBX5 mRNA 
expression mirrored that which was observed in the contractile assay, differentiation 
inhibition was more readily detected at mid- and high range concentrations compared to 
the lower concentrations seen with the contractile assay. Here, as with the 5-FU-treated 
cultures, it is possible that the early inhibitory impact of atRA at d10 of differentiation is 
readily observed via qPCR in middle and high concentration ranges. Lower ranges, 
however, may be better detected at a later timepoint. Treatment with the negative control 
PenG did not significantly impact TBX5 mRNA expression (Fig. 3.5).  
In contrast to expression patterns observed with TBX5 mRNA, MEF2c mRNA 
expression yielded inconsistent responses to compound treatment. No reductions in MEF2c 
mRNA expression were observed for any 5-FU-treated group compared to the untreated 
control (Fig. 3.5) and thus no ID50 value could be determined.   In cells dosed with atRA, 
however, MEF2c mRNA transcripts were dose-dependently downregulated in 
differentiating cardiomyocytes (Fig. 3.5). Here, a steady decline in MEF2c mRNA 
expression was observed at doses above 1 x 10-3 µg/ml with a final ID50 of 4 x10-2 µg/ml. 
MEF2c mRNA expression in cells dosed with PenG remained largely unchanged from that 
of the untreated control, though slight upregulation was observed at 800 and 900 µg/ml. 
Given the lack of altered MEF2c mRNA expression in cultures exposed to cytotoxic 5-FU 
compared to atRA, it is likely that MEF2c is an inconsistent indicator of early  
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Figure 3.5. Treatment with embryotoxicants 5-FU and atRA impeded cardiomyocyte 
differentiation as measured by day 10 TBX5 gene expression in hiPSCs. hiPSCs were 
treated with different concentrations of 5-FU, atRA, or PenG and evaluated for TBX5 
or MEF2c expression via qPCR. Inhibition of differentiation (ID50) was determined 
from dose-response curves as 50% reduction of gene expression in the control. hiPSC, 
human induced pluripotent stem cell; 5-FU, 5-fluorouracil; atRA, all-trans retinoic acid; 
PenG, penicillin G. 
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differentiation inhibition in cardiomyocytes. In contrast, TBX5 mRNA expression patterns 
suggest that TBX5 may be a better candidate for early differentiation inhibition assessment. 
To compare the relative sensitivity of qPCR-based embryotoxicity classifications 
versus contractile assay-based classifications, the ID50 values generated from 5-FU and 
atRA TBX5 mRNA dose-response curves were compared against the ID50 values from the  
contractile assay curves in the EST biostatistical model. Despite the slight reduction in 
sensitivity observed in the qPCR approach, both methods produced the same 
embryotoxicity classifications for 5-FU, atRA, and PenG of strongly embryotoxic, weakly 
embryotoxic, and non-embryotoxic, respectively (Table 3.3). 
Discussion 
Here, we have shown hiPSCs can be induced to produce a robust and consistent cardiac 
differentiation model suitable for embryotoxicity screening as outlined by the original EST 
protocol. Using the EST biostatistical model and chemical agents used in the original EST 
protocol, this hiPSC-based EST model correctly classified the embryotoxicants, 5-FU and 
atRA, as embryotoxic and our negative control, PenG, as non-embryotoxic. Moreover, the 
hiPSC-EST model demonstrated improved sensitivity over the original mESC-based EST 
in determining ID50 values by several magnitudes.  Mixed cytotoxicity sensitivity was 
observed in the hiPSC-EST, however. While hiPSC determined IC50 values indicated 
improved sensitivity for determining 5-FU-driven cytotoxicity, reduced sensitivity in 
cytotoxic assessment was observed for atRA treatment in the hiPSC-EST compared to the 
mESC-based EST. This could be driven by metabolic differences between the cell lines 
used in both studies. While studies comparing the metabolic efficiencies of mouse and 
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human pluripotent stem cells have yet to be reported, differential cytotoxic sensitivity 
between human and mouse has been previously observed in neuroblastoma cell lines 
exposed to organophosphate insecticides [40]. Such differences may be due to variations 
in the activation efficiency or robustness of biochemical processes related to apoptotic or 
necrotic responses. These differences underscore the importance of considering cellular 
vigor when selecting cell lines for toxicity screens and comparisons. However, in our study, 
the reduced cytotoxic sensitivity observed for atRA-treated cultures did not seem to impact 
the correct classification of atRA as a weak embryotoxicant. 
The observed discrepancies in assay sensitivity between the mouse- and human-
EST may be explained by molecular differences between species that influence how cells 
respond to particular agents. This is most readily observed in the case of atRA, which acts 
as a signaling molecule during development and governs critical early embryonic processes 
including axial patterning, proliferation, apoptosis, and cellular differentiation [41]. 
Moreover, excessive or deficient retinoic acid levels during development inhibit normal 
tissue development [42-45]. While retinoic acid signaling is conserved between mammals, 
it is plausible that these mechanisms may have precise, species-specific thresholds at which 
an excess of retinoic acid disrupts differentiation versus provoking cytotoxicity. 5-FU, in 
contrast, is a base analogue that mimics uracil and thymine and can be readily incorporated 
into DNA and RNA. In this way, 5-FU hinders normal nucleoside metabolism and 
consistently causes cytotoxicity and cell death regardless of species. While both chemicals 
are embryotoxic, 5-FU imparts embryotoxicity through cell death while atRA can cause 
embryotoxicity through differentiation inhibition or cell death. Thus, the nature of a  
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Cell Type Toxicity Parameter Penicillin G 5-Flurouracil
all-trans
Retinoic acid
hiPSCsa
(d25)
ID50 (µg/ml) > 1000 2.7 x 10-6 1.65 x 10-7
IC50 (µg/ml) > 1000 4.7 x 10-5 3
hiPSCs
(d10 Tbx5) ID50 (µg/ml) > 1000 5 x 10
-4 1.5 x 10--3
hFF IC50 (µg/ml) > 1000 4 x 10-4 4.5 x 10-2
hiPSC (Day 25 cluster) 
Biostatistical
Embryotoxicity Classification
Not
embryotoxic
Strongly 
embryotoxic
Weakly 
embryotoxic
hiPSC (Day 10 qPCR)
Biostatistical
Embryotoxicity Classification
Not
embryotoxic
Strongly 
embryotoxic
Weakly 
embryotoxic
Table 3.3. List of IC50 and ID50 values and embryotoxicity classifications determined 
from concentration-response curves for contractile and d10 qPCR assay endpoints. 
aData from Table 3.1.  hiPSC, human induced pluripotent stem cell; hFF, human foreskin 
fibroblast.  
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chemical as well as differences in tissue developmental requirements influence the precise 
embryotoxicity classification in the EST.   
Given the correct classification of the test embryotoxicants by the hiPSC-EST, we 
also assessed the ability of our model to determine the embryotoxicity of cigarette smoke 
and Snus tobacco toxicants connected to adverse pregnancy outcomes following prenatal 
maternal exposure (see citations). In the concentration ranges tested, the hiPSC-EST 
successfully identified ID50 values for both Marlboro Red and Camel Snus that were 
considerably lower than where cytotoxicity was observed in hFF-treated cultures. Our 
results harmonize with epidemiological studies that connect maternal tobacco use with 
congenital heart defects [46] and collectively suggest a molecular basis for the 
embryotoxicity of both tobacco products that operates through differentiation inhibition 
rather than cytotoxic effects on differentiating cardiomyocytes. Given this outcome and the 
robustness of our cardiac differentiation, the hiPSC-EST model could plausibly be used for 
molecular follow up analysis to determine root causes of environmental toxicant-elicited 
embryotoxicity observed at the screening phase. Furthermore, considering that cigarette 
smoke is a mixture of over 5000 chemicals [100], our results suggest that the hiPSC-EST 
model is also suitable for assessing embryotoxicity of environmental toxicant mixtures in 
addition to screens of individual toxicants. This feature could prove useful in risk 
assessment applications where the developmental toxicity potential of commercial, 
industrial, and/or environmental chemical moistures is sought. 
 In addition to providing a biologically-relevant platform for developmental toxicity 
screens, the model presented here was able to be modified with the addition of molecular 
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endpoints to shorten the overall screen duration and increase assessment throughput. 
Evaluation of cardiac gene expression at day 10 of differentiation produced higher IC50 
values than that observed in the traditional cardiac contractile assessment at day 25, which 
suggests a reduction in sensitivity with regard to lower dose ranges. This outcome suggests 
that the chemical(s) under study and the test concentration range is critical and should be 
carefully considered when using the qPCR-based hiPSC-EST. This is well-evidenced by 1 
x10-8 µg/ml atRA-dosed cells, which showed elevated TBX5 expression and contractile 
clusters. While atRA exposure can antagonize TBX5 expression [48], it can also work 
together with TBX5 in early tissue development—particularly in developing cardiac tissue 
[49]. Our results therefore show a threshold effect where very low doses of atRA enhanced 
cardiogenesis and mid-to-high concentrations inhibited cardiac differentiation. Similar 
concentration-range responses were obtained for chondrogenic and osteogenic endpoints 
[13].  
The differential response in expression between the two cardiac markers chosen for 
this study, TBX5 and MEF2c, also underscore the importance of carefully selecting tissue 
and timepoint specific markers for assessment in this screening model. Changes in TBX5 
expression patterns mirrored that of the contractile assay dose-response curve, while 
MEF2c expression patterns were not consistent between all of the tested chemicals. While 
MEF2c expression is specifically detectable in differentiating cardiomyocytes at day 10 of 
differentiation, additional studies by our group (not shown) have found that MEF2c 
expression is highest on day 25 of differentiation. Thus, it is possible that before day 25 of 
differentiation, MEF2c expression is not yet at a robust enough level of expression to 
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generate a consistent dose-response curve in actively differentiating cells. It should be 
noted, however, that the qPCR-derived ID50 values still successfully yielded the same 
embryotoxicity classifications for 5-FU, atRA, and PenG as the contractile assay when 
calculated with the EST biostatistical model. 
 
Conclusion  
In summary, we have shown that hiPSCs may be used as a more biologically-
relevant and robust replacement for mESCs in the EST embryotoxicity evaluation protocol. 
The hiPSC-based EST protocol is responsive in embryotoxicity screens using 
environmental embryotoxicants and chemical mixtures such as cigarette smoke and could 
serve as an in vitro model system of developmental disease, thereby reducing the number 
of animals required for developmental studies. Moreover, incorporating early tissue marker 
endpoints as outlined in this protocol also offers an opportunity to reduce the time 
commitments surrounding traditional animal embryotoxicity screens and the in vitro 
contractile assay to increase throughput with an opening for automated assessments and 
reduced culture time.  
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CHAPTER 4 
 
Sidestream smoke extracts from harm-reduction and conventional Camel cigarettes inhibit 
osteogenic differentiation via oxidative stress and differential activation of intrinsic 
apoptotic pathways 
 
Lauren M. Walker, Nicole RL Sparks, Steven R. Sera, Joseph V Madrid, Ivann KC 
Martinez, Michael Hanna, Prue Talbot, Nicole I zur Nieden 
 
Abstract 
Tobacco smoking has been implicated in an array of health-related diseases 
including those that affect adult bone. However, little is known regarding the impact of 
conventional and harm-reduction tobacco products on bone tissue as it develops in the 
embryo. To assess the effects of tobacco products on developing bone in vitro, human 
embryonic stem cells were differentiated into osteoblasts and concomitantly exposed to 
various concentrations of either mainstream or sidestream smoke solutions from Camel 
(conventional) and Camel Blue (harm-reduction) cigarettes. Differentiation inhibition was 
determined by calcium assays on osteogenically differentiating cells and compared to the 
cytotoxicity of the tobacco smoke solution.  
Exposure to mainstream smoke from both Camel and Camel Blue cigarettes caused 
no inhibition of cell viability or calcification of the osteogenic cultures. Sidestream smoke 
from conventional Camel cigarettes concentration-dependently elicited calcification 
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inhibition that was triggered by high levels of mitochondrially-generated oxidative stress, 
loss of mitochondrial membrane potential, and reduced ATP production. Moreover, Camel 
sidestream smoke induced DNA damage and caspase9-dependent apoptosis. Camel Blue 
exposed cells, in contrast, invoked only intermediate levels of reactive oxygen species 
insufficient to activate caspase3/7. In the absence of apoptotic gene activation, damage to 
the mitochondrial phenotype was noted in addition to completely retarded mineralization 
at subtoxic concentrations. Collectively, the presented findings in differentiating 
pluripotent stem cells imply that embryos may exhibit low bone mineral density if exposed 
to certain kinds of environmental smoke during development.  
 
Introduction 
A growing body of evidence has shown that cigarette smoking produces numerous 
adverse health effects, making cigarette use the leading cause of preventable death in the 
world. The most well-known of the adverse health consequences of tobacco use are cancer, 
cardiovascular disease, and respiratory complications. However, cigarette smoking has 
also been shown to have adverse effects on bone tissue. For example, smoking increases 
the occurrence of developing osteopathies, such as osteoporosis [1-3] and Legg-Calve-
Perthes Disease [4] and has been implicated in delayed healing of fractured bones [5-6].  
A recent trial suggested that nicotine replacement therapies to help women quit 
during pregnancy often deliver inadequate nicotine levels (as measured via nicotine 
metabolite content in urine) to aid in smoking cessation [7]. Consequently, smokers who 
become pregnant and are unsuccessful in quitting can expose their children in utero. This 
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is important since tobacco use during pregnancy may also adversely affect pregnancy 
outcomes and impair the health of the unborn [8-10]. Among other environmental factors, 
smoking while pregnant accounts for the high frequencies of congenital anomalies [11-12]. 
Limited research in young adults and immature animals suggests a detrimental effect of 
tobacco on bone during growth by suppressing bone formation [13]. 
Increasing concerns about the health risks associated with tobacco smoke led the 
tobacco industry to create “harm-reduction” products including “light” versions of their 
conventional cigarettes. Smoke from these products typically contain less tar, nicotine, and 
chemical additives than would be found in smoke from conventional products. Because 
users of harm-reduction products often engage in compensatory smoking, the frequency of 
smoking-associated cancer deaths seems equally high in those who use harm-reduction 
products [14]. While the beneficial impact of harm-reduction cigarettes on overall health 
is still being debated, it is even less clear whether the reduction of nicotine and tar content 
in harm-reduction products sufficiently eliminates embryotoxic effects in developing bone.  
Studies to understand adverse effects on embryo health are typically performed 
using rodent models [15-16]. These types of studies require the routine sacrifice of animals, 
are often not cost effective, and may not accurately predict the outcome of human exposure. 
Our group has recently shown that the yield of osteoblasts from in vitro exposed and 
differentiated human embryonic stem cells (hESCs) can predict adverse effects of a 
chemical towards bone development [17]. The purpose of this study was to investigate the 
molecular mechanisms of embryotoxicity exerted on osteogenesis by cigarette smoke. 
Further, this study also sought to evaluate the comparative embryotoxicity of harm-
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reduction cigarette smoke in contrast with conventional cigarettes.  The data revealed that 
sidestream (SS) smoke was more inhibitory to osteogenic differentiation than mainstream 
(MS) smoke in both tested brands. The detrimental effect of SS smoke from conventional 
Camel cigarettes was due to the general cytotoxicity of the smoke solution. In contrast, 
smoke extracts from harm-reduction Camel Blue cigarettes showed differentiation 
inhibition at sub-toxic concentrations in both the MS and the SS preparations. These data 
provide further evidence to suggest that in utero tobacco exposure could have detrimental 
effects on human bone development and that harm-reduction products may not be less 
harmful than conventional products.  
 
Methods 
Cell culture 
Human ESCs (H9), acquired from WiCell (WiCell Research Institute), were 
maintained in mTeSR® medium (Stem Cell Technologies) and kept in the undifferentiated 
state at 37°C in a humid 5% CO2 environment. Pluripotent colonies were passaged every 
5 days by dissociating cells with Accutase® (Innovative Cell Technologies, Inc.) and a cell 
scraper. Cells were replated on Matrigel (BD Biosciences) coated culture plates. Human 
foreskin fibroblasts (hFF) were a kind gift of Dr. Derrick Rancourt (University of Calgary) 
and were maintained in high glucose L-glutamine Dulbecco’s modified Eagle’s medium 
(DMEM, Corning) with 10% fetal bovine serum (FBS, Atlanta Biologicals), 1% non-
essential amino acids (NEAA, Gibco), and 0.5% penicillin/streptomycin (10,000 
units/10,000 units, Gibco).  
 96 
Osteogenic differentiation 
At confluency, pluripotent colonies were induced to undergo osteogenesis with 
control differentiation medium consisting of Dulbecco’s modified Eagle's medium 
(DMEM; Gibco) containing 15% FBS (Atlanta Biologicals), 1% non-essential amino acids 
(NEAA; Gibco), 1:200 penicillin/streptomycin (Gibco), and 0.1 mM β-mercaptoethanol 
(Sigma-Aldrich) for 5 days as described [18]. Starting from the fifth day of culture, control 
differentiation medium was supplemented for the remaining differentiation duration with 
osteogenic factors: 0.1 mM β-glycerophosphate (βGP; Sigma-Aldrich), 50 µg/ml ascorbic 
acid (AA; Sigma-Aldrich), and 1.2x10-7 M 1,25(OH)2 Vitamin D3 (VD3; Calbiochem). 
 
Production of smoke solution 
Commercially available conventional and harm-reduction Camel cigarettes were 
purchased from a local retailer and used to make mainstream (MS) and sidestream (SS) 
smoke solutions with a method described previously in detail [19-20]. Smoke solutions 
were generated using a University of Kentucky smoking machine that took a 2.2 second 
puff of MS every minute. MS smoke solution was generated by pulling 30 puffs of MS 
smoke through 10 ml of DMEM culture medium. During MS smoke production, SS smoke 
solution was produced by collecting the smoke that burned off the end of the cigarette and 
pulling it through 10 ml of DMEM. SS smoke was collected continuously, while MS smoke 
was collected during each puff. Both MS and SS solutions were made at concentrations of 
3 puff equivalents (PE). Immediately after preparation, smoke solutions were filtered 
through a 0.2 µm Acrodisc® PSF Syringe Filter (Pall Corporation, Port Washington, NY), 
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aliquoted into sterile Eppendorf tubes, and stored in a -80°C freezer until used. Desired 
PEs were acquired through serial dilutions, and experiments were performed using either 
MS or SS at indicated concentrations alongside an untreated control. Immediately after 
preparation, smoke solutions were filtered through a 0.2 µm Acrodisc®  PSF Syringe Filter 
(Pall Corporation, Port Washington, NY), aliquoted into sterile Eppendorf tubes, and stored 
in a -80°C freezer until used. Desired PEs were acquired through serial dilutions, and 
experiments were performed using either MS or SS at indicated concentrations alongside 
an untreated control. 
Osteogenic differentiation of hESCs was induced as described above, and cultures 
were treated with smoke solution throughout the 20-day differentiation protocol. Smoke 
solutions were replenished with each media change.  
 
Antioxidant and caspase inhibitor treatment 
To counteract tobacco-induced oxidative stress, three antioxidants were used 
concomitantly with tobacco treatment during days 5-7 of differentiation: ascorbic acid 
(AA; Sigma-Aldrich) [10 µM], dl-α-tocopherol acetate (vitamin E; Supelco, Sigma-
Aldrich) [10 µM], and glutathione reduced ethyl ester (GSHOEt; Sigma-Aldrich) [500 
µM]. The antioxidant medium was replaced with each media change. 
To explore the involvement of caspases 4 and 9 in tobacco-related inhibition of 
osteogenic differentiation, tobacco-treated cultures were simultaneously dosed with 
caspase 4 inhibitor (4i; Promokine) [3 µM] or caspase 9 inhibitor (9i; R&D Systems) [3 
µM] during days 5-7 of differentiation. Inhibitor-supplemented medium was replaced with 
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every media change. 
 
Cell viability assay 
Osteoblast and hFF survival in response to smoke solutions was determined by 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenylterazolium bromide (MTT) assay. Briefly, cells 
were incubated with MTT (120 mg/ml) at 37°C for 3 h. After the supernatant was removed, 
0.04 mol/l HCl in isopropanol was added to each well, and the optical density of the 
solution was read at 595 nm in an iMark™ microplate reader (Bio-Rad). As the generation 
of the blue product is proportional to the dehydrogenase activity, a decrease in the 
absorbance at 595 nm provided a direct measurement of the number of viable cells [17, 21-
25]. 
 
Calcium assay 
For quantification of calcium in the extracellular matrix, cells were harvested in 
modified radioimmunoprecipitation (RIPA) buffer [26]. Calcium deposition was 
determined based on calcium ions (Ca2+) reacting with Arsenazo III (Genzyme) to form a 
purple Ca-Arsenazo III complex, which was measured at 655 nm. The concentration of 
total calcium in the sample was calculated based on a CaCl2 standard [26]. Calcium content 
was normalized to the total protein content of the sample using the Lowry method [26]. 
 
Superoxide anion detection  
Generation of superoxide anion was determined using a Lumimax Superoxide 
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Anion Detection Kit (Agilent Technologies). H9 cells were trypsinized, washed with 
phosphate-buffered saline (PBS), and resuspended in fresh medium to incubate for 30 
minutes at 37°C. A total of 5 × 105 cells was incubated in superoxide anion assay medium 
including 0.1 mM luminol solution and 125 µM enhancer at room temperature for 30 min. 
The chemiluminescent light emissions of superoxide anion were measured with a 
luminometer (Lucetta™). 
 
MitoSOX assay 
Superoxide formation specially produced by mitochondria was assessed using the 
commercially available MitoSOX Red Mitochondrial Superoxide Indicator dye 
(ThermoFisher M36008). Adherent cells were washed with PBS and incubated with 2.5 
µM MitoSOX in PBS for 10 min in the dark. Cells were then immediately imaged on a 
Nikon Ti fluorescent microscope. MitoSOX positive cells were identified using NIH 
ImageJ analysis software as outlined by Jensen (2013). 
 
MitoTracker staining and mitochondrial analysis 
 Stress-related changes in mitochondrial morphology were visualized and quantified 
using the MitoTracker Deep Red FM fluorescent dye (ThermoFisher).  H9 cells were 
trypsinized, washed with PBS, and resuspended in 200 nM MitoTracker dye prepared in 
fresh medium. Cells were incubated in darkness for 20 minutes at 25°C, washed with PBS, 
and fixed in 4% paraformaldehyde for 15 minutes at room temperature. Fixed cells were 
then washed three times with PBS and permeabilized with 0.1% Triton X- 100 in PBS for 
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15 minutes at room temperature. Cells were washed again and counterstained with 1 µg/ml 
4', 6-diamidino-2-phenylindole (DAPI) in PBS for 30 minutes. Cells were washed three 
more times with PBS and resuspended in PBS supplemented with 2% FBS and 1 mM 
ethylenediaminetetraacetic acid (EDTA). Cell number was quantified and adjusted to a 
concentration of 5 x 105 cells/ml. Cells were spun onto pre-coated Shandon Single 
Cytoslides (ThermoFisher) using a Shandon Cytospin 3 (Shandon). For each treatment, a 
100 µl volume of fixed and stained cellular suspensions was loaded into a cytospin funnel 
and centrifuged at 200 rpm for 5 minutes at low acceleration/deceleration settings. Slides 
were allowed to air-dry overnight before mounting with Fluoro-Gel (Electron Microscopy 
Sciences) imaging. 
Z-stack images were taken for each slide using a Leica DMi8 fluorescent confocal 
microscope and max projected to flatten out each image. Resultant images were pre-
processed in ImageJ (NIH) to prepare for mitochondrial morphological analysis. The 
MitoTracker Deep Red channel was first separated from the nuclear DAPI channel to allow 
for specific analysis of the mitochondria.  Images were further processed using the 
Mitochondrial Network Analysis (MiNA) ImageJ plug-in to prepare images for evaluation 
of mitochondrial networks within individual cells. The MiNA plug-in is freely available at 
https://github.com/ScienceToolkit/MiNA. Using the default MiNA settings, images were 
subjected to a 2-pixel gaussian blur, rendering through the Enhance Local Contrast median 
filter, and a final processing through an unsharp mask tool to yield a “skeleton” or tracing 
of the mitochondrial networks in a given cell. Mitochondrial networks were evaluated 
using the MiNA analysis method as outlined by Valente et al., 2017. The mitochondrial 
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network length, number of branches, and area of mitochondrial footprint were measured 
from the skeletons to quantify tobacco-related changes to mitochondrial networks.   
 
Caspase 3/7 stain 
 For determination of activated caspases 3/7, cells were incubated for 1 hour in a 1X 
caspase 3/7 reagent conjugated to carboxyfluorescein fluorochrome (Guava Technologies, 
US). The fluorescent signal was detected in cells where the reagent is covalently bound to 
the activated caspases, any unbound reagent was washed away with 1X apoptosis buffer 
provided by the manufacturer. Cells were observed and imaged on a Nikon Ti fluorescent 
microscope. 
 
Apoptosis RT2 profiler qPCR array 
The correlation between tobacco exposure and apoptosis was examined based on 
expression changes of 84 apoptosis-associated genes using a Qiagen human Apoptosis RT2 
Profiler Array. For this, hESCs were differentiated into osteoblasts as described above with 
concomitant exposure to either solvent, non-effective, or effective doses (50% inhibition 
of calcification) of tobacco smoke solutions/extracts as determined from the concentration 
response curves shown in Fig. 4.1. RNA was isolated using the NucleoSpin RNA kit 
(Macherey-Nagel) and examined for RNA integrity using the Agilent 2100 Bioanalyzer. 
Only samples with an RNA integrity number of >8 were used for further processing. Five 
hundred nanograms of RNA were input into a cDNA reaction as described before [18]. 
qPCR reactions were set up using iQ SYBR Green Supermix (Bio-Rad) and 12.5 ng of 
 102 
cDNA per array well and cycled in a Bio-Rad iQ5 qPCR machine. Data were uploaded to 
the Qiagen Data Analysis Center at www.SABiosciences.com/pcrarraydataanalysis.php 
for analysis.  
 
Real-time quantitative PCR (qPCR) 
Changes in cellular stress-related gene expression related to DNA damage, growth 
arrest, and apoptosis were assessed using real-time quantitative PCR (qPCR) 
measurements of GADD45α, GADD45β, and GADD45γ isoform expression. RNA was 
extracted from cells and subsequently purified using the NucleoSpin RNA kit (Macherey-
Nagel) protocol. Isolated RNA was quantified using a NanoDrop® 1000 
spectrophotometer (Thermo Scientific) at 260nm. Synthesis of cDNA was performed using 
25ng of total RNA as a template and a cDNA mastermix as described before [18]. 
Quantitative  PCR analysis utilized resultant 25ng cDNA transcripts and iQ SYBR Green 
Supermix (Bio-Rad) on the CFX Connect thermocycler (Bio-Rad). Reactions were 
programmed for 5 minutes of initial denaturing at 94°C, followed by 40 cycles of 
denaturing at 94°C for 45 seconds and annealing at 60°C for 45 seconds. The ΔΔCT 
method [29] was used to calculate n-fold expression in target gene expression by 
normalizing target CT values to their respective GAPDH expression values. Primer 
sequences for human GADD45α were 5'-TTACTCAAGCAGTTACTCCCTACA-3' and 
5'-CCTTCTTCATTTTCACCTCTTTCCA-3', for GADD45β they were 5'-
ATGACATCGCCCTGCAAATC-3' and 5'-GTGACCAGGAGACAATGCAG-3', and for 
GADD45γ they were 5'-CGCGCTGCAGATCCATTTTA-3' and 5'-
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GGGGTTCGAAATGAGGATGC-3'. Primer sequences for human GAPDH were 5’-
GAGTCAACGGATTTGGTCGT-3’ and 5’-TTGATTTTGGAGGGATCTCG-3’ 
 
Comet assay and analysis  
Comet assay slides were prepared prior to cell collection by coating clean frosted 
microscope slides (Fisher Scientific) with 1% normal melting agarose (NMA, Sigma) in 
PBS. A volume of 75 µl of melted NMA was pipetted directly to the surface of each slide 
and immediately covered with a coverslip. The NMA layer was allowed to solidify at 25°C 
for 10 minutes prior to coverslip removal. Slides were stored at -20°C until use. Cells were 
trypsinized, washed with PBS, counted and resuspended in PBS supplemented with 2% 
FBS. A cell suspension of 200,000 cells per ml in 0.1% low melting point agarose (LMA, 
Fisher Bioreagents) was prepared immediately prior to distributing cells onto slides for the 
assay. NMA-coated slides were allowed to come to room temperature before coating with 
the LMA-cell mixture. The cell-LMA solution was pipetted directly onto each slide in a 
volume of 75 µL and immediately covered with a coverslip. The LMA-cell layer was 
allowed to solidify at 25°C for 10 minutes prior to coverslip removal. An additional 5-
minute solidification period at 25°C was observed after the coverslip was removed. The 
slides were then placed in a slide tray and the cells were lysed in comet assay lysis buffer 
(1.2 M NaCl, 100 mM Na2EDTA, 0.1% sodium lauryl sarcosinate, 0.26 M NaOH, pH >13) 
for 1 hour at 25°C. Next, lysis buffer was aspirated off the slides and replaced with 
electrophoresis solution (0.03 M NaOH, 2 mM Na2EDTA, pH~12.3) for 20 min at 4°C. 
Slides were transferred to an electrophoresis box and subjected to electrophoresis for 20 
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min at 1V/cm and 4°C. Slides were rinsed in ddH2O for 1 minute, then immersed in 70% 
ethanol for 5 minutes. Slides were air-dried overnight and stained with 1 µg/ml 4', 6-
diamidino-2-phenylindole (DAPI) in PBS for 30 minutes. Slides were rinsed with PBS and 
air dried prior to imaging on a Nikon Ti Eclipse fluorescent microscope. Three slides per 
treatment group were prepared and scored visually. Fifty cells per slide were scored. 
Fluorouracil (5-FU; Sigma-Aldrich) treated cells were evaluated as a positive control. To 
ensure accuracy of comet parameter measurements, DAPI signal intensity was subjected 
to a color threshold in ImageJ (commands used: Image > Adjust > Color Threshold). 
Comet score was determined by the presence of a comet tail as well as the relative length 
of the comet tail and % of DNA in the comet tail (if present). Comet tail length was 
manually quantified in ImageJ by measuring the distance spanned by comet tails (if 
present) from the edge of the cell nucleus to the furthest end of the comet tail.  
 
Western blotting 
Prior to lysing, cells were pretreated for 30 min with 1mM sodium orthovanadate 
to inhibit protein tyrosine phosphatases. Cells were then lysed with RIPA buffer (pH 7.4 
150 mM NaCl, 2 mM EDTA, 50 mM Tris-HCl pH 7.4, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1 mM sodium orthovanadate, 1 mM 
sodium fluoride, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 1:100 Halt Protease 
Inhibitor Cocktail (ThermoFisher) to collect whole-cell protein lysates. A modified Lowry 
protein assay (Bio-Rad DC™ protein assay) was used to determine protein concentration 
in fresh lysates. For western blot analysis, equal amounts of protein per treatment group 
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were loaded into a 6%-10% SDS/polyacrylamide gel and separated by electrophoresis prior 
to electrophoretic transfer to a polyvinylidene difluoride (PDVF) membrane. Membranes 
were immediately blocked in 5% bovine serum albumin (BSA) in tris-buffered saline with 
tween 20 (TBS-T) for 30 minutes at room temperature on an orbital shaker. Membranes 
were incubated with one of the following primary antibodies for 2 hours at room 
temperature with shaking: mouse anti-caspase 8 (CST 9746S), mouse anti-caspase 9 (CST 
9508S), rabbit anti-phospho-caspase 9 (Tyr153) (abcam ab79202), rabbit anti-c-Abl (CST 
2862S), rabbit anti-phospho-c-Abl (Tyr245) (CST 2868S), rabbit anti-phospho-c-Abl 
(Tyr412) (CST 247C7S), rabbit anti-caspase 4 (ab22687) mouse anti-actin (CST 3700S). 
Membranes were subsequently incubated for 1 hour at room temperature with horseradish 
peroxidase-conjugated anti-rabbit (CST 7074S) or anti-mouse (CST 7076S) secondary 
antibody was used to detect antigens of interest. Bands were visualized using 
chemiluminescence substrate (SuperSignal West Pico PLUS Chemiluminescent Substrate, 
ThermoFisher) and the Bio-Rad ChemiDoc MP System imager. 
 
Live/Dead assay 
Healthy live and apoptotic cell populations were quantified in different treatment 
groups using the LIVE/DEAD Viability/Cytotoxicity Kit (ThermoFisher L3224). H9 cells 
were trypsinized, washed with PBS, and resuspended in fresh medium containing 0.1 µM 
calcein AM and 8 µM ethidium homodimer-1 (EthD-1). Cells were incubated away from 
light for 20 minutes at 25°C, washed with PBS, and centrifuge-strained to encourage a 
single-cell suspension (Fisher Scientific, 08-771-23). Cells were resuspended in ice-cold 
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PBS supplemented with 2% FBS and immediately analyzed on a FACSCalibur Flow 
Cytometer (BD Biosciences). Fluorescence was detected at excitation/emission at λ = 
494/517 nm and 517/617 nm. Cytometer gating was set using unstained untreated samples 
and adjusting forward scatter and side-scatter light. For each sample, 10,000 events were 
recorded. 
 
Mitochondrial membrane potential 
 Changes in mitochondrial membrane potential were assessed using the 
commercially available JC-1 Dye (ThermoFisher T3168). Cells were trypsinized, washed 
with PBS, and resuspended in fresh medium containing 5 µM JC-1. Cells were incubated 
for 20 minutes at 25°C, washed with PBS, and centrifuge-strained to break up cells into a 
single-cell suspension (Fisher Scientific, 08-771-23). Cells were subsequently resuspended 
in ice-cold PBS supplemented with 2% FBS and immediately analyzed on a FACSCalibur 
Flow Cytometer (BD Biosciences). Fluorescence was detected at excitation/emission at λ 
= 488⁄530 nm and 488⁄585 nm. Cytometer gating was set using unstained untreated samples 
and adjusting forward scatter and side-scatter light. For each sample, 10,000 events were 
recorded. 
 
ATP:AMP assays 
 ATP and AMP levels were quantified via an ATP Determination Kit (ThermoFisher 
A22066) and an AMP ELISA (Kamiya Biomedical Company KT-52769), respectively. 
For both assessments, cells were washed with PBS, trypsinized, and resuspended in PBS.  
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In the ATP assay, a cell suspension for each treatment group was counted and 
readjusted to a final concentration of 12.5 × 106 cells/ml. For each reading, 10 µl of ATP 
standard or sample was combined with 90 µl of the ATP reaction solution provided by the 
ATP Determination Kit immediately before to recording the reaction luminescence output 
using a Lucetta luminometer (Lonza). Relative ng amounts of ATP in each treatment group 
were determined from an ATP standard curve. For AMP determination, each cell 
suspension was adjusted to a final concentration of 1.25 × 106 cells/ml. PBS-suspended 
cells were prepared for ELISA analysis by freeze-thawing three times with gentle mixing 
between freezing followed by centrifugation at 1,000 x g for 15 minutes at 4°C. Cell lysates 
were assessed according to the manufacturer’s ELISA protocol and final optical density 
was measured at 450 nm using an iMark microplate reader (Bio-Rad). Relative ng amounts 
of AMP were determined using a standard curve constructed from an AMP standard. 
 
Statistical analysis 
The lowest concentrations at which calcification or cell viability dropped below the 
untreated control were identified with one-way analysis of variance (ANOVA) followed 
by a paired student’s t-test. Half-maximal inhibitory doses of cytotoxicity (IC50) and 
differentiation (ID50) were taken from concentration-response curves and used to classify 
chemical embryotoxicity via an embryotoxicity biostatistical prediction model [30]. Other 
assays were also assessed with one-way analysis of variance (ANOVA) followed by a 
paired student’s t-test (GraphPad QuickCalcs). For all conducted tests, P-values below 0.05 
were considered significant.  
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Results 
The potency of mainstream (MS) and sidesteam (SS) smoke extracts of 
conventional and harm-reduction Camel cigarettes to induce differentiation defects in 
hESCs undergoing differentiation into osteoblasts was compared to assess the hazardous 
effects of smoking on developing bone tissue.  
 
MS smoke from conventional Camel cigarettes is neither cytotoxic nor teratogenic to 
differentiating osteogenic cultures 
First, MS smoke of conventional Camel cigarettes was tested to determine its 
effects on cell survival as measured by an MTT assay after 20 days of culture [25].  At that 
time these cultures express marker genes and proteins of osteoblasts [18]. No adverse 
effects on mitochondrial dehydrogenase activity were found (Fig. 4.1A). As osteoblasts 
emerge from hESC cultures, they begin to form nodules made of calcified extracellular 
matrix [18]. This process is unique to bone forming cells. This functional characteristic of 
bone was assayed via the quantification of calcium ions deposited into the matrix [25]. 
Conventional MS Camel tobacco smoke solution did not affect calcification, as assessed 
using Arsenazo III, a reagent for measuring calcium contents in samples [23, 26] (Fig. 
4.1A). These results suggest that MS Camel smoke extract has no observable effects on 
viability or functional calcification of osteogenic cultures at any of the concentrations 
tested. The half-maximal concentrations for cytotoxicity (IC50 MTT hESCs and IC50 MTT 
hFF) and differentiation inhibition (ID50 Calcium hESCs) obtained from the concentration-
response curves were then evaluated in a biostatistical model (Fig 4.1E) [30] which 
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revealed that MS Camel smoke extract was non-embryotoxic.  
 
SS from conventional Camel cigarettes demonstrates harmful effects on human osteoblast 
differentiation 
SS, the major component of secondhand smoke, was next investigated using the 
previously described method and concentrations. In contrast to the MS smoke solution, 
Camel SS smoke solution caused excessive cell death and a measurable lack of 
calcification at 0.3 PE (Fig. 4.1B). The biostatistical model classified Camel SS smoke 
extract as strongly embryotoxic (Fig. 4.1E).  
 
Harm-reduced Camel Blue cigarette smoke extract is harmful to differentiating osteoblasts 
at subtoxic concentrations 
To evaluate whether cigarettes that contain fewer carcinogens also cause less harm 
in differentiating hESCs, smoke extracts from Camel Blue cigarettes were screened using 
five concentrations. While cell viability was not inhibited in the tested range, calcification 
of the hESC-derived osteoblasts was severely inhibited at 1PE (Fig. 4.1C). The 
biostatistical model categorized MS Camel Blue smoke as weakly embryotoxic (Fig. 4.1E).  
As with the conventional Camel smoke extract, the SS smoke from Camel Blue 
cigarettes was more detrimental to differentiating osteoblasts than the MS smoke. Camel 
Blue SS smoke ablated calcification starting at 0.1 PE, one dose lower than for the 
conventional Camel SS. Notably, the absence of calcification occurred in the absence of 
changes in cell viability up to a dose of 0.3 PE (Fig. 4.1D). While the biostatistical model 
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Figure 4.1. SS smoke inhibited osteogenesis and cell viability. Human ESCs were 
treated with different concentrations of MS and SS smoke solution concurrently with 
osteogenesis. Cultures were assessed for on calcium deposition and cell viability using 
Arsenazo III and MTT assay, respectively. (A) Camel MS smoke solution. (B) Camel 
SS smoke solution. (C) Camel Blue MS smoke solution. (D) Camel Blue SS smoke 
solution. Each graphed point is the average of three independent experiments ± standard 
deviation. ΔP<0.05 represents the lowest concentration that is significantly below the 
untreated control in the calcium assay, as determined by one-way ANOVA. *P<0.05 
represents the lowest concentration significantly below the untreated control in the 
hESC MTT assay as determined by one-way ANOVA. §P<0.05 represents the lowest 
concentration that is significantly below the untreated control in the hFF MTT assay as 
determined by one-way ANOVA. (E) List of IC50 and ID50 values determined from 
concentration-response curves for all tobacco products grouped by mainstream and 
sidestream smoke and embryotoxicity classifications as calculated according to 
Genschow et al. (2000). hFF, human foreskin fibroblast; hESC, human embryonic stem 
cell; MS, mainstream; MTT, mitochondrial dehydrogenase activity assay; SS, 
sidestream. 
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also categorized Camel Blue SS smoke extract as strongly embryotoxic (Fig. 1E), it is of 
note that the embryotoxic effect was caused at subtoxic concentrations suggesting that this 
particular harm-reduction product inhibited differentiation producing developmentally 
toxic effects independent of cytotoxicity. 
 
Embryotoxicity of SS smoke is associated with oxidative stress 
Cytotoxicity in cells and tissues is commonly ascribed to oxidative stress, which 
arises as a consequence of chemical or environmental insult. Classically, oxidative stress 
is defined as the “imbalance of reducing and oxidizing equivalents where the latter 
predominates” [31]. In such cases, increased production of reactive oxygen species (ROS) 
contributes to a loss of tissue function [32-35]. Indeed, different human teratogens have 
recently been described to cause oxidative stress [36-38]. 
Due to this existing relationship between developmental inhibition and oxidative 
stress, we investigated the level of superoxide anion (•O2-) generated upon exposure to 
Camel and Camel Blue smoke extracts. An effective dose, determined from the 
concentration-response curve as the concentration that reduced calcification to 50%, and a 
non-effective dose (no effect) were compared to non-treated control cultures. MS Camel 
and MS Camel Blue showed no statistical difference in •O2- content, while the Camel SS 
revealed a 2.4-fold increase in the effective dose over the non-effective dose (Fig. 4.2A). 
In contrast, the Camel Blue SS effective dose evoked elevated •O2- content in the range 
between 1.6- and 1.9-fold. Further evaluation of the potential source of the •O2- uncovered 
elevated mitochondrial oxidative stress in the Camel SS, but not in Camel Blue (Fig. 4.2B).  
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In an effort to link oxidative stress-mediated embryotoxicity to altered gene 
regulation, we next performed a Qiagen RT2 Apoptosis Profiler qPCR array (Fig. 4.2C). A 
clustergram generated from all de-regulated genes across all treatment groups indicated a 
close relationship between the solvent controls, all non-effective doses, and the effective 
dose of Camel Blue SS smoke solution suggesting that there was very little gene de-
regulation observed (Appendix Fig. 1.4.1). In contrast, global apoptotic gene regulation 
was significantly different in the effective dose of Camel SS. Specifically—and as expected 
based on the elevated •O2- levels measured in the effective doses—genes involved in ROS 
signaling were increasingly expressed in the effective dose of Camel SS and to a lesser 
extent in the effective dose of Camel Blue SS. These same genes were mainly unaltered in 
the non-effective doses (Fig. 4.2D, Appendix Fig. 1.4.2). Calcification in both effective 
doses was rescued by the addition of antioxidants during tobacco treatment, causally 
relating oxidative stress to the osteogenic defect (Fig. 4.2E). 
 
Conventional Camel, but not the harm-reduction Camel Blue smoke extract elicits 
apoptotic gene expression and activates executioner caspases 
The high •O2- levels found in Camel SS effective doses cultures occurred in the 
presence of up-regulated caspase 8 mRNA (Fig. 4.3A) as well as higher levels of total and 
cleaved caspase 8 protein expression (Fig. 4.3B). Although caspase 9 mRNA was also 
elevated in Camel SS effective doses, Western blot could not detect increased total or 
cleaved Caspase 9 (Fig. 4.3B). However, when we probed with an antibody against the 
caspase 9 specifically phosphorylated at Y153, a well-established activation mark [39], it  
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Figure. 4.2. Differentiation inhibition caused by harm-reduction tobacco exposure 
occurred through generation of intermediate levels of reactive oxygen species. (A) 
Superoxide anion content measured upon reaction of the cells with luminol and charted 
as percent of the untreated cultures; n=3±SD. (B) Cells were exposed for seven days, 
incubated with MitoSOX, photographed and positive cells counted. Only Camel 
exposure elicited a significant increase specifically in mitochondrial oxidative stress. 
(C) Heat map of apoptotic genes de-regulated in tobacco exposed hESCs as measured 
with the RT2 qPCR array for apoptosis (D) Apoptosis qPCR array revealed upregulation 
of genes associated with ROS signaling. E) Calcium deposit was quantified from 
cultures exposed for 20 days with and without concomitant addition of antioxidants. 
Effective doses of tobacco smoke solutions and extracts reduced calcification, which 
was rescued with antioxidant treatment; n=3±SD. *P<0.05, one-way ANOVA followed 
by student’s t-test versus untreated cultures. AA, ascorbic acid; ED, effective dose; 
GSHOEt, glutathione reduced ethyl ester; MS, mainstream; NED, non-effective dose; 
RLU, relative light unit; SS, sidestream; UT, untreated; VitE, Vitamin E. 
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Figure. 4.3. Camel Blue SS elicits a weaker apoptosis response than Camel SS. (A) RT2 
qPCR array for apoptosis identified distinct expression patterns of various caspase 
isoforms between Camel and Camel Blue SS smoke exposed cells. n=3±SD. *P<0.05, 
One-Way ANOVA versus untreated cultures. (B) Western blots revealed the differential 
activation of caspases associated with extrinsic and intrinsic apoptotic pathways. (C) 
Accordingly, the executioner caspases 3/7 were highly activated in cells exposed to 
Camel, but only mildly when exposed to Camel Blue. Antioxidant treatment inhibited 
this activation. Insets show brightfield images of the same field of view. Bar = 100 µM. 
(C’) The ratio of Bcl2 to Bax mRNA expression suggested an antiapoptotic response in 
Camel Blue SS cultures. (D) Inhibition of these caspases rescues calcification in cells 
treated with effective doses of tobacco products; n=5±SD. *P<0.05, One-Way ANOVA 
versus untreated cultures. (E) Some proapoptotic genes were found upregulated in both 
Camel and Camel Blue SS cultures. n=5±SD. *P<0.05, One-Way ANOVA versus 
untreated cultures. (F) LIVE/DEAD assay reveals cell death in cells exposed to 
conventional smoke extracts only. AA, ascorbic acid; ED, effective dose; NED, non-
effective dose; SS, sidestream; UT, untreated. 
 118 
was higher in Camel SS effective doses than in any other treatment group. Concomitantly, 
downstream executioner caspases 3 and 7 were found to be highly activated in Camel SS 
(Fig. 4.3C).  
In contrast, the intermediate intracellular •O2- levels released upon exposure to 
Camel Blue SS were found to occur in the absence of apoptosis. Caspase 8 activation was 
milder in Camel Blue SS than in Camel SS (Fig. 4.3A, B) and caspase 9 was only slightly 
elevated at the mRNA level (Fig. 4.3A). This lower activation of upstream caspase 
activation may have been responsible for marginal activation signals observed in the 
caspase3/7 stain (Fig. 4.3C). Conversely, caspase 4 showed higher mRNA expression in 
Camel Blue SS (Fig. 4.3A, 4.3C). Inhibition of caspase 9 in Camel SS effective doses and 
inhibition of caspase 4 in Camel Blue SS effective doses rescued calcification, providing 
an isoform-specific causal link between caspase activation and differentiation inhibition 
for both Camel products.     
Changes in mRNA expression were also observed for other apoptosis-related genes 
(Fig. 4.3D). Significant upregulation of mRNA expression for pro-apoptotic factors XIAP 
and BAX were observed in both effective doses. Anti-apoptotic genes BCL2L10, BCL2A1, 
and BCL2 were also upregulated in both Camel SS and Camel Blue SS effective doses. 
However, the anti-apoptotic genes BCL2L10 and BCL2A1 were highest in the SS Camel 
non-effective dose—potentially explaining the survival noted in those cultures. Similarly, 
despite the activation of multiple apoptotic genes, the ratio between BCL2 and BAX was 
most beneficial for survival in the effect dose of SS Camel Blue (Fig. 4.3C’). 
While Camel SS and Camel Blue SS both cause cellular injury and pro-apoptotic 
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responses at the mRNA level, the type of molecular responses that may drive the cellular 
injury inflicted may also drive the differential molecular responses observed in cells treated 
with either tobacco extract. In line with this notion, a Live/Dead assay revealed Camel SS 
effective dose cultures to possess the highest percentage of dead cells but a similar number 
of injured cells as the Camel Blue SS exposed cultures (Fig. 4.3F). 
 
Conventional Camel, but not the harm-reduction Camel Blue smoke extracts elicit a DNA 
damage response 
The noted severity of apoptosis in the Camel SS effective dose may not only be 
founded in the different expression levels of pro- and anti-apoptotic genes, but could also 
be caused by an upregulation in genes associated with genotoxic response. Indeed, the cell 
cycle arrest and DNA damage genes GADD45α, GADD45β, and GADD45γ mRNA were 
significantly upregulated exclusively in cells treated with a Camel SS effective dose (Fig. 
4.4A). Furthermore, mRNA for the DNA-damage response kinase ABL1 was only 
upregulated in the Camel SS effective dose and was notably the highest upregulated gene 
observed (Fig. 4.4B). Western blot analysis confirmed greater ABL1 phosphorylation at 
Y412 and Y245 (Fig. 4.4C), residues that contribute to full kinase activation in the event 
of DNA damage and subsequent DNA repair response [40, 41]. Additional mRNA markers 
related to cellular stress, including BIRC5, CIDEA, CIDEB, were also examined. Rarely 
expressed in adult tissues, BIRC5 (also known as survivin) is reported to control apoptosis 
patterns in early embryos and is implicated in normal tissue development [42, 43]. BIRC5 
mRNA levels were conspicuously upregulated for Camel SS and Camel Blue SS effective  
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Figure. 4.4. Reduced viability in hESCs exposed to conventional Camel extract is due 
to DNA damage. (A) RT2 qPCR array for apoptosis found upregulation of genes 
associated with DNA damage response in Camel SS smoke exposed cells. n=3±SD. 
*P<0.05, One-Way ANOVA versus untreated cultures. (B) ABL1 mRNA expression 
was upregulated in the Camel SS effective dose. n=3±SD. *P<0.05, One-Way ANOVA 
versus untreated cultures. (C) Western blots confirmed ABL1 activation in Camel SS 
effective doses at the protein level. (D) Comet assays confirm DNA damage in response 
to Camel exposure, which was absent in Camel Blue exposed cells and cells treated with 
antioxidant. n=3±SD. *P<0.05, One-way ANOVA followed by paired student’s t-test 
versus untreated cultures. AA, ascorbic acid; 9i, caspase 9 inhibitor; ED, effective dose; 
NED, non-effective dose; SS, sidestream; UT, untreated. 
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doses, suggesting adverse molecular misregulation by both treatments. CIDEB mRNA was 
upregulated in both Camel SS and Camel Blue SS effective doses while CIDEA mRNA 
was only upregulated in Camel SS treated cultures. 
Milder intracellular •O2- levels and lack of apoptotic response in Camel Blue SS 
effective dose treated cultures corresponded with low or non-significant changes in 
GADD45α, GADD45β, GADD45γ despite upregulation of their upstream regulator TP53 
(Fig. 4.4A). ABL1 mRNA expression levels were also unchanged in Camel Blue SS treated 
cells (Fig. 4.4B). Cells exposed to the Camel Blue SS effective dose also showed lower 
protein levels of ABL1 both overall and in its activated phospho forms (Fig. 4.4C), 
suggesting the absence of a DNA damage response. 
Confirmatory assessment for DNA lesions was then performed using a Comet 
Assay. Camel SS effective dose exposed cells demonstrated a significantly higher 
proportion of the severely damaged comet phenotype and larger DNA lesion tails (Fig. 
4.4D). Ascorbic acid supplement of Camel SS cultures did not reduce comet severity or 
tail length, suggesting that antioxidant treatment was not efficient enough to prevent 
oxidative DNA damage during the exposure period. Supplementation with caspase 9 
inhibitor did not reduce comet severity either. Given that caspase 9 activity can drive 
downstream induction of apoptosis-mediated DNA fragmentation, this outcome suggests 
that the DNA lesions detected by the Comet Assay are predominantly from DNA damage 
events that occur following Camel SS ED exposure but upstream of caspase 9 activation. 
Camel and Camel Blue damage mitochondria with differential severity 
Observed differential mRNA upregulation patterns between Camel SS and Camel 
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Blue SS suggest that a precise molecular interplay may be responsible for ultimate 
phenotypic outcomes following exposure. As follows, this result also implies that while 
Camel SS and Camel Blue SS actively harm differentiating osteoblasts, both products act 
distinctly upon cellular regulatory mechanisms related to oxidative stress. As such, 
mitochondrial health was also investigated as mitochondrial dysfunction is a well-
documented source of oxidative stress-related genotoxicity and disease states [45]. 
Mitochondrial dysregulation can lead to pathologically high levels of mitochondria-
originating •O2- that can go on to damage the cell. Because high levels of mitochondria-
specific •O2- were observed in Camel SS effective dose cultures, mitochondrial health and 
morphological parameters were additionally evaluated to determine if mitochondrial 
dysfunction was also a factor in tobacco-related inhibition of osteogenic differentiation. 
Generated by proton pumps in mitochondrial Complexes I, III, and IV, 
mitochondrial membrane potential (ΔΨm) is used to make ATP and regarded as the 
essential component of oxidative phosphorylation energy storage [46].  Healthy 
mitochondria are characterized by stably maintained ΔΨm and ATP levels, while ΔΨm 
depolarization or depleted ATP are associated with pathological impacts on mitochondrial 
health and function. Changes in ΔΨm were assessed using the JC-1 Dye, which 
accumulates in the mitochondria and fluoresces green in the event of ΔΨm depolarization 
[46]. Mitochondrial membrane potential was significantly reduced in the Camel SS 
effective doses which suggested a disturbance to mitochondrial function (Fig. 4.5B). In 
contrast, mitochondrial membrane potential in Camel Blue SS effective doses was 
unchanged from the untreated group. Further, comparative analysis of cellular AMP and   
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Figure. 4.5. Deterioration of mitochondrial health in exposed hESCs. (A) qPCR array 
analysis revealed upregulation of genes associated with integral mitochondrial apoptosis 
in both Camel SS and Camel Blue ED. *P<0.05, One-way ANOVA followed by paired 
student’s t-test versus untreated cultures. (B) Mitochondrial membrane potential 
measurements revealed a reduced membrane potential in Camel exposed cells as a sign 
for execution of the intrinsic apoptotic pathway. *P<0.05, One-way ANOVA followed 
by paired student’s t-test versus untreated or NED cultures (C) AMP-to-ATP ratio was 
increased in Camel SS ED, suggesting mitochondrial dysfunction. *P<0.05, One-way 
ANOVA followed by paired student’s t-test versus untreated cultures (D) Mitotracker 
dye analysis revealed increased mitochondrial signal in the Camel Blue SS effective 
dose. *P<0.05, One-way ANOVA followed by paired student’s t-test versus untreated 
cultures. ED, effective dose; NED, non-effective dose; SS, sidestream; UT, untreated. 
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ATP levels revealed the AMP/ATP ratio to be increased in the Camel SS effective dose. 
This outcome signifies a potential underproduction of ATP and further evidence of 
mitochondrial dysfunction in Camel SS treated cells (Fig. 4.5C). 
To additionally explore molecular changes in connection with observed 
mitochondrial dysfunction, the expression of genes associated with mitochondrial intrinsic 
apoptosis was assessed. BAX, BID, and BNIP3 and CYCS were upregulated by the Camel 
SS effective dose, while a mild upregulation was observed in the Camel Blue SS effective 
dose (Fig. 4.5A). Given that the corresponding first three proteins are involved in 
permeabilization of the mitochondrial outer membrane to prepare for cytochrome C release 
[47-50], it follows that mitochondrial membrane potential was depolarized in Camel SS 
cultures versus Camel Blue SS cultures. Together, these results suggest a strong 
mitochondrial-driven apoptotic response in Camel SS cultures. However, the similar HRK 
and AIFM1 expression patterns between both Camel and Camel Blue SS indicate a 
potential issue with mitochondrial function in the Camel Blue SS as well. 
Thus, to assess mitochondrial behavior was further a quantitative measurement of 
mitochondrial number following tobacco exposure was conducted. Under normal 
conditions, mitochondria perpetually fuse and divide to maintain a balanced mitochondrial 
population and overall morphology [51 52]. Mitochondrial number in Camel SS and Camel 
Blue SS effective doses did not deviate from mitochondrial numbers in the untreated. Cells 
treated with Camel Blue SS, conversely, featured a significant increase in total 
mitochondrial “bright spots” (Fig. 4.5D). These spots may be indicative of mitochondrial 
congregation as a result of increased fusion activity. Collectively, these outcomes infer that 
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Camel SS and Camel Blue SS elicited differential responses in mitochondrial behavior. 
Next, altered mitochondrial networks were investigated by measuring 
mitochondrial network branch lengths, branch number per network, and mitochondrial 
footprint. Camel SS showed reduced network interconnection (Fig. 6A), as well as a 
significant increase in mitochondrial branch length, and decrease in overall mitochondrial 
footprint (Fig. 4.6B). Concurrent treatment of Camel SS effective doses with an inhibitor 
to caspase 9, but not caspase 4, restored network morphology (Fig. 4.6A) and rescued 
mitochondrial footprint (Fig. 4.6B).  
Camel Blue SS exposed cells, in contrast, featured variable branch lengths within 
mitochondrial networks that were not significantly different from the untreated cultures 
(Fig. 4.6B), although trends towards decreased branch lengths were detectable. Instead, 
cells exposed to Camel Blue SS demonstrated more highly branched networks and a 
significantly reduced mitochondrial footprint. Simultaneous treatment of Camel Blue SS 
effective doses with caspase 9 inhibitor yielded abnormal mitochondrial network 
morphology comprised of shorter fragmented networks mixed with some filamentous, 
interconnected networks (Fig. 4.6A). Caspase 9 inhibitor treatment did not significantly 
rescue mean branch length or mitochondrial footprint (Fig. 4.6B), suggesting a lack of 
intrinsic mitochondrial apoptosis response. Treatment with caspase 4 inhibitor did, 
however, restore interconnected mitochondrial network morphology (Fig. 4.6A), rescued 
mitochondrial footprint (Fig. 4.6B), and decreased the number of branches per network 
(Fig. 4.6B), suggesting caspase 4 involvement in these mitochondrial behaviors. 
Cellular redox status also appeared to partly influence mitochondrial network  
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Figure 4.6. Tobacco smoke exposure elicits changes in mitochondrial networks. (A) 
MitoTracker and MiNA visualization of mitochondrial networks. (B) Changes to 
mitochondrial networks were assessed via mean branch length, mitochondrial footprint, 
and branches per network. *P<0.05, One-way ANOVA followed by paired student’s t-
test versus untreated cultures, ΔP<0.05, One-Way ANOVA followed by paired student’s 
t-test versus ED. C, Camel; CB, Camel Blue Casp9i, caspase 9 inhibitor; Casp4i caspase 
4 inhibitor; ED, effective dose; NED, non-effective dose; SS, sidestream; UT, untreated. 
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morphology in both Camel SS and Camel Blue SS effective doses. Concurrent treatment 
with antioxidant ascorbic acid rescued branch length and slightly restored mitochondrial 
footprint in Camel SS cultures (Fig. 4.6B). Camel Blue SS effective doses with ascorbic 
acid reestablished interconnected mitochondrial network morphology (Fig. 4.6A) and 
modestly restored the mean branch length range (Fig. 4.6B), supporting an influential 
relationship between cellular redox conditions and mitochondrial morphology. 
Discussion 
Due to the shortage of information on teratogenic effects of tobacco smoke on the 
developing skeleton, hESCs directed through an osteogenic lineage were used to assess the 
potency of tobacco products to inhibit calcification in differentiating osteogenic cultures. 
Based on this endpoint, differential embryotoxicity was observed in cultures treated with 
cigarette smoke solutions from MS and SS smoke of Camel and Camel Blue cigarettes.  
Previous studies found that SS smoke from conventional cigarettes was more potent 
than MS smoke, in very diverse endpoints such as free radical species levels, angiogenesis, 
oviductal function, adverse IVF outcome, sperm motility, and attachment ability of peri-
implantation embryonic cells [56-63] With regard to differentiating osteoblasts, this 
current study finds that conventional MS smoke did not hinder the viability of developing 
osteoblasts or their differentiation. SS smoke, conversely, consistently showed detrimental 
effects on osteogenesis and inhibited both calcification and the survival of the osteogenic 
cultures, adding another item to the growing list of biological events that SS smoke inhibits 
more than MS smoke. 
Since SS smoke is a main component of environmental tobacco exposures, our data 
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is also relevant to pregnant women who may not themselves smoke but expose their fetuses 
to tobacco smoke when they enter a smoking environment. Even in countries with 
extensive tobacco control policies, this is still a relevant concern. For example, in New 
York City, which has a comprehensive tobacco control policy, almost 50% of nonsmoking 
pregnant women had elevated cotinine levels suggesting that their bodies and thus their 
fetuses were exposed to secondhand or thirdhand smoke [64]. As follows, it is likely that 
exposure levels would be exacerbated in countries that do not control tobacco use in public 
places. Therefore, our data may inform policy makers about yet another adverse health 
outcome of secondhand smoke exposure.  
Almost 20 years ago, a prospective mortality study performed by Thun and Heath 
(1997) revealed an increase rather than a decrease in smoking associated health risks over 
a 20-year period after the introduction of low nicotine low tar cigarettes, suggesting that 
harm-reduction products were not truly reducing risk of injury. Indeed, the first in vitro 
data gathered showed that harm-reduction products are just as capable of attributing harm 
as conventional products are [62], in agreement with the findings in the 1997 study. In a 
subsequent in vitro study, Lin and colleagues showed that the ability of hESCs to attach to 
a substratum was severely impaired by exposure to harm-reduction products, while 
conventional products had milder outcomes [66]. Although this was the first study to 
evaluate the health of unspecialized pluripotent stem cells in response to tobacco, it did not 
allow any conclusions as to the potential impairment of differentiation events. Simply 
extending these findings to differentiating cells may not be straightforward, since 
undifferentiated cells exhibit altered metabolic, transcriptional and epigenetic states than 
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differentiated cells [44, 67, 68], which could potentially dictate their responses to toxicants. 
Thus, in the current study, harm-reduction cigarettes were compared to conventional 
cigarettes to determine if these products also confer reduced harm on differentiating 
osteogenic cells. Similar to the previous findings, our data show that harm-reduction 
products are more embryotoxic than conventional products to differentiating osteoblasts, 
as exposure demonstrated differentiation inhibition in developing osteoblasts at sub-
cytotoxic concentrations. 
The fact that harm-reduction products inhibited osteogenesis in vitro more than 
conventional products may be explained by the alteration in chemical composition 
associated with the process of lowering tar and nicotine content. During this process, other 
constituents found in the complex chemical blend of cigarette smoke such as nitrate, 
nitrogen oxide, and tobacco-specific nitrosamines may be enriched [69]. Individually, 
these chemicals can cause adverse health effects in mammalian cells [70-73]. Not only can 
concentrations of such chemicals be higher in harm-reduction cigarettes because of the 
processing required to reduce content of other carcinogens, but smokers also compensate 
for the amount of delivered nicotine by smoking more cigarettes or by inhaling deeper 
while smoking [14]. For these reasons it is likely that concentrations of such harmful 
chemicals are even higher in mothers who have difficulty quitting smoking while pregnant 
and that the harmful effects of those chemicals are compounded in their unborn fetuses.  
While it may be assumed that such chemicals individually trigger signaling 
cascades that are detrimental to development, another potential mechanism of action is that 
they induce mild oxidative stress. As we show here, the embryotoxicity of tobacco 
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products, primarily the harm-reduction kind, seems defined by their ability to create ROS 
at levels that are insufficient to kill the cells. As recently put forth by Hansen and Harris 
(2013), teratogenesis is defined by dysmorphogenetic events that may be preceding 
excessive cell death. While cytotoxicity focuses on the accumulation of ROS, the 
impediment of antioxidant capacities, and consequent cell death, teratogenesis may be the 
result of untimely regulation of critical cellular signaling rather than the result of early cell 
death. Our results outlined here offer support for this notion in that while Camel SS and 
Camel Blue SS effective doses both demonstrated reduced osteogenesis and upregulation 
of pro-apoptotic gene expression, Camel Blue SS effective cultures specifically failed to 
achieve complete caspase cascade activation and cell death as seen in Camel SS effective 
doses. It follows, then, that additional molecular or cellular players may be involved in the 
differential outcomes mediated by different tobacco products.  
Our results also indicated that altered redox states as directed by exposure to either 
Camel or Camel Blue plays an influential role in observed embryotoxic outcomes.  
Antioxidant rescue of calcification suggests that elevated ROS levels may mediate some 
of the observed embryotoxic outcomes in Camel and Camel Blue ED cultures. Disruption 
of normal tissue redox balances has also been reported to interfere with normal biological 
processes that can lead to pathological outcomes including DNA damage [75, 76, 82]. 
Given that evidence of DNA damage was exclusively observed in cultures exposed to 
Camel SS effective doses, our results suggest that elevated ROS causes a DNA damage-
mediated mode of action for embryotoxicity outcomes following Camel but not Camel 
Blue exposure. This notion was further supported by exclusive antioxidant-mediated 
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reduction of DNA damage cell populations in Camel SS effective doses. Given that DNA 
damage is well-reported to activate caspase 9-mediated apoptosis [77-79], it follows that 
concurrent CASP9 mRNA upregulation and posttranslational activation of caspase 9 
protein in Camel SS effective dose cultures support a biochemical basis for intrinsic 
apoptotic responses observed exclusively with Camel exposure. 
During the intrinsic apoptosis process, caspase 9 has been reported to regulate the 
collapse of mitochondrial membrane potential, causing further mitochondrial disruption 
[80, 81]. Aberrant mitochondrial behavior is well-associated with stress responses and a 
variety of pathologies [53, 54] and also reported to follow mitochondrial membrane 
depolarization and precede mitophagy and apoptosis [82, 83].  In accordance with elevated 
caspase 9 activity, our study found concurrent functional and morphophological 
mitochondrial changes exclusively in Camel effective dose cultures that were reversed 
when caspase 9 was inhibited. These data provided further support for the notion that ROS-
mediated DNA damage elicited the caspase 9-driven cytotoxic responses that may be 
responsible for osteogenic inhibition following SS Camel exposure (Fig. 4.7). In contrast, 
mitochondrial morphological changes observed in the absence of altered mitochondrial 
function or DNA damage in Camel Blue effective dose cultures hint at divergent modes of 
embryotoxic action for conventional versus harm-reduction tobacco products.  
In contrast with Camel ED cultures, Camel Blue ED cells demonstrated 
upregulation of caspase 4 mRNA and protein in the absence of caspase 9 activation. 
Notably, caspase 4 has been proposed to function as an endoplasmic reticulum (ER)-stress 
specific caspase [84, 85].  Furthermore, the ER and mitochondria have an important cross- 
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talk relationship that may be of further relevance in the context of development [87-91]. 
Because treatment with caspase 4 inhibitor rescued mitochondrial network morphology, it 
is possible that ER stress is also involved in the differential molecular response of cells 
exposed to the Camel Blue effective dose. Notably, disruption to normal cross-talk between 
the mitochondria and ER has been implicated in early brain development [90, 91] as well 
as metabolic and degenerative diseases [87,88].  Moreover, ER stress can interfere with 
protein folding processes [92], which may be detrimental to osteogenic differentiation as 
new sets of proteins required for differentiation progression may be made incorrectly or 
not at all. Secretion of critical regulatory proteins by osteoblasts could also be adversely 
impacted in this context. Follow up studies, however, are required to confirm ER stress and 
dysfunction in Camel Blue exposed cultures. 
 
Conclusion 
International experts on tobacco policies recently urged the World Health 
Organization to embrace harm-reduction products to promote better health [93]. However, 
based on our data dealing with in vitro osteogenesis, SS smoke from some harm-reduction 
products may not be any safer than SS smoke from conventional products. Our data in 
combination with other studies on harm-reduction products suggest that women should 
abstain from smoking completely rather than switch to these products.  
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CHAPTER 5 
 
Snus smokeless tobacco extract inhibits osteogenic differentiation through manipulation of 
redox signaling pathways and biochemical survival networks 
 
Lauren M. Walker, Nicole RL Sparks, Steven R. Sera, Jolie Carreon, Edward Dominguez, 
Ivann KC Martinez, Avani Vaghela, Tiffany S Satoorian, Nicole I zur Nieden 
 
Abstract 
In recent years, concerns surrounding tobacco-related health disparities have 
shifted from conventional cigarette smoking to other forms of tobacco use. Harm-reduction 
tobacco products (HRTPs) are marketed as less harmful to users than conventional 
cigarettes. As such, pregnant women struggling with nicotine addiction may turn to HRTPs 
as a perceived safer alternative. Contrarily, some epidemiological and in vivo studies 
implicate HRTPs in adverse pregnancy outcomes though studies on molecular etiology of 
HRTP-mediated embryotoxicity have yet to be reported. Here, we demonstrate that Snus 
exposure, one type of HRTP, directly targets osteogenesis through modulation of redox 
signaling proteins and survival signaling networks. 
Developing mouse embryos exposed in utero to Snus smokeless tobacco extract 
during early gestation demonstrated reduced overall length, skull length, and skull 
mineralization. To explore molecular and biochemical changes in vitro, human embryonic 
stem cells were differentiated into osteoblasts to model early osteogenesis. Concurrent 
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Snus exposure revealed reduced osteoblast differentiation at sub-cytotoxic Snus doses 
concomitant with increased cellular reactive oxygen species and the absence of active 
apoptosis. Notably, osteogenic inhibition of osteogenesis occurred only when 
differentiating cells were exposed to Snus extract during the first week of differentiation. 
Mechanistic analysis found hyperphosphorylation and reduced nuclear levels of 
FOXO1/3a redox signaling transcription factors. Knockdown of FOXO1/3a significantly 
reduced osteogenic output, suggesting a role for FOXO1/3a misregulation in inhibitory 
impacts of Snus. Upstream of FOXO1/3a, survival kinase AKT1 was found to be 
upregulated. Global proteomic analysis of AKT signaling pathway targets found that Snus 
exposure also manipulated important aspects of the AKT signaling network with further 
implications for inhibited protein synthesis. Collectively, our data suggest that Snus can 
interrupt key biochemical events during early osteogenesis that inhibit proper osteoblast 
development. 
 
Introduction 
 In light of biomedical studies demonstrating a myriad of adverse health impacts 
connected to cigarette smoking [1, 2], the tobacco industry has endeavored to create new 
products aimed to reduce tobacco-related harm to users [3, 4]. These so-called “harm-
reduction” tobacco products (HRTPs) are characterized as products that have been 
modified via altered manufacturing processes to remove some of the harmful chemicals 
associated with tobacco use and/or present a method of tobacco use that reduces user 
chemical exposure [5].  
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Smokeless tobacco, one such HRTP, is considered to minimize some of the harmful 
chemical exposures associated with conventional cigarette use. Smokeless tobacco 
includes snuff, dip, chew and Snus products that are sniffed, dipped (that is, placed in the 
mouth and sucked on), or chewed by users [6]. In the absence of combustion, smokeless 
tobacco use reduces exposure to chemicals produced by pyrolysis and incomplete 
combustion reactions such as polycyclic aromatic hydrocarbons (PAHs) like naphthalene 
and benzo[a]pyrene [6, 7]. Within this category, Snus products (also referred to as oral 
moist snuff in Sweden) are unique in that raw cured tobacco is heat-treated for 24-36 hours 
to kill bacteria [8]. This production method is maintained to inhibit microbial metabolism 
of tobacco nitrites into harmful tobacco-specific nitrosamines (TSNAs) [9]. 
Public perception of smokeless tobacco products generally holds smokeless 
tobacco products as safer than smoking a conventional cigarette [10-13]. Studies 
examining health risks of Snus smokeless tobacco compared to conventional cigarettes 
have also found some evidence for modestly reduced user risk for cardiovascular disease, 
mortality, as well as lung, oral, and gastric cancer [8]. With regard to developmental and 
pregnancy risks, however, less information is readily available for risks posed by Snus use. 
Some epidemiological studies suggest that Snus use during pregnancy is likely to inhibit 
normal development and encourage adverse pregnancy outcomes by way of preterm 
delivery, reduced birth weight, neurological effects, and preeclampsia [14, 15]. In vivo 
studies examining the impact of smokeless tobacco on embryonic development have 
reported embryo growth retardation and reduced bone ossification in rats and mice [16, 
17], though it is unclear what type of smokeless tobacco was used for these studies. To 
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date, a mechanistic investigation of Snus-mediated embryotoxicity has yet to be reported. 
Here, we present an investigation of Snus-driven developmental toxicity as well as an 
investigation into the molecular basis for Snus-related embryotoxicity outcomes for the 
first time. 
 
Methods 
Animals 
Animal experiments were conducted in accordance with guidelines for care and use 
of laboratory animals [18] and approved by the Institutional Animal Care and Use 
Committee at the University of California, Riverside (AUP#20180064). Ten female and 
10 male mice on a mixed 129/Sv plus C57BL/6 (Charles River Laboratories) background 
were bred for one generation to produce enough females for experimental purposes. 
Animals were housed in specific pathogen free (SPF) conditions with a 12/12-hour light-
dark cycle, controlled temperature conditions (23 ± 2°C), and relative humidity of 50 ± 
10%. Mice had ad libitum access to food and water. 
 
Animal exposures and tissue collection 
Timed matings with virgin females were performed for Snus extract and negative 
control PBS exposure. Pregnant females were exposed via intravenous tail vein injection 
to 100 µl of 10% Snus extract or PBS on days E6.5 and E8.5 of pregnancy. Snus exposure 
dose was determined according to an analysis of nicotine in Snus content (data not shown) 
that determined a Snus dose with a nicotine level within range of nicotine levels found in 
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the blood of human tobacco users. Maternal weight was measured every other day starting 
on E0.5 of pregnancy and concluding on E17.5 when dams were euthanized. Mice were 
euthanized by carbon dioxide inhalation, in accordance with NIH guidelines. On E17.5, 
pups, placentas, and maternal organs were collected, washed in PBS, and weighed. Pups 
and placentas were also imaged for dimensional measurements. Pups were prepared for 
and subjected to Alizarin Red and Alcian Blue staining of the embryonic mouse skeleton 
and cartilage tissues, respectively, as previously described [19]. 
 
Liver histopathology preparation 
 Dam livers were fixed overnight in 10% neutral buffered formalin. Fixed livers 
were processed using ascending concentrations of 70-100% isopropyl alcohol to dehydrate 
the tissues. Processed livers were embedded in optimal cutting temperature compound 
(OCT compound) and sectioned into 5 µm sections using a cryostat. Sections were 
subsequently mounted and stained with hematoxylin and eosin (H&E) stain. Stained liver 
sections were imaged on a Leica dissection microscope for histological analysis. 
 
Human embryonic stem cell culture 
H9 human embryonic stem cell (hESC) (WiCell Research Institute) cultures were 
maintained in an undifferentiated state through maintenance culture in mTeSR® culture 
medium (Stem Cell Technologies) in incubator conditions set to 37°C, 5% CO2, and 95% 
relative humidity. hESC colonies were passaged every 5 days using Accutase® (Innovative 
Cell Technologies, Inc.) and a cell scraper to gently dissociate colonies without overly 
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dissociating cells. hESCs were then plated on culture plates coated with Matrigel (BD 
Biosciences). 
 
Human embryonic stem cell osteogenic differentiation 
Osteogenic differentiation using hESCs was performed as described previously by 
Sparks et al., 2018. Pluripotent hESCs were grown to approximately 70% confluency 
mTeSR® culture medium (Stem Cell Technologies) prior to osteogenic differentiation 
induction. Osteogenic induction commenced with application of control differentiation 
medium comprised of Dulbecco’s modified Eagle's medium (DMEM; Gibco) plus 15% 
FBS (Atlanta Biologicals), 1% non-essential amino acids (NEAA; Gibco), 1:200 
penicillin/streptomycin (Gibco), and 0.1mM β-mercaptoethanol (Sigma-Aldrich). 
Differentiating cells were cultured in control differentiation medium for 5 days. On the 
fifth day of culture, control differentiation medium was supplemented with osteogenic 
induction factors:  0.1 mM β-glycerophosphate (βGP; Sigma-Aldrich), 50 µg/ml ascorbic 
acid (AA; Sigma-Aldrich), and 1.2x10-7 M 1,25(OH)2 Vitamin D3 (VD3; Calbiochem). 
  
Human foreskin fibroblast cell culture 
Human foreskin fibroblasts (hFFs) were a gift of Dr. Derrick Rancourt (University of 
Calgary). hFFs cultures were in high glucose L-glutamine Dulbecco’s modified Eagle’s 
medium (DMEM, Corning) with 10% fetal bovine serum (FBS, Atlanta Biologicals), 1% 
non-essential amino acids (NEAA, Gibco), and 0.5% penicillin/streptomycin (10,000 
units/10,000 units, Gibco).   
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Mouse embryonic stem cell culture 
D3 mouse embryonic stem cells (mESCs) (ATCC) were maintained in culture 
medium consisting of Dulbecco’s modified Eagle's medium (DMEM; Gibco) 
supplemented with 15% FBS (Atlanta Biologicals), 1% non-essential amino acids (NEAA; 
Gibco), 1:200 penicillin/streptomycin (Gibco), 0.1mM β-mercaptoethanol (Sigma-
Aldrich), and 1000 U/ml Leukemia Inhibitory Factor (LIF) (EMD Millipore). mESCs were 
kept in an incubator set to 37°C, 5% CO2, and 95% relative humidity and passaged every 
48 hours using 0.25% trypsin-EDTA (Invitrogen) as a dissociation agent.  
 
Mouse embryonic stem cell osteogenic differentiation 
Osteogenic differentiation using hESCs was performed as described previously 
[23]. Using 0.25% trypsin-EDTA (Invitrogen), mESCs were made into a single cell 
suspension of 3.75×104 cells/ml in control differentiation medium consisting of 15% FBS 
(Atlanta Biologicals), 1% non-essential amino acids (NEAA; Gibco), 1:200 
penicillin/streptomycin (Gibco), and 0.1mM β-mercaptoethanol (Sigma-Aldrich). Drops of 
20 µL of cell suspension were applied to the underside of a Petri dish cover. Drop plates 
were kept in an incubator at 37°C, 5% CO2, and 95% relative humidity for 3 days to allow 
for passive embryoid body formation. On the third day of culture, embryoid bodies were 
collected and transferred to non-adherent culture dishes filled with control differentiation 
medium. Embryoid bodies were allowed to continue growing and differentiating until day 
5 of differentiation. On day 5, embryoid bodies were collected and dissociated into a single 
cell suspension using 0.25% trypsin-EDTA. Cells were then seeded at 50,000 cells/cm2 in 
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culture dishes filled with control differentiation medium supplemented with osteogenic 
induction factors 10 mM β-glycerophosphate (βGP; Sigma-Aldrich) and 25 µg/L ascorbic 
acid (AA; Sigma-Aldrich), and 5×10−8 M 1,25(OH)2 Vitamin D3 (VD3; Calbiochem). 
 
Creation of shFOXO1/3a mouse embryonic stem cell cell line 
A pSuperior-FOXO1/3a plasmid [20] was linearized using HindIII restriction 
enzyme, gel purified, and transfected into mESCs with Effectene using 1 µg of plasmid. 
Clones were chosen following 72 hours of puromycin selection.  Successful plasmid 
integration was confirmed via PCR for the puromycin gene (forward primer 5′-
TGCAAGAACTCTTCCTCACG-3′, reverse primer 5′-AGGCCTTCCATCTGTTGCT-3′) 
with a 65°C annealing temperature protocol. Approximate percentage of FOXO1/3a 
knockdown was also confirmed via western blot. 
 
Production of Snus smokeless tobacco extract 
For cell culture applications, a 10% (w/v) stock extract of Snus tobacco was made 
by incubating 10 grams of Camel Snus in 85 ml of DMEM with 15% FBS overnight at 
4°C. The extract was then centrifuged 450×g for 10 minutes at room temperature and again 
at 13,000 ×g for 1 hour. Extract supernatant was pH adjusted to 7.4, brought to a final 
volume of 100 ml with DMEM with 15% FBS, and filter sterilized. Snus tobacco extract 
intended for in vivo exposures was made following the same protocol using sterile PBS 
supplemented with 15% FBS in lieu of DMEM. 
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In vitro Snus exposures 
hESC and mESC cultures were treated with Snus tobacco extract throughout the 
entire 20-day osteogenic differentiation protocol with the exception of the timed exposure 
experiment.  
During the timed window Snus exposure experiment, cells were treated with Snus 
tobacco extract during a prescribed window of differentiation: days 0-20, days 0-3, days 3-
5, days 5-7, or days 7-20. Snus tobacco extract was screened at five different concentrations 
to generate a concentration-response curve and determine half-maximal inhibition of 
differentiation (ID50) and cell viability (IC50) concentrations. Culture medium containing 
Snus extract was replenished with each media change.  
 
Cell viability assay 
Cell survival for differentiating osteoblasts and hFFs was assessed via the -[4,5-
dimethylthiazol-2-yl]-2,5-diphenylterazolium bromide (MTT) assay. Cells were incubated 
with MTT for 3 hours at 37°C. Culture media was then removed and 0.04 mol/L HCl in 
isopropanol was added to each well. Optical density was measured at 595 nm in an iMark™ 
microplate reader (Bio-Rad). A decrease in absorbance at 595 nm was interpreted as a 
measurement of reduction in viable cell populations as the previously described [21-23]. 
 
Calcium assay 
Cells were lysed in a modified radioimmunoprecipitation (RIPA) buffer [24]. 
Extracellular matrix calcification was quantified based on the interaction of calcium ions 
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(Ca2+) in cell lysates with Arsenazo III (Genzyme) to form a purple Ca-Arsenazo III 
complex. The concentration of total calcium in the sample was calculated based on solution 
absorbance at 655 nm and a CaCl2 standard [24]. A modified Lowry protein assay (Bio-
Rad DC™ protein assay) was used to normalize total calcium content to total protein 
content in each sample as described by Davis et al., 2011. 
 
Live/Dead assay 
The LIVE/DEAD Viability/Cytotoxicity Kit (ThermoFisher L3224) was used to 
quantify healthy live, apoptotic, and necrotic cell populations in untreated and Snus-
exposed cultures. Cells were dissociated into a single cell suspension using 0.25% trypsin-
EDTA (Invitrogen), washed with PBS, and resuspended in fresh medium containing 0.1 
µM calcein AM and 8 µM ethidium homodimer-1 (EthD-1) assay stains. Cells were then 
incubated in the dark for 20 minutes at 25°C. Freshly stained cells were washed with PBS 
and strained using strain-cap centrifuge tubes (FisherScientific, 08-771-23) to dissociate 
any remaining cell aggregates into a single cell suspension. Cells were resuspended in ice-
cold PBS with 2% FBS and promptly analyzed using a FACScalibur Flow Cytometer (BD 
Biosciences). Fluorescence was detected at excitation/emission at λ = 494/517 nm and 
517/617 nm. Cytometer gating was set using unstained untreated samples and adjusting 
forward scatter and side-scatter light. For each sample, 10,000 events were recorded. 
 
Caspase 3/7 stain 
Executioner caspase 3 and 7 activation was visually assessed via staining with a 
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caspase 3/7 reagent conjugated to carboxyfluorescein fluorochrome (Guava Technologies). 
Live cells were incubated for 1 hour in a solution of 1X caspase 3/7 reagent to allow for 
covalent binding of reagent to activated caspases. Excess, unbound reagent was washed 
away with 1X apoptosis buffer provided by the kit manufacturer. Stained cultures were 
imaged using a Nikon Ti fluorescent microscope. 
 
Superoxide anion detection 
A Lumimax Superoxide Anion Detection Kit (Agilent Technologies) was used to 
measure endogenous superoxide anion levels. Cells were rendered into a single cell 
suspension using 0.25% trypsin-EDTA (Invitrogen), washed with PBS, and resuspended 
in fresh culture medium. Cells were then incubated at 37°C for 30 minutes. This was 
followed by second incubation of 5×105 cells in 190 µL of superoxide anion (SOA) assay 
medium with 5 µL of 4.0 mM luminol solution and 5 µL of 5.0 mM enhancer medium for 
30 minutes at 25°C. Endogenous superoxide anion species were detected as 
chemiluminescent light emissions measured on a luminometer (Lucetta™). 
 
Hydrogen peroxide detection 
Endogenous hydrogen peroxide was measured using dihydrorhodamine 123 
(DHR123; Invitrogen, D23806), a hydrogen peroxide indicator that fluoresces green 
proportional to hydrogen peroxide levels [25-26]. Cells were washed with PBS and 
incubated wtih 1µM of DHR123 in PBS for 30 min at 37°C. Cells were then washed twice 
with PBS and collected in 500µl of ice-cold PBS for flow analysis using a Beckman Coulter 
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flow cytometer. Detection was set at excitation/emission at λ = 485/535 nm and unstained 
control samples were used to set appropriate gating according to forward and side scatter 
light. A total of 10,000 events per sample were recorded. 
 
8-isoprostane assay 
 8-isoprostane levels were measured using an ELISA assay kit from Cayman 
Chemical (516351). Medium from cell cultures was collected and assayed immediately to 
avoid storage-induced sample degradation. For each sample, 50 µl of sample was combined 
with 50 µl of 8-Isoprostane acetylcholinesterase (AChE) Tracer, and 50 µl of 8-Isoprostane 
ELISA Antiserum prior to incubation for 18 hours at 4°C. The ELISA assay plate then 
washed five times with kit wash buffer. Each sample well received 200 µl of Ellman’s 
Reagent and incubated for 90 minutes to facilitate detection. Absorbance was measured at 
405 nm in 2-minute intervals until the blank-subtracted wells reached a minimum of 0.3 
absorbance units. Sample absorbance results were compared to a 8-point standard curve. 
Assay results were normalized to cellular protein content as determined via modified 
Lowry protein assay (Bio-Rad DC™ protein assay). 
 
Superoxide dismutase enzymatic activity assay 
Superoxide dismutase activity was measured using an assay kit from Cayman 
Chemical (706002). Cells were washed with PBS, harvested in 300 µl of RIPA buffer, and 
stored at -20°C until assayed. For each sample, 10 µl of lysate was combined with 200 µl 
of radical detector. Enzymatic activity was initiated with the addition of 20 µl of xanthine 
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oxidase. The solutions were incubated for 20 min at 25°C and absorbance was measured 
at 450 nm. Sample absorbance results were compared to a 7-point superoxide dismutase 
activity standard curve to calculate sample enzyme activity. A modified Lowry protein 
assay (Bio-Rad DC™ protein assay) was subsequently performed to normalize superoxide 
dismutase activity for each sample to respective total protein content. 
 
Antioxidant treatment 
 Three antioxidants were used to counter Snus-induced oxidative stress: ascorbic 
acid (AA; Sigma-Aldrich) [10 µM], dl-α-tocopherol acetate (vitamin E; Supelco, Sigma-
Aldrich) [10 µM], and glutathione reduced ethyl ester (GSHOEt; Sigma-Aldrich) [500 
µM]. Oxidants were added to medium concomitantly with Snus exposure during days 5-7 
of differentiation. Antioxidant-containing medium was replaced with every media change. 
 
Catalase enzymatic activity assay 
Catalase activity was measured using an assay kit from Cayman Chemical 
(707002). Cells were washed with PBS, harvested in 300 µl of RIPA buffer, and stored at 
-20°C until assayed. For each sample, 20 µl of sample, 30 µl of methanol, and 20 µl of 
hydrogen peroxide substrate were combined to initiate the reaction. Sample solutions were 
incubated for 20 minutes at 25°C then subsequently the reactions were terminated with the 
addition of 30 µl of potassium hydroxide. Purpald, a chromogen, was added to 
colorimetrically measure catalase formaldehyde product formation. Finally, 10 µl of 
catalase potassium periodate was added to each sample. After a 5-minute incubation at 
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25°C, sample solution absorbance was measured at 540 nm. Sample absorbance outcomes 
were compared to a 7-point catalase formaldehyde standard curve. A modified Lowry 
protein assay (Bio-Rad DC™ protein assay) was also performed to normalize catalase 
activity for each sample to respective total protein content. 
 
Glutathione peroxidase enzymatic activity assay 
Glutathione peroxidase activity was measuring using an assay kit from Cayman 
Chemical (703102). Cells were washed with PBS, harvested in 300 µl of RIPA buffer, and 
stored at -20°C until assayed. For each sample, 20 µl of sample, 50 µl of assay buffer, 50 
µl of co-substrate mixture, and 50 µl of NADPH were combined. Cumene hydroperoxide 
was added at a volume of 20 µl to initiate the reactions. Absorbance was read at 340 nm 
initially and once every 10-minutes for a total of 5 minutes.  
Sample absorbance outcomes were compared to a 6-point glutathione peroxidase 
activity standard curve. A modified Lowry protein assay (Bio-Rad DC™ protein assay) 
was performed to normalize glutathione peroxidase activity for each sample to respective 
total protein content. 
 
Hydrogen peroxide treatment 
To assess the effects of ROS alone on osteogenic differentiation, cells were treated 
with 0.5 µM hydrogen peroxide. Hydrogen peroxide was added to cell culture medium 
during specified windows of osteogenic differentiation: days 0-3, days 3-5, days 3-7, days 
5-7, and days 7-20. 
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Real-time quantitative (qPCR) 
 Changes in FOXO1 and FOXO3A mRNA gene expression were assessed using 
real-time quantitative PCR (qPCR) analysis. cDNA was synthesized using 25ng of total 
RNA as a template and a cDNA mastermix: 5x reaction buffer, 1.25µl 10mM dNTPs, 
1.25µl 400U/µl RNase inhibitor, 0.1µl 200 U/µl reverse transcriptase, 0.1µl 3µg/µl random 
primer, and 1.5µl DEPC H2O. A total volume of 25µl per cDNA reaction was used. iQ 
SYBR Green Supermix (Bio-Rad) was used to measure relative expression on the CFX 
Connect thermocycler system (Bio-Rad). Reactions were programmed for 5 minutes of 
initial denaturing at 94°C, followed by 40 cycles of denaturing at 94°C for 45 seconds and 
annealing at 60°C for 45 seconds. The ΔΔCT method was used to calculate n-fold 
expression in target gene expression by normalizing target Ct values to their respective 
GAPDH expression values. and 5'-GGGGTTCGAAATGAGGATGC-3'. Primer sequences 
for Primer sequences for human FOXO1 were 5'- TAGCATAAACCTGGGCCCAA-3' and 
5'- ACCCAGCTTGCCCATTACTCT-3', FOXO3A were 5'- 
CGCACCAATTCTAACGCCAG-3' and 5'- CTGCCATATCAGTCAGCCGT-3', human 
GAPDH were 5’-ACAGTCAGCCGCATCTTCTT-3’ and 5’-
ACGACCAAATCCGTTGACTC-3’. 
 
Whole cell protein lysis and western blotting 
Cells were pretreated for 30 minutes with 1mM sodium orthovanadate to inhibit 
protein tyrosine phosphatases. Cells were subsequently lysed with protein RIPA buffer (pH 
7.4 150 mM NaCl, 2 mM EDTA, 50 mM Tris-HCl pH 7.4, 1% NP-40, 0.5% sodium 
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deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1mM sodium orthovanadate, 1mM 
sodium fluoride, 1mM phenylmethylsulfonyl fluoride (PMSF), 1:100 Halt Protease 
Inhibitor Cocktail (ThermoFisher). Protein concentration was measured via a modified 
Lowry protein assay (Bio-Rad DC™ protein assay). Equal amounts of protein per sample 
were loaded into a 6%-10% SDS/polyacrylamide gel. Proteins were separated by 
electrophoresis then electrophoretically transferred to a polyvinylidene difluoride (PDVF) 
membrane. Membranes were blocked in 5% milk or 5% bovine serum albumin (BSA) (for 
phospho proteins) in tris-buffered saline with tween 20 (TBS-T) for 30 minutes at 25°C on 
an orbital shaker. Membranes were incubated with one of the following antibodies for 2 
hours at 25°C on an orbital shaker: rabbit anti-FOXO3a (abcam, ab70315), rabbit anti-
FOXO1 (abcam, ab61760), rabbit anti-FOXO3 (S253) (CST, 9466), rabbit anti-FOXO1 
(S256) (CST, 9461), rabbit anti-phospho AKT (S473) (CST, 4060), rabbit anti-AKT 
(abcam, ab8805), rabbit anti-phospho AMPKα (T172) (CST, 50081S), rabbit anti-AMPKα 
(abcam, ab32047), rabbit anti-phospho ERK1/2 (T202/Y204) (CST, 9101), rabbit anti-
ERK1/2 (CST, 4695S), rabbit anti-phospho JNK1/2 (T185/Y185) (abcam, ab4821), rabbit 
anti-JNK1/2 (abcam, ab112501), mouse anti-TBP (abcam, ab51841), mouse anti-beta actin 
(CST, 3700) and mouse anti-tubulin (CST, 2146). Membranes were then incubated for 1 
hour at 25°C with horseradish peroxidase-conjugated anti-rabbit (CST 7074S) or anti-
mouse (CST 7076S) secondary antibody. Bands were visualized using chemiluminescence 
substrate (SuperSignal West Pico PLUS Chemiluminescent Substrate, ThermoFisher) and 
the Bio-Rad ChemiDoc MP System imager. 
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Phospho-AKT protein array 
Snus-induced disruption of the AKT and related signaling pathways was assessed 
according to phosphorylation changes at 72 distinct protein phosphorylation sites using an 
AKT Pathway Phospho Antibody Array (PAA137; Full Moon BioSystems) and Antibody 
Array Assay Kit (KAS02; Full Moon Biosystems). Whole cell protein lysates were 
collected as described above with additional mechanical lysis as outlined by the assay kit 
protocol. Protein lysates were purified and RIPA buffer exchanged for array kit labeling 
buffer using exchange columns provided by the assay kit. Protein concentration in each 
sample was measured by modified Lowry protein assay (Bio-Rad DC™ protein assay) and 
150 µg of protein for each sample was biotin-labeled. Array slides were blocked in kit 
blocking buffer for 45 minutes at 25°C on an orbital shaker before subjection to thorough 
rinses in Milli-Q grade water. Biotin-labeled protein lysates were subsequently coupled to 
array slides by incubating protein lysates and array slides in kit coupling buffer for 2 hours 
at 25°C. Array slides were thoroughly rinsed in in Milli-Q grade water and incubated in kit 
detection buffer with 1:1000 0.5 mg/ml Cy3-streptavidin (ThermoFisher) for 20 minutes 
at 25°C. Cy3-streptavidin was introduced to slide to allow streptavidin to bind biotin-
labeled proteins and thus fluorescently label biotin-labeled proteins that have been captured 
on the slide. Slides were rinsed well with Milli-Q grade water and air-dried via 
centrifugation at 1300 x g for 10 minutes. Slides were scanned for imaging and collection 
using a GenePix® Microarray Scanner. For each sample, mean fluorescence intensity for 
each protein was normalized to respective mean actin signal to allow for comparison 
between slides. Normalized signal intensities were used to perform visual heatmap analysis 
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and clustering to using the limma [27], dplyr [28], and gplots [29] packages in RStudio 
0.99.903 [30].  Normalized signal intensities were also subjected to log2 transformation 
for statistical analysis of protein and phosphorylation fold changes between treatment 
groups. Fold changes of greater than  
 
AKT inhibitor treatment 
AKT inhibitor (AbMole, M4988) was used to explore the specific impact of AKT1 
and AKT2 isoforms on osteogenic differentiation. AKT inhibitor (58 nM AKT1; 210 nM 
AKT2) was added to culture medium on days 5-7 of differentiation, with fresh inhibitor 
replaced every 24 hours.  
 
JNK activator treatment 
 JNK1/2 activator treatment was used to investigate the influence of supplemented 
JNK activity with concurrent Snus exposure. JNK activator (0.01 µM; AbMole, M5145) 
was added to culture medium on days 5-7 of differentiation, with fresh inhibitor replaced 
every 24 hours. 
 
Dual-energy X-ray absorptiometry (DXA) Analysis 
Skull bone mineral density and bone mineral content measurements for 13-month-
old mice PBS or Snus exposed mice were acquired from DXA using the UltraFocusDXA 
(Faxtiron®). Mouse in utero exposures were performed as described above. 
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Statistical analysis 
One-way analysis of variance (ANOVA) statistical testing followed by Moses Test 
of Extreme Reactions and Mann-Whitney U tests were used to determine statistical 
differences in in vivo experimental parameters. One-way analysis of variance (ANOVA) 
statistical testing followed by a paired student’s t-test was used to identify the lowest 
concentrations at which in vitro calcification or cell viability dropped below that of the 
untreated control. Differences between exposure outcomes mediated by half-maximal 
inhibitory doses for differentiation (ID50) and cell viability (IC50) were assessed with a one-
way ANOVA followed by an appropriate post hoc test (GraphPad QuickCalcs). For all 
assessments, P-values below 0.05 were considered significant. 
 
Results 
In utero exposure to Snus extract does not elicit maternal toxicity or excessive cytotoxicity 
in exposed pups 
 Before evaluating the effects of in utero exposure on embryonic development, dams 
were assessed for signs of maternal toxicity that could influence adverse outcomes in pups. 
Parameters were selected based on their classic use in in vivo teratology assessments [31]. 
Normal progression of pregnancies was measured by semi-daily evaluation of maternal 
weight gain from E0.5 through termination of the pregnancy at E17.5. PBS- and Snus-
exposed dams demonstrated similar trends in weight gain, with no noted significant 
deviations (Fig. 5.1A). Similarly, no difference in total pregnancy weight gain was 
observed between PBS- and Snus- exposed dams (Fig. 5.1B). Gross necropsy of maternal 
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organs (not shown) did not indicate signs of maternal toxicity in Snus-exposed dams. 
Maternal organ masses respective to body weight were not significantly different between 
PBS- and Snus-exposed mice (Fig. 5.1D, 1E, 1F, 1G). Histopathological assessment of 
dam livers did not find any evidence of maternal liver toxicity (Fig. 5.1D). 
Litter and pup parameters were also assessed for evidence of cytotoxic effects on 
the exposed embryos. Late-stage embryo loss or resorptions were quantified at E17.5. No 
significant differences in resorptions were found between PBS- and Snus-exposed dams 
(Fig. 5.1C). Litter sizes were not significantly different between PBS- and Snus-exposed 
pups, though some Snus-exposed dams did produce smaller litter sizes than those observed 
in PBS dams (Fig. 5.1H). Pup and placental masses were not significantly changed between 
PBS- and Snus-exposed litters (Fig. 5.1I, J). Gross necropsy of fetal placentas (not shown) 
did not show evidence of placental injury.  The ratio of placental mass to respective pup 
mass was not significantly different either (Fig. 5.1K). Collectively, these data suggest that 
in utero Snus extract exposure did not elicit cytotoxic effects on maternal, placental, or 
fetal tissues. 
 
Normal pup morphological development and skull mineralization is disrupted by Snus in 
utero 
PBS- and Snus-exposed pups were visually and quantitatively assessed for changes 
in overall and skeletal morphology. Gross morphological evaluation (Fig. 5.2A) did not 
find any striking alterations in Snus-exposed offspring compared to the PBS group.  Snus-
exposed mice did, however, demonstrate quantitative differences in overall morphology.  
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Figure. 5.1. In utero Snus exposure did not impart maternal toxicity or reduce pup 
viability.  In vivo pregnancies were monitored for signs of maternal toxicity or cytotoxic 
effects on pups. A) Gestational weight gain patterns did not significantly deviate 
between PBS- and Snus- exposed dams. Δp<0.05 represents a significant shift in 
maternal mass on E0.5 for PBS-exposed dams. p*<0.05 represents a significant shift in 
maternal mass on E0.5 for Snus-exposed dams. P-values were determined using One-
way ANOVA. B) PBS- and Snus-exposed dams gained similar amounts of weight over 
the course of pregnancy. C) No difference was observed in the average incidence of late 
stage resorptions (embryo loss) in PBS and Snus exposed litters. D-G) Maternal organ 
masses were also evaluated for signs of maternal toxicity. Liver, kidney, heart, and lung 
masses were not significantly different for Snus-exposed dams. Moreover, liver sections 
from livers of Snus-exposed dams did not show any signs of pathology. Bar = 0.5 mm.  
H) Some Snus-exposed dams produced litters with fewer pups, though no significant 
distance in overall litter size was found. I-K) Pup and placental masses as well as 
placental-to-pup mass ratio were not significantly different between PBS and Snus 
exposed litters. PBS dams n = 10. Snus dams n = 10. PBS pups n = 119. Snus pups n = 
101. 
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Pup height (crown-to-rump) varied significantly between Snus and PBS mice (Fig. 5.2B) 
while pup width (across the widest part of the pup) was significantly increased compared 
to PBS-exposed mice (Fig. 5.2C). Skull length was also affected by Snus exposure, with a 
significant reduction in length compared to PBS-exposed pups (Fig. 5.2F). No difference 
was observed in skull height between both groups (Fig. 5.2E). 
 Histochemical staining of pup skeletons revealed a pattern of increased porosity in 
the parietal bone of the skull (Fig. 5.2D) for Snus-exposed pups. Further, the total 
percentage of mineralized skull area was found to be significantly reduced in Snus-exposed 
pups, compared to PBS-exposed offspring (Fig. 5.2G). Evaluation of Snus-exposed pups 
at approximately 1 year of age suggested long-term persistence of impaired bone function 
(Appendix Fig. 1.5.1). 
 
Human osteoblast differentiation is negatively impacted by Snus at sub-cytotoxic doses 
 The capacity of Snus extract to induce differentiation defects and cytotoxicity was 
also assessed in human embryonic stem cells (hESCs) undergoing osteogenic 
differentiation. Cell survival and osteogenic output were measured on day 20 of 
differentiation, when hESC-derived osteogenic cultures express osteoblast markers [32]. 
While dose-dependent reductions in cell viability and osteogenesis were both observed 
(Fig. 5.3A), osteogenic inhibition occurred in both non-cytotoxic and cytotoxic doses. This 
duality suggests that at mid-range doses Snus extract inhibited osteogenesis without 
concurrently inducing cell death. Dose-dependent reductions in cell viability were also 
observed in hFFs exposed to Snus extract (Fig. 5.3A). Half-maximal concentrations for  
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Figure 5.3. Snus inhibits in vitro osteogenic differentiation at sub-cytotoxic doses. 
Human ESCs were treated with different concentrations of Snus extract as they were 
differentiated into osteoblasts. Cultures were evaluated for differentiation inhibition and 
cell viability via calcium and MTT assays, respectively. A) Snus exposure reduced 
osteogenesis and cell viability in a dose-dependent manner. Differentiation inhibition 
was observed in the absence of cytotoxicity. Using the EST biostatistical model, Snus 
was classified as strongly embryotoxic. B) Snus exposure failed to activate executioner 
caspases 3 and 7, suggesting the absence of active apoptosis concurrent with an 
osteogenic defect. Bar = 100 µm. C) Snus seems to impart a time-dependent effect on 
differentiation inhibition—suggesting additional mechanisms are responsible for 
observed inhibition of Snus-dependent osteotoxicity. Snus inhibition of osteogenesis 
was most potent during early differentiation periods, as later time point exposures did 
not negatively impact osteogenesis.. *, ‡, ΔP<0.05 represents the lowest concentration of 
Snus exposure that features significant reduction in given parameter as compared to the 
untreated control, as determined by One-Way ANOVA. hFF, human foreskin fibroblast; 
hESC, human embryonic stem cell; NED, non-effective dose; ED, effective dose. 
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cytotoxicity (IC50MTT hESCs, IC50 hFF MTT) and differentiation inhibition (ID50 hESCs) 
were obtained from concentration-response curves. Half-maximal concentration input into 
the embryonic stem cell test (EST) biostatistical model [33] classified Snus as strongly 
embryotoxic (Fig. 5.3A). 
Snus effective (ED) and non-effective (NED) doses were also determined from the 
dose-response curve. The effective dose was defined as the dose that reduced calcification 
to 50% (0.1% Snus extract), while the non-effective dose was the lowest Snus dose that 
did not elicit any reduction in calcification (0.001% Snus extract) (Fig. 5.3A). An active 
apoptosis response was absent in both Snus NED and ED treatment groups, as indicated 
by a lack of active executioner caspase 3 and 7 species (Fig. 5.3B). This result followed 
trends observed in the initial dose-response curve and suggested that mechanisms specific 
to osteogenic differentiation were disturbed upon Snus exposure. Further investigation 
revealed that Snus-mediated disruption of osteogenesis was dependent on time-of-
exposure during the differentiation process (Fig. 5.3C).  Targeted early exposures during 
days 0-3 or days 5-7 of differentiation significantly reduced osteogenic outcomes on day 
20 of differentiation exclusively. Notably, late stage Snus exposure during days 7-20 of 
differentiation did not significantly inhibit osteogenic differentiation.  
 
Snus-mediated embryotoxicity occurs concurrently with induction of oxidative stress 
conditions 
 Disease pathogenesis and teratogenic outcomes have been previously ascribed to 
excessive ROS generation [34-39] that causes a state of imbalance between reducing and 
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oxidizing cellular counterparts known as oxidative stress [40]. To investigate if Snus 
exposure encouraged oxidative stress conditions, several ROS species and markers of 
oxidative stress were evaluated. Cellular levels of two ROS species, superoxide anion (•O2-
) and hydrogen peroxide (H2O2), were significantly increased in Snus ED cultures (Fig. 
5.4A). Levels of 8-isoprostane, a well-established biomarker of oxidative stress and 
oxidative lipid damage [41-43], were also significantly increased in Snus ED cultures (Fig. 
5.4A). 
Assessments to investigate causality between ROS and poor osteogenic outcomes 
found evidence for ROS-mediated inhibition of osteogenesis. Dosing differentiating 
osteoblasts with hydrogen peroxide alone during defined windows of osteogenesis 
significantly reduced osteogenic output in all tested time points (Fig. 5.4C). Co-treatment 
of Snus effective dose cultures with antioxidants rescued mineralization in cultures co-
treated with ascorbic acid or glutathione reduced ethyl ester (Fig. 5.4B). Vitamin E did not 
significantly rescue osteogenic output. Together, these data suggest that elevated ROS 
contributes to Snus-mediated osteogenic inhibition. 
Follow up analysis evaluated the activity of endogenous antioxidant enzymes 
responsible for the degradation of superoxide anion and hydrogen peroxide ROS species.  
Superoxide dismutase enzyme species convert superoxide anion into hydrogen peroxide 
and oxygen (O2) molecules. Hydrogen peroxide can be subsequently processed by 
glutathione peroxidase and catalase enzymes into water and O2 [44]. Superoxide dismutase 
and catalase activity was significantly reduced in Snus ED cultures (Fig. 5.4D), suggesting 
Snus-facilitated inhibition of normal activity for these enzymes. Glutathione peroxidase  
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Figure 5.4. Snus exposure elicits oxidative stress. A) Superoxide anion, hydrogen 
peroxide, and 8-isoprostane content was significantly increased in Snus-exposed ED 
cultures. Superoxide anion content was measured via luminol-based reaction and 
reported as RLU output per a defined number of cells. Hydrogen peroxide content was 
measured using dihydrorhodamine 123. 8-isoprostane was measured via ELISA.  
n=3±SD. B) Concurrent treatment of Snus ED cultures with antioxidants ascorbic acid 
and glutathione reduced ethyl ester rescued osteogenic output. C) Exposing 
differentiating osteoblasts to hydrogen peroxide alone inhibited differentiation at any 
stage of osteogenesis. D) Endogenous antioxidant enzyme activity for SOD and catalase 
species were significantly reduced in Snus ED. GPx activity was not significantly 
affected by Snus exposure. n=3±SD.  *P<0.05 represents a significant deviation for a 
given measured parameter compared to the untreated control, as determined by One-
Way ANOVA. AA, ascorbic acid; VitE, vitamin E; GSH-OEt, glutathione reduced ethyl 
ester; RLU, relative light unit; H2O2, hydrogen peroxide; UT, untreated; NED, non-
effective dose; ED, effective dose; O2
·- , superoxide anion. 
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activity, however, was not significantly altered between either of the groups (Fig. 5.4D). 
 Overall, these results infer that Snus exposure induces molecular or biochemical 
changes that reduce antioxidant enzyme activity and increase ROS levels that could alter 
cellular behavior and differentiation outcomes.  
 
Snus exposure reduces nuclear levels of key redox transcription factors FOXO1 and 
FOXO3A 
 The forkhead box, class O (FOXO) family of transcription factors are well-reported 
mediators of oxidative stress defense and cellular stress response [45, 46]. Given that 
FOXO activates transcription of MnSOD and catalase mRNA expression, FOXO1 and 
FOXO3a mRNA expression and protein content were investigated in Snus-exposed hESC 
cultures. Reduced mRNA expression was observed for both FOXO1 and FOXO3a with 
increasing Snus dose (Fig. 5.5A). Western blot and densitometry analysis revealed that 
Snus ED reduced nuclear levels of both FOXO1 and FOXO3A (Fig. 5.5B), though a more 
dramatic reduction was observed for FOXO3A. To investigate if reduced FOXO1 and 
FOXO3A levels during differentiation alone could impact osteogenic outcomes, 
FOXO1/3a knockdown mESCs were differentiated into osteoblasts against wild-type D3 
mESCs. Generally, differentiations with wild-type cells produced more robust osteogenic 
output compared to differentiated shFOXO1/3a cells (Fig. 5.5C), suggesting an influential 
role for FOXO1 and/or FOXO3a during normal osteogenic differentiation. When 
concurrently exposed to Snus, both wild-type and shFOXO1/3a cultures showed similar 
responses in that Snus ED significantly reduced osteogenic output compared (Fig. 5.5C). 
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Figure 5.5. Snus exposure alters nuclear localization of FOXO1 and FOXO3a 
transcription factors via phosphorylation at S253 and S256 residues in osteogenic hESC 
cultures. A) Snus exposure reduced FOXO1 and FOXO3a mRNA expression in a dose-
dependent manner. B) Nuclear levels of FOXO1 and FOXO3a are reduced in Snus ED 
cultures. C) Knockdown of FOXO1 and FOXO3a reduces osteogenic output. This 
reduction is enhanced with the addition of Snus ED. *P<0.05 represents a significant 
deviation for a given measured parameter compared to the untreated wild-type control, 
as determined by One-Way ANOVA. ΔP<0.05 represents a significant deviation for a 
given measured parameter compared to the untreated shFOXO1/3a control, as 
determined by One-Way ANOVA.  D) FOXO1 and FOXO3a featured enhanced 
phosphorylation of S253 and S256, respectively, in Snus ED. These phosphorylation 
events are responsible for reduced DNA binding of FOXO1 and FOXO3a as mediated 
by AKT activity.  E) Additional anti-nuclear FOXO1 and FOXO3a phosphorylation 
events were assessed via protein array. AKT-mediated T24/32 phosphorylation and 
CK1-driven p322/325 phosphorylation were non-significantly reduced in Snus ED. 
Significant reductions in FOXO1 phosphorylation at AKT-mediated S319 and DYRK1-
mediated S329 were significantly reduced in Snus ED. *P<0.05 represents a significant 
deviation in log2 fold change as compared to the untreated control, as determined by 
One-Way ANOVA. UT, untreated; NLS, nuclear localization signal; NED, non-effective 
dose; ED, effective dose; TUB, Tubulin; WT. wild-type. 
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Changes in cellular redox state have also been reported to influence 
posttranslational modification patterns in FOXOs that can direct FOXO subcellular 
localization and activity [47]. AKT-mediated phosphorylation at nuclear exclusion sites 
S253 and S256 were evaluated for FOXO1 and FOXO3A, respectively, via western blot 
(Fig. 5.5D). Increased phosphorylation was observed at each residue in Snus ED cultures, 
indicating that Snus exposure targets FOXO1 and FOXO3a isoforms for nuclear exclusion 
through AKT. Additional AKT FOXO1 and FOXO3a phosphorylation sites were 
investigated via protein array (Fig. 5.5E). AKT-mediated phosphorylation at FOXO1/3a 
T24/32 residues and FOXO1 S319 were reduced in Snus ED cultures. Nuclear exclusion 
phosphorylation events driven by CK1 on FOXO1/3a S322/325 and DYRK1 on FOXO1 
S329 were also reduced. Given that phosphorylation at S256/3 also obscures the 
FOXO1/3a nuclear localization signal region of FOXO1/3a, observed reductions in other 
FOXO1/3a phosphorylation patterns suggest that AKT phosphorylation at S256/253 may 
the critically misregulated phosphorylation marker in the context of Snus-exposure. 
Collectively, these results suggest that Snus exposure misregulates FOXO1 and 
FOXO3a at the transcriptional and post-translational level. Snus extract appears to 
stimulate nuclear exclusion of FOXO1 and FOXO3a by modulating specific 
phosphorylation by AKT that redirects FOXO subcellular localization. Downstream, this 
misregulation of FOXO1 and FOXO3a could cause poor osteogenic outcomes. 
 
Snus exposure exerts differential effects on key players of PI3K/AKT signaling pathway 
Global misregulation of the AKT signaling pathway by Snus exposure was 
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investigated using a commercially available phospho protein array that featured key 
signaling partners and targets involved in AKT signal propagation and crosstalk. Array 
analysis revealed unique differences in posttranslational phosphorylation modifications 
between untreated, non-effective, and effective doses (Fig. 5.6A, B). Comparing non-
effective and effective doses alone identified 18 unique deviations in AKT-signaling 
related protein profiles in Snus ED cultures (Fig. 5.6C). 
Snus ED cultures demonstrated unique phosphorylation patterns that suggested 
increased IRS1/PI3K signaling events (Fig. 5.6D). Levels of inactivated pIRS1S312 [48] 
were significantly reduced in Snus ED cultures, implying an increase in active IRS1 
proteins upstream of PI3K activation. Snus exposure also significantly increased levels of 
activated pPI3K regulatory subunit p85α/γY467/Y199 protein, supporting implications of 
increased activation of PI3K signaling activities as well [49]. In addition, triple 
phosphorylated pPTENS380/T382/T383 was significantly reduced in Snus ED exposed cells. 
Given that PTEN activity reverses PI3K signaling, this result also suggests Snus-mediated 
increases in PI3K signaling activity. Together, these data provide support for Snus-
mediated alterations of signaling events upstream of AKT that may lead to aberrant AKT 
activation. 
Our results also indicated a potential for differential regulation of downstream 
IRS1/PI3K targets. Conspicuously, levels of phosphorylated PI3K downstream kinase 
pPDK1S241 were significantly reduced in Snus ED cells inferring downstream interference 
with the propagation of the PI3K signaling cascade through the PDK1 signaling arm (Fig. 
5.6D). PDK1 is a well-reported key player in mediating translational machinery through  
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Figure 5.6. Snus exposure disrupts key players in the AKT signaling pathway. A) 
Heatmap visualization showing differential phosphorylation patterns for various protein 
targets involved in AKT signaling as revealed by AKT signaling protein array. B) 
Comparative analysis of pathway target protein phosphorylation and content patterns 
found 29 common elements between Snus NED and ED. Six elements were exclusively 
featured in the NED, while 18 elements included exclusively in the Snus ED group. C)  
AKT1 and AKT2 isoforms were differentially regulated in Snus ED exposed cultures. 
Snus ED exposure significantly upregulated AKT1 activation and significantly reduced 
AKT2 activation. D) An AKT signaling phospho protein array identified several key 
players within the IRS1/PI3K/AKT signaling pathway to be uniquely misregulated upon 
Snus ED exposure. *P<0.05 represents a significant deviation in log2 transformed signal 
fold change as compared to the untreated control, as determined by One-Way ANOVA. 
NED, non-effective dose; ED, effective dose. 
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downstream phosphorylation of S6RP [51, 52] at S235/236 and subsequent activation of 
S6RP. S6RP phosphorylation increases translation of mRNA transcripts with 5' UTR that 
contain an oligopyrimidine tract [53]. In line with the observed PDK1 phosphorylation 
pattern, pS6RPS235 (S6 Ribo. Prot.) was also significantly reduced in Snus ED cultures. 
Collectively, these data suggest that Snus exposure disrupts normal signaling 
patterns within different arms of the IRS1/PI3K signaling pathway that elicit adverse 
effects on normal cellular functions. 
 
Snus-mediated AKT signaling disruption is AKT isoform-specific and associated with 
negative consequences for osteogenic differentiation outcomes 
Evaluation of the AKT signaling phospho protein results also found differential 
activation of AKT1 and AKT2 in Snus ED cultures compared to the untreated control (Fig. 
5.7A). Activated pAKT1S473 was significantly increased in Snus ED cultures. Conversely, 
Snus ED exposure also significantly reduced activated pAKT2S474 levels. Pre-activated 
pAKT1T450 [54] was also significantly upregulated in Snus ED. PI3K has been reported to 
activate AKT1 in a PDK1-independent manner and AKT2 in a PDK2-dependent manner 
[55], suggesting an etiology for the differential AKT isoform activation observed here.  
 Western blot analysis was performed to verify pAKT1S473 upregulation and also 
assess the activation status of other major signaling kinases involved in cellular 
differentiation, stress response, and FOXO regulation (Fig. 5.7B). Increased levels of 
pAKT1S473 were confirmed in Snus ED alongside reduced activation of ERK1/2 and 
JNK1/2 kinases. Levels of active AMPK did not differ between Snus NE and ED groups.  
 183 
  
Oxidative Stress (OS)
JNK
AKT
14-3-3
14-3-3FOXO1/3a
14-3-3
P
FOXO1/3a
14-3-3
P
FOXO1/3a
P
FOXO1/3a
P
Reduced DNA 
binding
Nuclear export
Release of nuclear 
export chaperones
B
C D
0
0.1
0.2
0.3
0.4
0.5
AK
T1
 (p
T4
50
)
AK
T (
pS
47
3)
AK
T2
 (p
S4
74
)
**
M
ea
n 
lo
g2
FC
AK
T1
 (p
S
)
A
*
0
20
40
60
Δ
*
Δ
M
at
ri
x 
m
in
er
al
iz
at
io
n
[µ
g 
C
a2
+ \
m
g 
pr
ot
ei
n]
NE
D
ED
pAKT1S473
pan AKT
pAMPKT172
pan AMPK
pERKT202/Y204
pan ERK
NE
D
ED
ACTINB
pJNK1/2T183/Y185
pJNK2 
JNK2
pJNK1
JNK1
Pa
n 
JN
K
Snus ED
Snus NED
Untreated
U
T
N
ED ED
ED
 +
 A
kt
1i
ED
 +
 A
kt
2i
ED
 +
 J
nk
a
 184 
  
Figure 5.7. Snus disruption of AKT signaling pathway may negatively impact 
osteogenesis by augmenting the antagonistic relationship between JNK and AKT. A) 
AKT signaling phospho protein array found AKT1 and AKT2 isoforms to be 
differentially regulated in Snus ED exposed cultures. Snus ED significantly upregulated 
AKT1 activation and significantly reduced AKT2 activation. P<0.05 represents a 
significant reduction in log2 fold change as compared to the untreated control, as 
determined by One-Way ANOVA B) Western blot analysis confirmed increased 
phosphorylation of AKT1 at S473 and also revealed differential activation of JNK1 and 
JNK2 isoforms. JNK1 activation was reduced in Snus ED, but remained unchanged for 
JNK2. ERK activation was reduced in Snus ED cultures.  C) Treatment of Snus ED 
cultures with AKT1 inhibitor and JNK1/2 activator rescued osteogenesis. *P<0.05 
represents a significant reduction in  osteogenesis compared to the untreated control, as 
determined by One-Way ANOVA. ΔP<0.05 represents an increase in osteogenesis 
compared to Snus ED, as determined by One-Way ANOVA. D) AKT and JNK exert 
opposite effects on FOXO subcellular localization. FOXO phosphorylation by AKT 
encourages reduced nuclear binding and increased nuclear export of FOXO via 14-3-3 
protein interactions. JNK, conversely, can reverse this process by facilitating the release 
of FOXOs from 14-3-3 proteins. Thus, Snus upregulation of AKT1 in combination with 
reduced JNK1 activity may ultimately encourage a cellular environment that bars 
FOXO from the nucleus and may have implications for normal osteogenic development.  
UT, untreated; NED, non-effective dose; ED, effective dose. 
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With regard to FOXO regulation, active ERK1/2 is associated with targeting FOXO species 
for poly-ubiquitination and degradation [56], [57]. Considering the reduction in active 
pERK1/2T202/Y204 levels, it is unlikely that reductions in nuclear FOXO1 and FOXO3a may 
also be attributed to ERK activity. Downregulation of ERK1/2 could, however, have other 
negative impacts on normal cellular differentiation [58]. Patterns of pJNK1/2T183/Y185 
activation demonstrated reduced pJNK1Y185 levels in Snus ED.  As active JNK has been 
shown to antagonize AKT-directed nuclear exclusion of FOXO3a [59], reduced activation 
of JNK1 may cause a balance shift in direction of FOXO localization towards nuclear 
exclusion. JNK achieves this by phosphorylating of 14-3-3 proteins that escort and/or 
sequester FOXO out of the nucleus, causing 14-3-3 to release FOXO. Subsequent 
phosphatase removal of AKT phosphorylation modifications on FOXO can subsequently 
allow for full restoration of nuclear FOXO [60]. 
To investigate the impact of excessive AKT on osteogenesis, Snus ED cultures 
were concurrently treated with an inhibitor to block AKT1 or AKT2 activity or an activator 
of JNK1/2. Both inhibition of AKT1 and activation of JNK1/2 exclusively rescued 
osteogenic output in Snus ED cultures (Fig. 5.7C). Collectively, these results support the 
notion of a two-fold impact of biochemical misregulation as mediated by Snus exposure 
(Fig. 5.7D). First, AKT1 activity is upregulated targeting FOXO1 and FOXO3a species for 
nuclear exclusion mediated by phosphorylation events that create binding sites for 14-3-3 
nuclear exclusion proteins [61]. Second, simultaneously reduced levels of active JNK 
creates an environment where cytoplasmically sequestered FOXO1/3a predominates 
within cells and effectively inhibits normal osteogenesis. 
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Discussion 
 Here we have shown for the first time, a comprehensive analysis of the embryotoxic 
impact of Snus exposure on the developing skeleton using a combination of in vivo 
exposures and developing osteoblasts produced by differentiating human embryonic stem 
cells into a osteogenic lineage.  Using these approaches revealed that Snus inhibited normal 
skeletal development by mediating several molecular and biochemical changes in 
developing osteoblasts in the absence of outright cytotoxicity. 
 Previously reported in vivo studies have shown connections between smokeless 
tobacco exposure and adverse osteogenic outcomes, including reduced ossification in fetal 
bones including the skull and long bone tissues [16, 17] and reduced bone nodule formation 
[62]. These studies, however, did not investigate the molecular or biochemical events 
responsible for these outcomes. Our study found similar detrimental effects on skull 
mineralization and morphological development in in utero Snus-exposed offspring and 
differentiating osteoblasts in vitro while extending our investigation into mechanistic 
analyses to reveal Snus-mediated molecular changes that may be responsible for adverse 
osteogenic outcomes. 
 Induction of oxidative stress conditions in developing tissues is a well-reported 
mechanism of chemically-mediated teratogenicity [38, 39]. Here, we provide evidence that 
Snus embryotoxicity is mediated at least in part by generation of sub-cytotoxic levels of 
ROS. Redox driven teratogenesis is characterized by alterations to intracellular 
biochemical events that are critical to normal cell function and development. Such changes, 
in turn, can cause dysmorphogenetic outcomes in developing cells in the absence of 
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outright cell death. Our findings support this concept in that Snus doses showing reduced 
osteoblast mineralization did not possess active pro-apoptotic activation of executioner 
caspases despite increased levels of ROS. Furthermore, antioxidant treatment rescued 
osteogenesis, suggesting that excessive ROS likely plays a role in Snus-reduced osteogenic 
outcomes by manipulating cellular redox sensitive regulatory components or signaling 
pathways. 
 Environmental toxicant interference with key signaling pathways has also been 
reported to have a myriad of adverse effects on early development in a variety of contexts 
[63-66]. Precise activation or inhibition of particular signaling players at key points in the 
development of differentiating tissues can derail correct cell fate decisions. Results from 
this study support such a mode of action for Snus-driven inhibition of normal osteogenesis. 
Snus exposure upregulated activation of key players in the IRS1/PI3K/AKT signaling 
pathway, which showed downstream inhibitory actions on normal FOXO1 and FOXO3A 
subcellular localization. Further, this effect seems to be exacerbated by reduced activation 
of JNK1. Considering that our data also show FOXO1 and FOXO3A to be required for 
robust osteogenic differentiation, it is possible that osteogenic reduction by Snus is 
mediated downstream of AKT signaling through developmentally-relevant inhibition of 
FOXO1/3A function. 
 As FOXO1/3a proteins mediate oxidative stress defense, Snus-driven inhibition of 
FOXO1/3A may be responsible for observed increases in ROS and reduced superoxide 
dismutase and catalase antioxidant enzyme activity. While elevated ROS alone has been 
previously associated with antagonism of signaling pathways, bone loss pathology, and 
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inhibited osteogenesis [67-69], several researchers have also reported that reduced FOXO 
activity in osteoblasts elicits similar outcomes in adult bone tissue [70, 71]. While our 
results support Snus-driven inhibition of FOXO1/3A oxidative stress defense that 
subsequently encourages increased developmentally-harmful levels of ROS, it is unclear if 
FOXO1/3a proteins also influence embryonic osteogenesis, specifically. Thus, further 
study is required to dissect the precise relationship between FOXO1/3a and key events 
during developmental osteogenesis. 
It is also worth noting that misregulation of other developmentally-relevant 
components of the IRS1/PI3K/AKT pathway suggest an additional avenue for adverse 
osteogenic outcomes following Snus exposure. Given that differentiating cells regularly 
require new sets of proteins to facilitate cell fate decisions and changes [75], reduced S6RP 
activity as reported here could also be detrimental for developing osteoblasts. The 
complexity of Snus-altered interplay between members of the IRS1/PI3K/AKT signaling 
pathway demonstrate a need for further study. 
Further exploration of Snus-driven osteogenic inhibition is required to more clearly 
discern which of these disruptive events contributes most to observed adverse osteogenic 
outcomes. 
  
Conclusion 
Smokeless tobacco—both in general and with specific regard to Snus—has been 
hailed as a potential means to reduce mortality and pathology burden from tobacco-related 
diseases [76], [77]. With particular regard to developmental health, however, our data show 
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that Snus smokeless tobacco may not reduce harm to health of the developing embryo. In 
the context of previous studies on smokeless tobacco use and adverse pregnancy outcomes, 
our results indicate that women who are pregnant or planning to become pregnant should 
opt for complete cessation of tobacco for a healthy pregnancy. 
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CONCLUSION 
 
 To reduce the burden of birth defects both domestically and abroad, the role of 
environmental toxicants in developmental and reproductive disruption must be addressed. 
To this end, traditional animal models have been useful but are burdened by low 
throughput, high expense, and the risk of false negative assessments. In vitro cell-based 
assays provide one means to addressing these concerns. In particular, the embryonic stem 
cell test (EST) protocol provides an avenue for faster and less costly evaluations. By 
coupling this approach with human pluripotent stem cells (hPSCs), as this thesis has shown, 
the EST approach can be made more sensitive (than a mouse-based counterpart) and 
provide assessments that are more biologically relevant to humans.  
 hPSCs are a powerful tool for both embryotoxicity screens and modeling 
mechanisms of developmental toxicity. This thesis has shown for the first time a full 
comparison of the mouse embryonic stem cell-based EST (mEST) to a human pluripotent 
stem cell-based EST (hEST). Conclusively, the tested hEST yielded accurate 
embryotoxicity classifications while performing more sensitively than the standard mEST. 
Moreover, the hEST was able to accurately classify “real-world” embryotoxicants in the 
form of two tobacco products. While it is unlikely that in vitro approaches will completely 
replace traditional models in the near future, hPSC-based in vitro assessments provide a 
faster, less costly means to generating data relevant to human health and investigating the 
potential embryotoxicity of a chemical or chemical mixture (as is the case with tobacco 
products). 
 199 
The hEST model is also an effective approach to investigating molecular and 
biochemical mechanisms of chemical embryotoxicity. Here, this thesis has presented the 
investigative and comparative analysis of conventional cigarette and harm-reduction 
tobacco product (HRTP) embryotoxicity. While both types of products inhibited normal 
osteogenic output in differentiating osteoblasts, conventional cigarettes were found to 
impart this outcome by eliciting mitochondrially-mediated apoptosis and DNA damage. 
Molecular and investigation of the HRTPs, however, suggested that harm-reduction 
cigarettes and Snus smokeless tobacco operate predominantly through differentiation 
inhibition mechanisms—instead of outright cytotoxicity mechanisms—to prevent normal 
osteogenesis. In particular, biochemical assessment of Snus-induced molecular changes 
was found to be mediated through specific alterations to developmentally relevant 
signaling pathways. 
Through their special production processes, HRTPs are manufactured to expose users 
to chemical mixtures that are distinct from conventional cigarettes. As such, it can be 
hypothesized that molecular differences observed here between conventional cigarettes 
and HRTPs may lie in the unique composition of HRTPs. Current work in our lab seeks to 
explore the relationship between developmental osteogenic outcomes and some of the 
known chemical components shared by conventional cigarettes and HRTPs. Our earliest 
results have found that some of these chemicals inhibit osteogenic differentiation with 
enhanced potency dependent on whether they are presented alone or in a combination with 
two or three other chemicals. As such, altering the chemical exposure profile between 
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conventional cigarettes and HRTPs may not actually reduce harm in developing osteoblasts 
but rather augment differentiation inhibition potency. 
Results outlined in this thesis also infer that early exposure to Snus during cell 
specification events during osteogenesis can have lasting impacts on developing bone. 
Ongoing studies in our lab are investigating the extent of in vivo long-term impacts 
following developmental in utero exposure. Thus far, we have observed reduced bone 
mineral density in the skulls, ribs, and hips of in utero exposed offspring at 12 months of 
age as well as evidence of adipose metabolic dysfunction (Appendix Fig. 1.5.1-1.5.3). 
These early results suggest that HRTPs may impart an additional injury to health outcomes 
by disrupting key early events in embryonic development. These early results, however, 
only represent part of human exposure conditions for Snus as they are mediated through 
intravenous tail vein injection and feature a chemical profile that is restricted to only the 
aqueously soluble chemical components of Snus. Future follow-up studies, therefore, will 
be designed to verify similar osteotoxic outcomes under conditions that are closer to human 
physiological exposure circumstances. 
In sum, we have successfully determined the comparative sensitivity of human and 
mouse pluripotent stem cells in embryotoxicity evaluations. We also utilized an in vitro 
developmental osteotoxicity screening model with human embryonic stem cells to 
successfully investigate embryotoxic mechanisms in conventional cigarettes and HRTPs. 
These assessments found harm-reduction cigarettes and Snus smokeless tobacco to elicit 
osteotoxic outcomes by differentiation inhibition and modulating cellular behaviors 
involved in key developmental events. The results presented here provide much needed 
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support for the use of hPSCS in mechanistic embryotoxicity assessments. Furthermore, 
findings from the presented studies on HRTPs address the current gaps in knowledge 
regarding HRTP-driven skeletal defects. Together, our results should be useful in 
advancing embryotoxicity screening efforts as well as for efforts to inform global health 
initiatives to reduce birth defects burdens. 
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Chapter 4: Supplemental information 
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Appendix Figure 1.4.1. Heatmap of candidate genes showing their regulation across 
all five treatments.   
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Appendix Figure 1.5.1. Snus-exposed mice demonstrated long-term skeletal 
impairment. (A, C, D) Bone mineral density was significantly reduced in the skulls, 
ribs, and hips of Snus-exposed mice. (B) Skull length was unchanged in Snus-exposed 
mice. (E) Femur bone mineral density did not differ between PBS and Snus-exposed 
mice. (F) Tail length was significantly reduced in Snus-exposed mice.  Given that 
reduced bone mineral density has been associated with higher fat mass and serum lipids 
(29089152, 16400063), it is possible that Snus-exposure misregulates interconnected 
mechanisms that influence adipose tissue metabolism and osteogenesis. (G) Cobb angle 
measurement did not present a significant difference in spinal curvature between PBS 
and Snus mice. BMD, bone mineral density. PBS n = 29. Snus n = 47. *p<0.05, 
represents a significant difference between PBS control mice and Snus-exposed mice.  
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Appendix Figure 1.5.2. 12-month-old in utero exposed mice possess increased adipose 
tissue and liver fat deposition. (A-C) Liver and heart mass were not significantly 
different between PBS and Snus exposed mice. Kidney mass, however, was 
significantly increased in Snus mice. (D-E) White and brown adipose tissue pads were 
significantly larger in Snus mice. (F) Subcutaneous fat, as measured by caliper, was 
significantly increased in Snus mice, compared to PBS mice. (G) Snus mice showed 
significantly increased liver triglyceride levels. (H) Blood glucose was not found to 
differ between PBS and Snus mice. Collectively, these results infer in utero Snus-
exposed mice to possess impaired lipid metabolism and altered lipid deposition patterns. 
PBS n = 29. Snus n = 47. *p<0.05, represents a significant difference between PBS 
control mice and Snus-exposed mice. 
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Appendix Figure 1.5.3. qPCR analysis found significantly reduced expression of LPL 
mRNA in 12-month-old Snus-exposed mice. (A-D) No difference was observed for 
expression of genes associated with lipogenesis (PPARγ2, CEBPA) and fatty acid 
accumulation (LEP, FABP4)  (E) mRNA expression of lipoprotein lipase enzyme (LPL) 
was significantly reduced in Snus-exposed mice. Together these data suggest that 
triglyceride lipolysis not adipogenesis is misregulated in Snus-exposed mice. PBS n = 
4. Snus n = 7. *p<0.05, represents a significant difference between PBS control mice 
and Snus-exposed mice. CEBPA, CCAAT enhancer binding protein alpha; FABP4, 
fatty acid binding protein 4; LEP, leptin; LPL, lipoprotein lipase; PPARγ2, peroxisome 
proliferator activated receptor gamma. 
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Tobacco Product Genes upregulated
Camel SS NED
BCL2A1, BCL2L10, CASP1, CASP14, LTA, LTBR
Camel SS ED
ABL1, AIFM1, BAX, BCL2, BCL2A1, BCL2L10, BID, BIRC5, 
BNIP3L, CASP8, CASP9, CD27, CD40, CIDEA, CIDEB, 
CRADD, CYCS, DFFA, FASLG, GADD45A, HRK, LTA, 
LTBR, NAIP, TNF, TNFRSF10B, TNFRSF1B, TNFSF10, 
TP53, TP73, TRADD, TRAF2, TRAF3, XIAP
Camel Blue SS 
NED
AIFM1, BSC2L10, BIRC5, LTBR
Camel Blue SS
ED
AIFM1, BAX, BCL2, BCL2A1, BCL2L10, BIRC5, BNIP3L, 
CASP4, CASP5, CASP8, CASP9, Casp14, CD27, CD40, 
CRADD, CYCS, DFFA, FASLG, HRK, IL10, LTA, LTBR, 
TNSFRSF9, TNFRSF10B, TNFRSF1B, TNFSF10, TP53, 
TP73, TRADD, TRAF2, TRAF3, XIAP
Appendix Table 2.4.1. List of genes significantly regulated per treatment group 
compared to time-matched untreated cells as found with qPCR array.    
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29 common elements in Camel Snus 
NED and Camel Snus ED
Cyclin D1, FAK p53 (pT81), LYN, 14-3-
3ζ/δ, Bax (N-term), Cyclin D1 (pT286),
AKT1S1, p53 (pS20), 14-3-3ζ/δ (pT232),
PTEN, MDM2, Tuberin, PP2Aα, IRS1,
FAK (pS910), Paxillin, BAD (pS91/128),
Gab1, MYT1, p53, PDK1, FAK (pY925),
FAK (pY861), AKT1, AKT1 , eNOS
(pS1177), FOXO1/3/4 (pT24/32),
FOXO1A(pS329)
6 elements included exclusively in 
Camel Snus NED
p53 (pS6), IRS1 (pS612), BAD (pS112),
p53 (pS315), IKKα/β (pS180/181)
18 elements included exclusively in 
Camel Snus ED
p70S6K, AKT (pS473), PI3K p85α/γ
(pY467/Y199), FOXO1 (pS256), p53
(pS46), PDK1 (pS241), PTEN, p70S6K
(pS424), IRS1 (pS312), AKT2 (pS474),
SYK (inter), S6 Ribosomal Protein
(pS235), PFKFB2 (inter), FOXO1
(pS319), PTEN (pS380/T382/T383),
JAK1 (pY1022), GSK3β (pS9),
FOXO1A/3A(pS322/325)
Appendix Table 2.5.1. List of proteins significantly misregulated per treatment group 
on AKT phospho protein array. 
